

# WEST Search History






DATE: Thursday, November 18, 2004

Hide?	Set Name	Query	Hit Count
	<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L23	L22 AND peptide	110
<input type="checkbox"/>	L22	L21 AND Fc receptor	113
<input type="checkbox"/>	L21	immunoglobulin heavy chain constant region	407
<input type="checkbox"/>	L20	L19 AND Fc receptor AND immunoglobulin	149
<input type="checkbox"/>	L19	514/2.CCLS.	6383
<input type="checkbox"/>	L18	L17 AND peptide	543
<input type="checkbox"/>	L17	L16 AND Fc receptor AND immunoglobulin	563
<input type="checkbox"/>	L16	435/7.1.CCLS.	9015
<input type="checkbox"/>	L15	L14 AND peptide	176
<input type="checkbox"/>	L14	L13 AND Fc receptor AND immunoglobulin	202
<input type="checkbox"/>	L13	424/130.1.CCLS.	1492
<input type="checkbox"/>	L12	Gosselin.IN.	633
<input type="checkbox"/>	L11	Gosselin-M.IN.	12
<input type="checkbox"/>	L10	Gosselin-Michael.IN.	2
<input type="checkbox"/>	L9	Joyal.IN.	37
<input type="checkbox"/>	L8	Joyal-J.IN.	0
<input type="checkbox"/>	L7	Joyal-John.IN.	0
<input type="checkbox"/>	L6	Israel.IN.	3948
<input type="checkbox"/>	L5	Israel-D.IN.	12
<input type="checkbox"/>	L4	Israel-David.IN.	14
<input type="checkbox"/>	L3	Gefter.IN.	214
<input type="checkbox"/>	L2	Gefter-M.IN.	5
<input type="checkbox"/>	L1	(Gefter-Malcolm.IN.)	4

END OF SEARCH HISTORY



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for Fc receptor AND immunoglobulin heavy chain con Go Clear

Limits Preview/Index History Clipboard Details

Display Summary Show: 500 Sort Send to Text

About Entrez

Items 1 - 34 of 34

One page.

Text Version

1: [Wagner B, Greiser-Wilke I, Wege AK, Radbruch A, Leibold W.](#) Related Articles, Links

Evolution of the six horse IGHG genes and corresponding immunoglobulin gamma heavy chains.  
Immunogenetics. 2002 Aug;54(5):353-64. Epub 2002 Jul 04.  
PMID: 12185539 [PubMed - indexed for MEDLINE]

2: [Reitan SK, Hannestad K.](#) Related Articles, Links

Immunoglobulin heavy chain constant regions regulate immunity and tolerance to idiotypes of antibody variable regions.  
Proc Natl Acad Sci U S A. 2002 May 28;99(11):7588-93.  
PMID: 12032327 [PubMed - indexed for MEDLINE]

3: [Newman R, Hariharan K, Reff M, Anderson DR, Braslawsky G, Santoro D, Hanna N, Bugelski PJ, Brigham-Burke M, Crysler C, Gagnon RC, Dal Monte P, Doyle ML, Hensley PC, Reddy MP, Sweet RW, Truneh A.](#) Related Articles, Links

Modification of the Fc region of a primatized IgG antibody to human CD4 retains its ability to modulate CD4 receptors but does not deplete CD4(+) T cells in chimpanzees.  
Clin Immunol. 2001 Feb;98(2):164-74.  
PMID: 11161972 [PubMed - indexed for MEDLINE]

4: [Kim MK, Pan XQ, Huang ZY, Hunter S, Hwang PH, Indik ZK, Schreiber AD.](#) Related Articles, Links

Fc gamma receptors differ in their structural requirements for interaction with the tyrosine kinase Syk in the initial steps of signaling for phagocytosis.  
Clin Immunol. 2001 Jan;98(1):125-32.  
PMID: 11141335 [PubMed - indexed for MEDLINE]

5: [Lima JO, Zhang L, Atkinson TP, Philips J, Dasanayake AP, Schroeder HW Jr.](#) Related Articles, Links

Early expression of iepsilon, CD23 (FcepsilonRII), IL-4Ralpha, and IgE in the human fetus.  
J Allergy Clin Immunol. 2000 Nov;106(5):911-7.  
PMID: 11080714 [PubMed - indexed for MEDLINE]

6: [Pioli C, Gatta L, Ubaldi V, Doria G.](#) Related Articles, Links

Inhibition of IgG1 and IgE production by stimulation of the B cell CTLA-4 receptor.  
J Immunol. 2000 Nov 15;165(10):5530-6.  
PMID: 11067906 [PubMed - indexed for MEDLINE]





















7: [Xu D, Alegre ML, Varga SS, Rothermel AL, Collins AM, Pulito VL, Hanna LS, Dolan KP, Parren PW, Bluestone JA, Jolliffe LK, Zivin RA.](#) Related Articles, Links




















In vitro characterization of five humanized OKT3 effector function variant antibodies.  
Cell Immunol. 2000 Feb 25;200(1):16-26.  
PMID: 10716879 [PubMed - indexed for MEDLINE]


Entrez PubMed  
Overview  
Help | FAQ  
Tutorial  
New/Noteworthy  
E-Utilities


PubMed Services  
Journals Database  
MeSH Database  
Single Citation Matcher  
Batch Citation Matcher  
Clinical Queries  
LinkOut  
Cubby

Related Resources  
Order Documents  
NLM Catalog  
NLM Gateway  
TOXNET  
Consumer Health  
Clinical Alerts  
ClinicalTrials.gov  
PubMed Central


-  **8:** [Bhushan A, Barnhart B, Shone S, Song C, Covey LR.](#) [Related Articles, Links](#)  
 **A transcriptional defect underlies B lymphocyte dysfunction in a patient diagnosed with non-X-linked hyper-IgM syndrome.**  
J Immunol. 2000 Mar 15;164(6):2871-80.  
PMID: 10706672 [PubMed - indexed for MEDLINE]
-  **9:** [Park HJ, So EY, Lee CE.](#) [Related Articles, Links](#)  
 **Interferon-gamma-induced factor binding to the interleukin-4-responsive element of CD23b promoter in human tonsillar mononuclear cells: role in transient up-regulation of the interleukin-4-induced CD23b mRNA.**  
Mol Immunol. 1998 Mar;35(4):239-47.  
PMID: 9736340 [PubMed - indexed for MEDLINE]
-  **10:** [Cole MS, Anasetti C, Tso JY.](#) [Related Articles, Links](#)  
 **Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells.**  
J Immunol. 1997 Oct 1;159(7):3613-21.  
PMID: 9317161 [PubMed - indexed for MEDLINE]
-  **11:** [Coloma MJ, Morrison SL.](#) [Related Articles, Links](#)  
 **Design and production of novel tetravalent bispecific antibodies.**  
Nat Biotechnol. 1997 Feb;15(2):159-63.  
PMID: 9035142 [PubMed - indexed for MEDLINE]
-  **12:** [Chen Y, Maguire T, Marks RM.](#) [Related Articles, Links](#)  
 **Demonstration of binding of dengue virus envelope protein to target cells.**  
J Virol. 1996 Dec;70(12):8765-72.  
PMID: 8971005 [PubMed - indexed for MEDLINE]
-  **13:** [Schuurman J, Lourens TE, Perdok GJ, Parren PW, Aalberse RC.](#) [Related Articles, Links](#)  
 **Mouse/human chimeric IgE antibodies directed to the house dust mite allergen Der p 2.**  
Int Arch Allergy Immunol. 1995 May-Jun;107(1-3):465-6. No abstract available.  
PMID: 7613217 [PubMed - indexed for MEDLINE]
-  **14:** [Shin SU, Friden P, Moran M, Olson T, Kang YS, Pardridge WM, Morrison SL.](#) [Related Articles, Links](#)  
 **Transferrin-antibody fusion proteins are effective in brain targeting.**  
Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2820-4.  
PMID: 7708731 [PubMed - indexed for MEDLINE]
-  **15:** [Michaelsen TE, Brekke OH, Aase A, Sandin RH, Bremnes B, Sandlie I.](#) [Related Articles, Links](#)  
 **One disulfide bond in front of the second heavy chain constant region is necessary and sufficient for effector functions of human IgG3 without a genetic hinge.**  
Proc Natl Acad Sci U S A. 1994 Sep 27;91(20):9243-7.  
PMID: 7937748 [PubMed - indexed for MEDLINE]
-  **16:** [Wright A, Morrison SL.](#) [Related Articles, Links](#)  
 **Effect of altered CH2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1.**  
J Exp Med. 1994 Sep 1;180(3):1087-96.  
PMID: 8064227 [PubMed - indexed for MEDLINE]
-  **17:** [Carayannopoulos L, Max EE, Capra JD.](#) [Related Articles, Links](#)  
 **Recombinant human IgA expressed in insect cells.**  
Proc Natl Acad Sci U S A. 1994 Aug 30;91(18):8348-52.  
PMID: 8078886 [PubMed - indexed for MEDLINE]


-  **18:** [Amin AR, Tamma SM, Swenson CD, Kieda CC, Oppenheim JD, Finkelman FD, Coico RF](#). [Related Articles, Links](#)  
 The immunoaugmenting properties of murine IgD reside in its C delta 1 and C delta 3 regions: potential role for IgD-associated glycans.  
Int Immunol. 1993 Jun;5(6):607-14.  
PMID: 8347555 [PubMed - indexed for MEDLINE]
-  **19:** [Shin SU, Wei CF, Amin AR, Thorbecke GJ, Morrison SL](#). [Related Articles, Links](#)  
 Structural and functional properties of mouse-human chimeric IgD.  
Hum Antibodies Hybridomas. 1992 Apr;3(2):65-74.  
PMID: 1633267 [PubMed - indexed for MEDLINE]
-  **20:** [McMillan DR, Faust C](#). [Related Articles, Links](#)  
 The expression and characterization of rat IgE produced by construction of the epsilon-heavy chain gene from exon modules.  
J Biol Chem. 1992 Mar 5;267(7):4904-10.  
PMID: 1537868 [PubMed - indexed for MEDLINE]
-  **21:** [Lund J, Pound JD, Jones PT, Duncan AR, Bentley T, Goodall M, Levine BA, Jefferis R, Winter G](#). [Related Articles, Links](#)  
 Multiple binding sites on the CH2 domain of IgG for mouse Fc gamma R11.  
Mol Immunol. 1992 Jan;29(1):53-9.  
PMID: 1530984 [PubMed - indexed for MEDLINE]
-  **22:** [Amin AR, Tamma SM, Oppenheim JD, Finkelman FD, Kieda C, Coico RF, Thorbecke GJ](#). [Related Articles, Links](#)  
 Specificity of the murine IgD receptor on T cells is for N-linked glycans on IgD molecules.  
Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):9238-42.  
PMID: 1924387 [PubMed - indexed for MEDLINE]
-  **23:** [Tamma SM, Amin AR, Finkelman FD, Chen YW, Thorbecke GJ, Coico RF](#). [Related Articles, Links](#)  
 IgD receptors on murine T-helper cells bind to Fd and Fc regions of immunoglobulin D.  
Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):9233-7.  
PMID: 1833776 [PubMed - indexed for MEDLINE]
-  **24:** [Gillies SD, Wesolowski JS](#). [Related Articles, Links](#)  
 Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities.  
Hum Antibodies Hybridomas. 1990;1(1):47-54.  
PMID: 2129419 [PubMed - indexed for MEDLINE]
-  **25:** [Traunecker A, Schneider J, Kiefer H, Karjalainen K](#). [Related Articles, Links](#)  
 Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules.  
Nature. 1989 May 4;339(6219):68-70.  
PMID: 2541344 [PubMed - indexed for MEDLINE]
-  **26:** [Shaw DR, Khazaeli MB, LoBuglio AF](#). [Related Articles, Links](#)  
 Mouse/human chimeric antibodies to a tumor-associated antigen: biologic activity of the four human IgG subclasses.  
J Natl Cancer Inst. 1988 Dec 7;80(19):1553-9.  
PMID: 3143014 [PubMed - indexed for MEDLINE]
-  **27:** [Burton DR, Jefferis R, Partridge LJ, Woof JM](#). [Related Articles, Links](#)

-  **Molecular recognition of antibody (IgG) by cellular Fc receptor (FcRI).**  
Mol Immunol. 1988 Nov;25(11):1175-81.  
PMID: 2975762 [PubMed - indexed for MEDLINE]


 **28:** [Mathur A, Lynch RG, Kohler G.](#)


[Related Articles](#), [Links](#)

-  **Expression, distribution and specificity of Fc receptors for IgM on murine B cells.**  
J Immunol. 1988 Sep 15;141(6):1855-62.  
PMID: 2971716 [PubMed - indexed for MEDLINE]


 **29:** [Vojtiskova J, Franek F.](#)


[Related Articles](#), [Links](#)

-  **The CH3 domain of pig immunoglobulin G. A study of structural heterogeneity and enzymic fragmentation.**  
Folia Biol (Praha). 1986;32(5):311-24.  
PMID: 3147201 [PubMed - indexed for MEDLINE]


 **30:** [Burton DR, Gregory L, Jefferis R.](#)

[Related Articles](#), [Links](#)

-  **Aspects of the molecular structure of IgG subclasses.**  
Monogr Allergy. 1986;19:7-35. No abstract available.  
PMID: 2945094 [PubMed - indexed for MEDLINE]


 **31:** [Birshtein BK, Campbell R, Diamond B.](#)


[Related Articles](#), [Links](#)

-  **Effects of immunoglobulin structure on Fc receptor binding: a mouse myeloma variant immunoglobulin with a gamma 2b-gamma 2a hybrid heavy chain having a complete gamma 2a Fc region fails to bind to gamma 2a Fc receptors on mouse macrophages.**  
J Immunol. 1982 Aug;129(2):610-4.  
PMID: 6806375 [PubMed - indexed for MEDLINE]


 **32:** [Ratcliffe A, Stanworth DR.](#)


[Related Articles](#), [Links](#)

-  **The use of synthetic gamma-chain peptides in the localization of the binding site(s) on human IgG1 for the Fc receptors of homologous monocytes and heterologous mouse macrophages.**  
Immunol Lett. 1982 Apr;4(4):215-21.  
PMID: 6212539 [PubMed - indexed for MEDLINE]


 **33:** [Klein M, Haeffner-Cavaillon N, Isenman DE, Rivat C, Navia MA, Davies DR, Dorrington KJ.](#)





[Related Articles](#), [Links](#)

-  **Expression of biological effector functions by immunoglobulin G molecules lacking the hinge region.**  
Proc Natl Acad Sci U S A. 1981 Jan;78(1):524-8.  
PMID: 6787591 [PubMed - indexed for MEDLINE]

 **34:** [Johanson RA, Shaw AR, Schlamowitz M.](#)

[Related Articles](#), [Links](#)

-  **Evidence that the CH2 domain of IgG contains the recognition unit for binding by the fetal rabbit yolk sac membrane receptor.**  
J Immunol. 1981 Jan;126(1):194-9. No abstract available.  
PMID: 6778915 [PubMed - indexed for MEDLINE]

**Display** **Summary**  Show: **500**  **Sort**  **Send to** **Text** 

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Nov 16 2004 07:00:47

Connecting via winsock to STN

\*\*\*\*\* welcome to STN International \*\*\*\*\*  
\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 16:34:17 ON 18 NOV 2004

=> File BIOSCIENCE

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

FILE 'ADISCTI' ENTERED AT 16:34:25 ON 18 NOV 2004

COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 16:34:25 ON 18 NOV 2004

COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 16:34:25 ON 18 NOV 2004

COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 16:34:25 ON 18 NOV 2004

FILE 'ANABSTR' ENTERED AT 16:34:25 ON 18 NOV 2004

COPYRIGHT (c) 2004 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'ANTE' ENTERED AT 16:34:25 ON 18 NOV 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'AQUALINE' ENTERED AT 16:34:25 ON 18 NOV 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'AQUASCI' ENTERED AT 16:34:25 ON 18 NOV 2004

COPYRIGHT 2004 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 16:34:25 ON 18 NOV 2004

Copyright (c) 1998 The Thomson Corporation.

FILE 'BIOCOMMERCE' ENTERED AT 16:34:25 ON 18 NOV 2004

COPYRIGHT (C) 2004 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All rights reserved

FILE 'BIOENG' ENTERED AT 16:34:25 ON 18 NOV 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'BIOSIS' ENTERED AT 16:34:25 ON 18 NOV 2004

Copyright (c) 2004 The Thomson Corporation.

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 16:34:25 ON 18 NOV 2004

COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'BIOTECHNO' ENTERED AT 16:34:25 ON 18 NOV 2004

COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 16:34:25 ON 18 NOV 2004

COPYRIGHT (C) 2004 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 16:34:25 ON 18 NOV 2004

FILE 'CAPLUS' ENTERED AT 16:34:25 ON 18 NOV 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 16:34:25 ON 18 NOV 2004

COPYRIGHT (c) 2004 DECHEMA ev

FILE 'CEN' ENTERED AT 16:34:25 ON 18 NOV 2004

COPYRIGHT (C) 2001 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 16:34:25 ON 18 NOV 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 16:34:25 ON 18 NOV 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'CROPB' ENTERED AT 16:34:25 ON 18 NOV 2004

COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'CROPU' ENTERED AT 16:34:25 ON 18 NOV 2004  
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'DDFB' ENTERED AT 16:34:25 ON 18 NOV 2004  
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 16:34:25 ON 18 NOV 2004  
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'DISSABS' ENTERED AT 16:34:25 ON 18 NOV 2004  
COPYRIGHT (C) 2004 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'DRUGB' ENTERED AT 16:34:25 ON 18 NOV 2004  
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'DRUGMONOG2' ENTERED AT 16:34:25 ON 18 NOV 2004  
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 16:34:25 ON 18 NOV 2004  
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'EMBAL' ENTERED AT 16:34:25 ON 18 NOV 2004  
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 16:34:25 ON 18 NOV 2004  
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 16:34:25 ON 18 NOV 2004  
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 16:34:25 ON 18 NOV 2004

FILE 'FOMAD' ENTERED AT 16:34:25 ON 18 NOV 2004  
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 16:34:25 ON 18 NOV 2004  
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 16:34:25 ON 18 NOV 2004  
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 16:34:25 ON 18 NOV 2004  
COPYRIGHT (C) 2004 International Food Information Service

FILE 'GENBANK' ENTERED AT 16:34:25 ON 18 NOV 2004

FILE 'HEALSAFE' ENTERED AT 16:34:25 ON 18 NOV 2004  
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 16:34:25 ON 18 NOV 2004  
COPYRIGHT (C) 2004 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSDRUGNEWS' ENTERED AT 16:34:25 ON 18 NOV 2004  
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'IMSPRODUCT' ENTERED AT 16:34:25 ON 18 NOV 2004  
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'IMSRESEARCH' ENTERED AT 16:34:25 ON 18 NOV 2004  
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'JICST-EPLUS' ENTERED AT 16:34:25 ON 18 NOV 2004  
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'KOSMET' ENTERED AT 16:34:25 ON 18 NOV 2004  
COPYRIGHT (C) 2004 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 16:34:25 ON 18 NOV 2004  
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 16:34:25 ON 18 NOV 2004  
COPYRIGHT (c) 2004 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 16:34:25 ON 18 NOV 2004

FILE 'NIOSHTIC' ENTERED AT 16:34:25 ON 18 NOV 2004  
COPYRIGHT (C) 2004 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 16:34:25 ON 18 NOV 2004  
Compiled and distributed by the NTIS, U.S. Department of Commerce.  
It contains copyrighted material.  
All rights reserved. (2004)

FILE 'NUTRACEUT' ENTERED AT 16:34:25 ON 18 NOV 2004  
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 16:34:25 ON 18 NOV 2004  
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 16:34:25 ON 18 NOV 2004  
Any reproduction or dissemination in part or in full,  
by means of any process and on any support whatsoever  
is prohibited without the prior written agreement of INIST-CNRS.  
COPYRIGHT (C) 2004 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 16:34:25 ON 18 NOV 2004  
COPYRIGHT (C) 2004 WIPO

FILE 'PHAR' ENTERED AT 16:34:25 ON 18 NOV 2004  
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHARMAML' ENTERED AT 16:34:25 ON 18 NOV 2004  
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 16:34:25 ON 18 NOV 2004  
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 16:34:25 ON 18 NOV 2004  
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PROMT' ENTERED AT 16:34:25 ON 18 NOV 2004  
COPYRIGHT (C) 2004 Gale Group. All rights reserved.

FILE 'PROUSDDR' ENTERED AT 16:34:25 ON 18 NOV 2004  
COPYRIGHT (C) 2004 Prous Science

FILE 'PS' ENTERED AT 16:34:25 ON 18 NOV 2004  
COPYRIGHT (C) 2004 Thieme on STN

FILE 'RDISCLOSURE' ENTERED AT 16:34:25 ON 18 NOV 2004  
COPYRIGHT (C) 2004 Kenneth Mason Publications Ltd.

FILE 'SCISEARCH' ENTERED AT 16:34:25 ON 18 NOV 2004  
Copyright (c) 2004 The Thomson Corporation.

FILE 'SYNTHLINE' ENTERED AT 16:34:25 ON 18 NOV 2004  
COPYRIGHT (C) 2004 Prous Science

FILE 'TOXCENTER' ENTERED AT 16:34:25 ON 18 NOV 2004  
COPYRIGHT (C) 2004 ACS

FILE 'USPATFULL' ENTERED AT 16:34:25 ON 18 NOV 2004  
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 16:34:25 ON 18 NOV 2004  
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 16:34:25 ON 18 NOV 2004  
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'VETU' ENTERED AT 16:34:25 ON 18 NOV 2004  
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'WATER' ENTERED AT 16:34:25 ON 18 NOV 2004  
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'WPIDS' ENTERED AT 16:34:25 ON 18 NOV 2004  
COPYRIGHT (C) 2004 THE THOMSON CORPORATION



FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> S Fc receptor  
25 FILES SEARCHED...  
52 FILES SEARCHED...  
L1 70975 FC RECEPTOR

=> S immunoglobulin heavy chain constant region  
19 FILES SEARCHED...  
32 FILES SEARCHED...  
53 FILES SEARCHED...  
69 FILES SEARCHED...  
L2 1459 IMMUNOGLOBULIN HEAVY CHAIN CONSTANT REGION

=> S L1 AND L2  
36 FILES SEARCHED...  
L3 209 L1 AND L2

=> DUP REM L3  
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE, DRUGMONOG2, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, IMSRESEARCH, KOSMET, MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, PROUSDDR, RDISCLOSURE, SYNTHLINE'.  
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE  
PROCESSING COMPLETED FOR L3  
L4 201 DUP REM L3 (8 DUPLICATES REMOVED)

=> D L4 1-201

L4 ANSWER 1 OF 201 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 1  
AN 10494653 IFIPAT;IFIUDB;IFICDB  
TI CHIMERIC ANTIGENS FOR ELICITING AN IMMUNE RESPONSE  
IN George Rajan (CA); Noujaim Antoine (CA); Tyrrell Lorne (CA)  
PA Unassigned Or Assigned To Individual (68000)  
PI US 2004001853 A1 20040101  
AI US 2003-365620 20030213  
PRAI US 2002-390564P 20020620 (Provisional)  
US 2002-423578P 20021105 (Provisional)  
FI US 2004001853 20040101  
DT Utility; Patent Application - First Publication  
FS CHEMICAL  
APPLICATION  
OS CA 140:75948  
CLMN 39  
GI 61 Figure(s).

FIG. 1 is a schematic diagram illustrating the structure of the chimeric antigen of the present invention as a monomer, wherein the chimeric antigen has two portions, namely a viral antigen and a xenotypic murine Fc fragment with the hinge region present.

FIG. 1a is a schematic diagram illustrating the structure of the chimeric antigen of FIG. 1 in its normal, assembled state as a dimer.

FIG. 2 is a schematic diagram illustrating the structure of a modified chimeric antigen as a monomer, wherein the chimeric antigen has two portions, namely a modified viral antigen portion which incorporates in the Complementarity Determining Regions (CDR) any viral antigen or antigens, antigenic protein fragments or peptides, or any of these with glycosylation at specific sites, and a xenotypic binding agent, namely a murine Fc fragment with the hinge region present.

FIG. 2a is a schematic diagram illustrating the structure of the modified chimeric antigen of FIG. 2 in its normal, assembled state as a dimer. The abbreviations "Ag1," "Ag2," and "Ag3" represent different viral antigenic peptides or proteins.

FIG. 3 is a schematic diagram illustrating the structure of a modified biotinylated viral protein and a fusion protein of a streptavidin-Fc fragment with the hinge region present.

FIG. 3a is a schematic diagram illustrating the structure of the modified chimeric antigen of FIG. 3 in its normal, assembled state as a dimer.

FIG. 4 is a schematic diagram illustrating a recombinant bacmid.

FIG. 5 is a schematic embodiment of TBD of the present invention.

FIG. 6 shows the nucleotide sequences of the open reading frame encoding the TBD of FIG. 5.

FIG. 7 is a schematic embodiment of an exemplary chimeric antigen of the present invention, suitable for use with an insect cell expression

system.

FIG. 8 shows the nucleotide and deduced amino acid sequences of the chimeric antigen molecule of FIG. 7.

FIG. 9 shows the nucleotide and deduced amino acid sequences of the expressed HBV S1/S2 protein.

FIG. 10 is a schematic embodiment of an exemplary chimeric antigen of the present invention, illustrating an exemplary IRD of the present invention.

FIG. 11 shows the nucleotide and deduced amino acid sequences of the chimeric antigen molecule of FIG. 10.

FIG. 12 shows the nucleotide and deduced amino acid sequences of the expressed HBV S1/S2/S protein.

FIG. 13 is a schematic embodiment of an exemplary chimeric antigen of the present invention, illustrating an exemplary IRD of the present invention.

FIG. 14 shows the nucleotide and deduced amino acid sequences of the chimeric antigen molecule of FIG. 13.

FIG. 15 shows the nucleotide and deduced amino acid sequences of the expressed HBV core protein.

FIG. 16 is a schematic embodiment of an exemplary chimeric antigen of the present invention, illustrating an exemplary IRD of the present invention.

FIG. 17 shows the nucleotide and deduced amino acid sequences of the chimeric antigen molecule of FIG. 16.

FIG. 18 shows the nucleotide and deduced amino acid sequences of the expressed DHBV PreS protein.

FIG. 19 is a schematic embodiment of an exemplary chimeric antigen of the present invention, illustrating an exemplary IRD of the present invention.

FIG. 20 shows the nucleotide and deduced amino acid sequences of the chimeric antigen molecule of FIG. 19.

FIG. 21 shows the nucleotide and deduced amino acid sequences of the expressed DHBV PreS/S protein.

FIG. 22 is a schematic embodiment of an exemplary chimeric antigen of the present invention, illustrating an exemplary IRD of the present invention.

FIG. 23 shows the nucleotide and deduced amino acid sequences of the chimeric antigen molecule of FIG. 22.

FIG. 24 shows the nucleotide and deduced amino acid sequences of the expressed DHBV core protein.

FIG. 25 shows that a chimeric antigen embodiment of the invention can be taken up by dendritic cells.

FIG. 26 shows that dendritic cells uptake a chimeric antigen of the present invention (CS12), as compared to the target binding domain (TBD) alone, or the immune response domain (IRD) alone.

FIG. 27 shows the expression of MHC Class II by dendritic cells.

FIG. 28 shows that a cellular response is generated after contact with dendritic cells activated with a chimeric antigen of the present invention.

FIG. 29 shows T cell stimulation by a chemical conjugate of the present invention.

FIG. 30 shows the time course of expression of antigen binding receptors on maturing dendritic cells.

FIG. 31 shows the time course of expression of various dendritic cells activation markers.

FIG. 32 shows the nucleotide (A) and amino acid (B) sequences of the ORF of TBD protein in the plasmid pFastbachta-tbd.

FIG. 33 shows the nucleotide (A) and amino acid (B) sequences of the ORF of HBV S1/S2-TBD in the plasmid pFastbachta-tbd.

FIG. 34 shows the comparison of binding of HBV S1/S2-TBD, IgG1, and IgG2 over time.

FIG. 35 shows the comparison of HBV S1/S2-TBD, IgG1, and IgG2a binding to maturing dendritic cells on day 1.

FIG. 36 shows the comparison of HBV S1/S2-TBD, IgG1, and IgG2a binding to maturing dendritic cells on day 4.

FIG. 37 shows the comparison of uptake between HBV S1/S2-TBD, IgG1, and IgG2 as a function of concentration.

FIG. 38 shows the correlation of HBV S1/S2-TBD to CD32 and CD206 expression on dendritic cells.

FIG. 39 shows that the binding of HBV S1/S2-TBD to DC32 and DC206 receptors on dendritic cells is abolished by anti-Fc Mab.

FIG. 40 shows that glycosylation of S1/S2 antigen increases the uptake via the CD206 receptor.

FIG. 41 shows intracellular interferon-gamma positive T cells after antigen presentation.

FIG. 42 shows secretion of interferon-gamma after antigen presentation.

FIG. 43 shows intracellular interferon-gamma positive cells as a function of S1/S2-TBD concentration  
 FIG. 44 shows interferon-gamma secretion by T cells as a function of S1/S2-TBD concentration.  
 FIG. 45 shows the effect of glycosylation on intracellular interferon-gamma production in T cells.  
 FIG. 46 shows the effect of glycosylation on interferon-gamma secretion by T cells.  
 FIG. 47 shows the nucleotide (A) and amino acid (B) sequences of the ORF of HCV Core in the plasmid pFastbachta-HCV.  
 FIG. 48 shows the nucleotide (A) and amino acid (B) sequences of the ORF of HCV Core in the plasmid pFastbachta-HCV-TBD.  
 FIG. 49 shows the nucleotide (A) and amino acid (B) sequences of the ORF of HCV Core in the plasmid pFastbachta-HCV-core.  
 FIG. 50 shows the nucleotide (A) and amino acid (B) sequences of the ORF of HCV Core-TBD protein in the plasmid pFastbachta-HCVcore-TBD.  
 FIG. 52 shows the nucleotide (A) and amino acid (B) sequences of the ORF of HCV NS5A in the plasmid pFastbachta-HCV-NS5A.  
 FIG. 52 shows the nucleotide (A) and amino acid (B) sequences of the ORF of HCV NS5A-TBD in the plasmid pFastbachta-HCV-NS5A-TBD  
 FIG. 53 shows the nucleotide (A) and amino acid (B) sequences of the ORF of HCV E1 in the plasmid pFastbachta-HCV-E1.  
 FIG. 54 shows the nucleotide (A) and amino acid (B) sequences of the ORF of HCV E1-TBD in the plasmid pFastbachta-HCV-E1-TBD.  
 FIG. 55 shows the nucleotide (A) and amino acid (B) sequences of the ORF of HCV E2 in the plasmid pFastbachta-HCV-E2.  
 FIG. 56 shows the nucleotide (A) and amino acid (B) sequences of the ORF of HCV E2-TBD in the plasmid pFastbachta-HCV-E2-TBD.  
 FIG. 57 shows the nucleotide (A) and amino acid (B) sequences of the ORF of HCV E1/E2 in the plasmid pFastbachta-HCV-E1/E2.  
 FIG. 58 shows the nucleotide (A) and amino acid (B) sequences of the ORF of HCV E1/E2-TBD in the plasmid pFastbachta-HCV-E1/E2TBD.

L4 ANSWER 2 OF 201 USPATFULL on STN  
 AN 2004:273303 USPATFULL  
 TI Antibodies against PD-1 and uses therefor  
 IN Collins, Mary, Natick, MA, UNITED STATES  
 Wood, Clive R., Boston, MA, UNITED STATES  
 Carreno, Beatriz M., Acton, MA, UNITED STATES  
 Luxenberg, Deborah, Melrose, MA, UNITED STATES  
 Jussif, Jason, Salem, NH, UNITED STATES  
 Carter, Laura L., Medford, MA, UNITED STATES  
 Bennett, Frances K., Sudbury, MA, UNITED STATES  
 Valge-Archer, Viia, Little Abington, UNITED KINGDOM  
 Andrews, John, Little Hadham Ware, UNITED KINGDOM  
 Russell, Caroline, Royston, UNITED KINGDOM  
 PA Wyeth, Madison, NJ, UNITED STATES (U.S. corporation)  
 Cambridge Antibody Technology, Cambridge, UNITED KINGDOM (U.S. corporation)  
 PI US 2004213795 A1 20041028  
 AI US 2003-741481 A1 20031222 (10)  
 PRAI US 2002-435354P 20021223 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 2114  
 INCL INCLM: 424/155.100  
 INCLS: 530/388.800  
 NCL NCLM: 424/155.100  
 NCLS: 530/388.800  
 IC [7]  
 ICM: A61K039-395  
 ICS: C07K016-30  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 3 OF 201 USPATFULL on STN  
 AN 2004:260603 USPATFULL  
 TI Immunocytokine sequences and uses thereof  
 IN Gillies, Stephen D., Carlisle, MA, UNITED STATES  
 Lo, Kin-Ming, Lexington, MA, UNITED STATES  
 PA EMD Lexigen Research Center Corp., Billerica, MA, UNITED STATES (U.S. corporation)  
 PI US 2004203100 A1 20041014  
 AI US 2003-737208 A1 20031216 (10)  
 PRAI US 2002-433945P 20021217 (60)  
 DT Utility  
 FS APPLICATION

LN.CNT 1267  
INCL INCLM: 435/069.100  
INCLS: 435/320.100; 435/326.000; 530/387.100; 536/023.530  
NCL NCLM: 435/069.100  
NCLS: 435/320.100; 435/326.000; 530/387.100; 536/023.530  
IC [7]  
ICM: C07K016-18  
ICS: C07H021-04; C12N005-06  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 4 OF 201 USPATFULL on STN  
AN 2004:203409 USPATFULL  
TI Glycoprotein vi fusion proteins  
IN Burger, Christa, Darmstadt, GERMANY, FEDERAL REPUBLIC OF  
Gleitz, Johannes, Darmstadt, GERMANY, FEDERAL REPUBLIC OF  
Frech, Mathias, Darmstadt, GERMANY, FEDERAL REPUBLIC OF  
PI US 2004157300 A1 20040812  
AI US 2004-483810 A1 20040115 (10)  
WO 2002-EP7796 20020712  
PRAI EP 2001-116717 20010718  
DT Utility  
FS APPLICATION  
LN.CNT 1202  
INCL INCLM: 435/069.700  
INCLS: 435/320.100; 435/328.000; 530/391.100  
NCL NCLM: 435/069.700  
NCLS: 435/320.100; 435/328.000; 530/391.100  
IC [7]  
ICM: C07K016-46  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 5 OF 201 USPATFULL on STN  
AN 2004:177822 USPATFULL  
TI Methods and compositions comprising glycoprotein glycoforms  
IN Raju, T. Shantha, San Mateo, CA, UNITED STATES  
PA Genentech, Inc., South San Francisco, CA (U.S. corporation)  
PI US 2004136986 A1 20040715  
AI US 2003-744844 A1 20031223 (10)  
RLI Continuation of Ser. No. US 1998-183824, filed on 30 Oct 1998, ABANDONED  
PRAI US 1997-63871P 19971031 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 1909  
INCL INCLM: 424/144.100  
NCL NCLM: 424/144.100  
IC [7]  
ICM: A61K039-395  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 6 OF 201 USPATFULL on STN  
AN 2004:158160 USPATFULL  
TI Use of A33 antigens JAM-it  
IN Ashkenazi, Avi, San Mateo, CA, UNITED STATES  
Fong, Sherman, Alameda, CA, UNITED STATES  
Goddard, Audrey, San Francisco, CA, UNITED STATES  
Gurney, Austin L., Belmont, CA, UNITED STATES  
Napier, Mary A., Hillsborough, CA, UNITED STATES  
Tumas, Daniel, Orinda, CA, UNITED STATES  
Lookeren, Menno Van, San Francisco, CA, UNITED STATES  
Wood, William I., Hillsborough, CA, UNITED STATES  
PI US 2004120957 A1 20040624  
AI US 2003-633008 A1 20030731 (10)  
RLI Continuation-in-part of Ser. No. US 2002-265542, filed on 3 Oct 2002,  
PENDING Continuation-in-part of Ser. No. WO 2000-US4414, filed on 22 Feb  
2000, PENDING Continuation-in-part of Ser. No. WO 2000-US14042, filed on  
22 May 2000, PENDING Continuation-in-part of Ser. No. WO 2000-US32678,  
filed on 1 Dec 2000, PENDING Continuation-in-part of Ser. No. US  
1999-254465, filed on 5 Mar 1999, GRANTED, Pat. No. US 6410708  
Continuation-in-part of Ser. No. WO 1999-US5028, filed on 8 Mar 1999,  
PENDING Continuation-in-part of Ser. No. US 1999-380138, filed on 25 Aug  
1999, ABANDONED Continuation-in-part of Ser. No. US 1999-380139, filed  
on 25 Aug 1999, ABANDONED Continuation-in-part of Ser. No. WO  
1998-US19330, filed on 16 Sep 1998, PENDING Continuation-in-part of Ser.  
No. US 2001-953499, filed on 14 Sep 2001, PENDING Continuation of Ser.  
No. WO 1998-US24855, filed on 20 Nov 1998, PENDING  
DT Utility

FS APPLICATION  
LN.CNT 6476  
INCL INCLM: 424/146.100  
NCL NCLM: 424/146.100  
IC [7]  
ICM: A61K039-395

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 7 OF 201 USPATFULL on STN  
AN 2004:152111 USPATFULL  
TI Modulators of P-selectin glycoprotein ligand 1  
IN Lin, Rong-Hwa, Taipei, TAIWAN, PROVINCE OF CHINA  
Chang, Chung Nan, Foster City, CA, UNITED STATES  
PI US 2004116333 A1 20040617  
AI US 2003-662906 A1 20030915 (10)  
RLI Continuation-in-part of Ser. No. US 2002-51497, filed on 18 Jan 2002,  
PENDING  
PRAI US 2001-310196P 20010803 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 1607  
INCL INCLM: 514/008.000  
NCL NCLM: 514/008.000  
IC [7]  
ICM: A61K038-17  
ICS: A61K038-16

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 8 OF 201 USPATFULL on STN  
AN 2004:145259 USPATFULL  
TI Cytokine zalphall ligand  
IN Novak, Julia E., Bainbridge Island, WA, UNITED STATES  
Presnell, Scott R., Tacoma, WA, UNITED STATES  
Sprecher, Cindy A., Seattle, WA, UNITED STATES  
Foster, Donald C., Lake Forest Park, WA, UNITED STATES  
Holly, Richard D., Seattle, WA, UNITED STATES  
Gross, Jane A., Seattle, WA, UNITED STATES  
Johnston, Janet V., Seattle, WA, UNITED STATES  
Nelson, Andrew J., Shoreline, WA, UNITED STATES  
Dillon, Stacey R., Seattle, WA, UNITED STATES  
Hammond, Angela K., Maple Valley, WA, UNITED STATES  
PA ZymoGenetics, Inc. (U.S. corporation)  
PI US 2004110932 A1 20040610  
AI US 2003-659684 A1 20030910 (10)  
RLI Continuation of Ser. No. US 2000-522217, filed on 9 Mar 2000, GRANTED,  
Pat. No. US 6307024  
PRAI US 1999-123547P 19990309 (60)  
US 1999-123904P 19990311 (60)  
US 1999-142013P 19990701 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 8687  
INCL INCLM: 530/388.220  
INCLS: 424/143.100  
NCL NCLM: 530/388.220  
NCLS: 424/143.100  
IC [7]  
ICM: A61K039-395  
ICS: C07K016-28

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 9 OF 201 USPATFULL on STN  
AN 2004:107639 USPATFULL  
TI Artificial proteins with reduced immunogenicity  
IN Gillies, Stephen, Carlisle, MA, UNITED STATES  
Carr, Francis J, Balmedie, UNITED KINGDOM  
Tim, Jones, Babraham, UNITED KINGDOM  
Carter, Graham, By Newmachar, UNITED KINGDOM  
Hamilton, Anita, Aberdeen, UNITED KINGDOM  
Williams, Stephen, Auchleven, Inch, UNITED KINGDOM  
Hanlon, Marian, Cambridge, UNITED KINGDOM  
Watkins, John P, Girton, UNITED KINGDOM  
Baker, Matthew, Littleport, Ely, UNITED KINGDOM  
Way, Jeffrey C, Cambridge, UNITED KINGDOM  
PI US 2004082039 A1 20040429  
AI US 2003-468370 A1 20030819 (10)

WO 2002-EP1690 20020218  
PRAI EP 2001-103955 20010219  
EP 2001-108291 20010405  
DT Utility  
FS APPLICATION  
LN.CNT 6991  
INCL INCLM: 435/069.700  
INCLS: 424/185.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500  
NCL NCLM: 435/069.700  
NCLS: 424/185.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500  
IC [7]  
ICM: C07H021-04  
ICS: C12P021-04; A61K039-00; C07K014-74  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 10 OF 201 USPATFULL on STN  
AN 2004:101671 USPATFULL  
TI Compositions and methods for modulating physiology of epithelial  
junctional adhesion molecules for enhanced mucosal delivery of  
therapeutic compounds  
IN Quay, Steven C., Edmonds, WA, UNITED STATES  
PA Nastech Pharmaceutical Company Inc. (U.S. corporation)  
PI US 2004077540 A1 20040422  
AI US 2003-601953 A1 20030624 (10)  
PRAI US 2002-392512P 20020628 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 13170  
INCL INCLM: 514/012.000  
NCL NCLM: 514/012.000  
IC [7]  
ICM: A61K038-17  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 11 OF 201 USPATFULL on STN  
AN 2004:94846 USPATFULL  
TI Multiple cytokine protein complexes  
IN Gillies, Stephen D., Carlisle, MA, UNITED STATES  
Lo, Kin-Ming, Lexington, MA, UNITED STATES  
PI US 2004072299 A1 20040415  
AI US 2003-603064 A1 20030624 (10)  
RLI Continuation of Ser. No. US 2000-634368, filed on 9 Aug 2000, GRANTED,  
Pat. No. US 6617135  
PRAI US 1999-147924P 19990809 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 2752  
INCL INCLM: 435/069.500  
INCLS: 435/320.100; 435/325.000; 530/351.000; 530/391.100; 536/023.530  
NCL NCLM: 435/069.500  
NCLS: 435/320.100; 435/325.000; 530/351.000; 530/391.100; 536/023.530  
IC [7]  
ICM: C07K016-46  
ICS: C07K014-52  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 12 OF 201 USPATFULL on STN  
AN 2004:89782 USPATFULL  
TI Transgenic ungulates capable of human antibody production  
IN Robl, James M., Brandon, SD, UNITED STATES  
Collas, Philippe, Oslo, NORWAY  
Sullivan, Eddie, Manhattan, KS, UNITED STATES  
Kasinathan, P., Manhattan, KS, UNITED STATES  
Goldsby, Richard A., Leverett, MA, UNITED STATES  
Kuroiwa, Yoshimi, Sionx Falls, JAPAN  
Tomizuka, Kazuma, Takasaki, JAPAN  
Ishida, Isao, Isehara, JAPAN  
PI US 2004068760 A1 20040408  
AI US 2003-441503 A1 20030519 (10)  
RLI Continuation-in-part of Ser. No. US 2001-988115, filed on 16 Nov 2001,  
PENDING Continuation-in-part of Ser. No. US 2000-714185, filed on 17 Nov  
2000, PENDING Continuation-in-part of Ser. No. US 2001-32191, filed on  
21 Dec 2001, PENDING  
PRAI US 2002-381531P 20020517 (60)  
US 2002-425056P 20021108 (60)  
US 2001-311625P 20010809 (60)

US 2000-256458P 20001220 (60)  
US 1999-166410P 19991119 (60)  
US 2000-258151P 20001222 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 8417  
INCL INCLM: 800/006.000  
INCLS: 800/014.000; 800/015.000; 800/016.000; 800/017.000  
NCL NCLM: 800/006.000  
NCLS: 800/014.000; 800/015.000; 800/016.000; 800/017.000  
IC [7]  
ICM: A01K067-027  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 13 OF 201 USPATFULL on STN  
AN 2004:82681 USPATFULL  
TI UMLR polypeptides  
IN Xu, Wenfeng, Mukilteo, WA, UNITED STATES  
Lofton-Day, Catherine E., Brier, WA, UNITED STATES  
Henne, Randal M., Seattle, WA, UNITED STATES  
Presnell, Scott R., Tacoma, WA, UNITED STATES  
Yao, Yue, Kenmore, WA, UNITED STATES  
Novak, Julia E., Bainbridge Island, WA, UNITED STATES  
PA ZymoGenetics, Inc. (U.S. corporation)  
PI US 2004063132 A1 20040401  
AI US 2003-660968 A1 20030912 (10)  
RLI Continuation of Ser. No. US 2000-695369, filed on 23 Oct 2000, ABANDONED  
PRAI US 1999-160880P 19991022 (60)  
US 1999-163215P 19991102 (60)  
US 2000-218769P 20000717 (60)  
US 2000-222221P 20000801 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 5048  
INCL INCLM: 435/006.000  
INCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 530/388.220;  
536/023.500  
NCL NCLM: 435/006.000  
NCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 530/388.220;  
536/023.500  
IC [7]  
ICM: C12Q001-68  
ICS: C07H021-04; C12P021-02; C12N005-06; C07K014-715; C07K016-28  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 14 OF 201 USPATFULL on STN  
AN 2004:70139 USPATFULL  
TI Expression and export of anti-obesity proteins as Fc fusion proteins  
IN Lo, Kin-Ming, Lexington, MA, UNITED STATES  
Zhang, Jinyang, Arlington, MA, UNITED STATES  
Gillies, Stephen D., Carlisle, MA, UNITED STATES  
PA Lexigen Pharmaceuticals Corp., Lexington, MA, UNITED STATES (U.S. corporation)  
PI US 2004053366 A1 20040318  
AI US 2003-419058 A1 20030418 (10)  
RLI Continuation of Ser. No. US 2000-479508, filed on 7 Jan 2000, ABANDONED  
PRAI US 1999-115079P 19990107 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 1851  
INCL INCLM: 435/069.100  
INCLS: 435/320.100; 435/326.000; 530/387.100; 536/023.530  
NCL NCLM: 435/069.100  
NCLS: 435/320.100; 435/326.000; 530/387.100; 536/023.530  
IC [7]  
ICM: C12P021-02  
ICS: C12P021-06; C07H021-04; C12N005-06; C07K016-18  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 15 OF 201 USPATFULL on STN  
AN 2004:69559 USPATFULL  
TI Erbb4 antagonists  
IN Gerritsen, Mary E, San Mateo, CA, UNITED STATES  
Sliwowski, Mark X., San Carlos, CA, UNITED STATES  
PI US 2004052786 A1 20040318  
AI US 2003-362380 A1 20030806 (10)

WO 2001-US26984 20010829  
DT Utility  
FS APPLICATION  
LN.CNT 3313  
INCL INCLM: 424/143.100  
NCL NCLM: 424/143.100  
IC [7]  
ICM: A61K039-395  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 16 OF 201 USPATFULL on STN  
AN 2004:63731 USPATFULL  
TI Novel nucleic acids and secreted polypeptides  
IN Tang, Y. Tom, San Jose, CA, UNITED STATES  
Yang, Yonghong, San Jose, CA, UNITED STATES  
Weng, Gezhi, Piedmont, CA, UNITED STATES  
Zhang, Jie, Campbell, CA, UNITED STATES  
Ren, Feiyan, Cupertino, CA, UNITED STATES  
Xue, Aidong, Sunnyvale, CA, UNITED STATES  
Wang, Jian-Rui, Cupertino, CA, UNITED STATES  
Wehrman, Tom, Stanford, CA, UNITED STATES  
Ghosh, Malabika J., Sunnyvale, CA, UNITED STATES  
Wang, Dunrui, Poway, CA, UNITED STATES  
Zhao, Qing A., San Jose, CA, UNITED STATES  
Wang, Zhiwei, Sunnyvale, CA, UNITED STATES  
PI US 2004048249 A1 20040311  
AI US 2002-112944 A1 20020328 (10)  
RLI Continuation-in-part of Ser. No. US 2000-488725, filed on 21 Jan 2000,  
PENDING Continuation-in-part of Ser. No. US 2000-491404, filed on 25 Jan  
2000, ABANDONED Continuation-in-part of Ser. No. US 2000-496914, filed  
on 3 Feb 2000, ABANDONED Continuation-in-part of Ser. No. US  
2000-515126, filed on 28 Feb 2000, ABANDONED Continuation-in-part of  
Ser. No. US 2000-519705, filed on 7 Mar 2000, ABANDONED  
Continuation-in-part of Ser. No. US 2000-540217, filed on 31 Mar 2000,  
ABANDONED Continuation-in-part of Ser. No. US 2000-552929, filed on 18  
Apr 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-577408,  
filed on 18 May 2000, ABANDONED  
PRAI US 2001-306971P 20010721 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 23809  
INCL INCLM: 435/006.000  
INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 435/455.000;  
530/350.000; 536/023.200  
NCL NCLM: 435/006.000  
NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 435/455.000;  
530/350.000; 536/023.200  
IC [7]  
ICM: C12Q001-68  
ICS: C07H021-04; C12N009-00; C12P021-02; C12N005-06; C07K014-47;  
C12N015-85  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 17 OF 201 USPATFULL on STN  
AN 2004:58174 USPATFULL  
TI Novel nucleic acids and polypeptides  
IN Tang, Y. Tom, San Jose, CA, UNITED STATES  
Liu, Chenghua, San Jose, CA, UNITED STATES  
Asundi, Vinod, Foster City, CA, UNITED STATES  
Wehrman, Tom, Stanford, CA, UNITED STATES  
Ren, Feiyan, Cupertino, CA, UNITED STATES  
Zhou, Ping, Cupertino, CA, UNITED STATES  
Zhao, Qing A., San Jose, CA, UNITED STATES  
Drmanac, Radoje T., Palo Alto, CA, UNITED STATES  
Zhang, Jie, Campbell, CA, UNITED STATES  
Xue, Aidong, Sunnyvale, CA, UNITED STATES  
Wang, Jian-Rui, Cupertino, CA, UNITED STATES  
Wang, Dunrui, Poway, CA, UNITED STATES  
PI US 2004044181 A1 20040304  
AI US 2003-363616 A1 20030715 (10)  
WO 2001-US27093 20010831  
DT Utility  
FS APPLICATION  
LN.CNT 17667  
INCL INCLM: 530/350.000  
INCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.500



NCL NCLM: 530/350.000  
NCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.500  
IC [7]  
ICM: C07K014-705  
ICS: C12P021-02; C12N005-06; C07H021-04  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 18 OF 201 USPATFULL on STN  
AN 2004:57455 USPATFULL  
TI Bifunctional fusion proteins with glucocerebrosidase activity  
IN Schumacher, Silke, Heidelberg, GERMANY, FEDERAL REPUBLIC OF  
Gillies, Stephen, Carlisle, MA, UNITED STATES  
PI US 2004043457 A1 20040304  
AI US 2003-466593 A1 20030717 (10)  
WO 2001-EP15328 20011227  
PRAI EP 2001-101056 20010118  
DT Utility  
FS APPLICATION  
LN.CNT 931  
INCL INCLM: 435/069.700  
INCLS: 530/391.100; 435/326.000; 435/320.100  
NCL NCLM: 435/069.700  
NCLS: 530/391.100; 435/326.000; 435/320.100  
IC [7]  
ICM: C12P021-04  
ICS: C07K016-46; C12N005-06  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 19 OF 201 USPATFULL on STN  
AN 2004:50383 USPATFULL  
TI Compositions and methods for enhanced mucosal delivery of interferon  
beta  
IN Quay, Steven C., Edmonds, WA, UNITED STATES  
Gupta, Malini, Dix Hills, NY, UNITED STATES  
de Meireles, Jorge C., Syosset, NY, UNITED STATES  
Abd El-Shafy, Mohammed, Hauppauge, NY, UNITED STATES  
PA Nastech Pharmaceutical Company Inc. (U.S. corporation)  
PI US 2004037809 A1 20040226  
AI US 2003-462452 A1 20030616 (10)  
PRAI US 2002-393066P 20020628 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 10725  
INCL INCLM: 424/085.600  
NCL NCLM: 424/085.600  
IC [7]  
ICM: A61K038-21  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 20 OF 201 USPATFULL on STN  
AN 2004:44569 USPATFULL  
TI Immunoglobulin DNA cassette molecules, monobody constructs, methods of  
production, and methods of use therefor  
IN O'Keefe, Theresa L., Waltham, MA, UNITED STATES  
Healey, Judith Jacques, Newton, MA, UNITED STATES  
Newman, Walter, Boston, MA, UNITED STATES  
Ponath, Paul D., San Francisco, CA, UNITED STATES  
Keyt, Bruce A., Hillsborough, CA, UNITED STATES  
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)  
PI US 2004033561 A1 20040219  
AI US 2002-272899 A1 20021017 (10)  
PRAI US 2001-350166P 20011019 (60)  
US 2002-392364P 20020626 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 4267  
INCL INCLM: 435/069.100  
INCLS: 435/320.100; 435/326.000; 530/388.100; 536/023.530  
NCL NCLM: 435/069.100  
NCLS: 435/320.100; 435/326.000; 530/388.100; 536/023.530  
IC [7]  
ICM: C07H021-04  
ICS: C12P021-02; C12N005-06; C07K016-00  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 21 OF 201 USPATFULL on STN

AN 2004:38689 USPATFULL  
TI Cytokine receptor  
IN Presnell, Scott R., Tacoma, WA, UNITED STATES  
Xu, Wenfeng, Seattle, WA, UNITED STATES  
Novak, Julia E., Suquamish, WA, UNITED STATES  
Whitmore, Theodore E., Redmond, WA, UNITED STATES  
Grant, Francis J., Seattle, WA, UNITED STATES  
Kindsvogel, Wayne R., Seattle, WA, UNITED STATES  
Klucher, Kevin M., Bellevue, WA, UNITED STATES  
PI US 2004029228 A1 20040212  
AI US 2003-420034 A1 20030418 (10)  
PRAI US 2002-373813P 20020419 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 6929  
INCL INCLM: 435/069.100  
INCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500  
NCL NCLM: 435/069.100  
NCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500  
IC [7]  
ICM: C07K014-705  
ICS: C07H021-04; C12P021-02; C12N005-06  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 22 OF 201 USPATFULL on STN  
AN 2004:38077 USPATFULL  
TI Dopamine agonist formulations for enhanced central nervous system delivery  
IN Quay, Steven C., Edmonds, WA, UNITED STATES  
PA Natestch Pharmaceutical Company Inc, Hauppauge, NY (U.S. corporation)  
PI US 2004028613 A1 20040212  
AI US 2001-891630 A1 20010625 (9)  
DT Utility  
FS APPLICATION  
LN.CNT 8045  
INCL INCLM: 424/045.000  
INCLS: 514/295.000  
NCL NCLM: 424/045.000  
NCLS: 514/295.000  
IC [7]  
ICM: A61K031-473  
ICS: A61L009-04  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 23 OF 201 USPATFULL on STN  
AN 2004:4396 USPATFULL  
TI Muscle cells and their use in cardiac repair  
IN Edge, Albert, Cambridge, MA, United States  
PA Diacrin, Inc., Charlestown, MA, United States (U.S. corporation)  
PI US 6673604 B1 20040106  
AI US 2000-624885 20000724 (9)  
PRAI US 1999-145849P 19990723 (60)  
DT Utility  
FS GRANTED  
LN.CNT 2127  
INCL INCLM: 435/347.000  
INCLS: 435/325.000; 435/371.000  
NCL NCLM: 435/347.000  
NCLS: 435/325.000; 435/371.000  
IC [7]  
ICM: C12N005-06  
ICS: C12N005-08  
EXF 435/325; 435/347; 435/371; 424/93.21

L4 ANSWER 24 OF 201 USPATFULL on STN DUPLICATE 2  
AN 2003:181690 USPATFULL  
TI Novel cytokine zalpall ligand  
IN Novak, Julia E., Bainbridge Island, WA, UNITED STATES  
Presnell, Scott R., Tacoma, WA, UNITED STATES  
Sprecher, Cindy A., Seattle, WA, UNITED STATES  
Foster, Donald C., Lake Forest Park, WA, UNITED STATES  
Holly, Richard D., Seattle, WA, UNITED STATES  
Gross, Jane A., Seattle, WA, UNITED STATES  
Johnston, Janet V., Seattle, WA, UNITED STATES  
Nelson, Andrew J., Shoreline, WA, UNITED STATES  
Dillon, Stacey R., Seattle, WA, UNITED STATES

Hammond, Angela K., Maple Valley, WA, UNITED STATES  
PA ZymoGenetics, Inc. (U.S. corporation)  
PI US 2003125524 A1 20030703  
US 6686178 B2 20040203  
AI US 2002-295723 A1 20021115 (10)  
RLI Division of Ser. No. US 2000-522217, filed on 9 Mar 2000, GRANTED, Pat.  
No. US 6307024  
DT Utility  
FS APPLICATION  
LN.CNT 8817  
INCL INCLM: 530/351.000  
INCLS: 435/069.500; 435/320.100; 435/325.000; 536/023.500  
NCL NCLM: 435/069.520  
NCLS: 424/130.100; 424/143.100; 435/069.100; 435/070.100; 435/320.100;  
435/325.000; 536/023.100; 536/024.100  
IC [7]  
ICM: C07K014-52  
ICS: C07H021-04; C12P021-02; C12N005-06  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 25 OF 201 USPATFULL on STN  
AN 2003:295758 USPATFULL  
TI Transgenic animals for producing specific isotypes of human antibodies  
via non-cognate switch regions  
IN Green, Larry L., San Francisco, CA, UNITED STATES  
Ivanov, Vladimir E., Fremont, CA, UNITED STATES  
Davis, C. Geoffrey, Burlingame, CA, UNITED STATES  
PA Abgenix, Inc. (U.S. corporation)  
PI US 2003208781 A1 20031106  
AI US 2003-349706 A1 20030121 (10)  
RLI Continuation of Ser. No. US 1999-329582, filed on 10 Jun 1999, PENDING  
DT Utility  
FS APPLICATION  
LN.CNT 3588  
INCL INCLM: 800/006.000  
INCLS: 800/018.000; 435/354.000; 536/023.530  
NCL NCLM: 800/006.000  
NCLS: 800/018.000; 435/354.000; 536/023.530  
IC [7]  
ICM: A01K067-027  
ICS: C07H021-04; C12N005-06  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 26 OF 201 USPATFULL on STN  
AN 2003:283079 USPATFULL  
TI ICAM-related protein  
IN Gallatin, W. Michael, Mercer Island, WA, UNITED STATES  
Vazeux, Rosemay, Seattle, WA, UNITED STATES  
PI US 2003199423 A1 20031023  
AI US 2002-163942 A1 20020605 (10)  
RLI Continuation of Ser. No. US 2001-753436, filed on 3 Jan 2001, ABANDONED  
Continuation of Ser. No. US 1999-382289, filed on 24 Aug 1999, ABANDONED  
Continuation-in-part of Ser. No. US 1995-487113, filed on 7 Jun 1995,  
GRANTED, Pat. No. US 5837822 Continuation-in-part of Ser. No. US  
1993-102852, filed on 5 Aug 1993, ABANDONED Continuation-in-part of Ser.  
No. US 1993-9266, filed on 22 Jan 1993, ABANDONED Continuation-in-part  
of Ser. No. WO 1993-US787, filed on 26 Jan 1993, PENDING  
Continuation-in-part of Ser. No. US 1992-894061, filed on 5 Jun 1992,  
ABANDONED Continuation-in-part of Ser. No. US 1992-889724, filed on 26  
May 1992, ABANDONED Continuation-in-part of Ser. No. US 1992-827689,  
filed on 27 Jan 1992, ABANDONED  
DT Utility  
FS APPLICATION  
LN.CNT 7097  
INCL INCLM: 514/001.000  
INCLS: 530/388.260; 435/007.900; 435/338.000  
NCL NCLM: 514/001.000  
NCLS: 530/388.260; 435/007.900; 435/338.000  
IC [7]  
ICM: A61K031-00  
ICS: G01N033-53; G01N033-542; C07K016-40  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 27 OF 201 USPATFULL on STN  
AN 2003:271148 USPATFULL  
TI Directed switch-mediated DNA recombination

IN Jakobovits, Aya, Menlo Park, CA, UNITED STATES  
Gallo, Michael Lajos, San Jose, CA, UNITED STATES  
Yang, Xiao-Ping, Foster City, CA, UNITED STATES  
PI US 2003190751 A1 20031009  
AI US 2002-115668 A1 20020403 (10)  
RLI Continuation of Ser. No. US 1999-369635, filed on 6 Aug 1999, GRANTED,  
Pat. No. US 6395515 Continuation of Ser. No. US 1997-878166, filed on 17  
Jun 1997, GRANTED, Pat. No. US 5985615 Continuation of Ser. No. US  
1996-619109, filed on 20 Mar 1996, GRANTED, Pat. No. US 5714352  
DT Utility  
FS APPLICATION  
LN.CNT 1423  
INCL INCLM: 435/455.000  
INCLS: 435/069.100; 435/320.100; 435/326.000  
NCL NCLM: 435/455.000  
NCLS: 435/069.100; 435/320.100; 435/326.000  
IC [7]  
ICM: C12P021-02  
ICS: C12N005-06; C12N015-85  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 28 OF 201 USPATFULL on STN  
AN 2003:257784 USPATFULL  
TI In vitro modification of glycosylation patterns of recombinant  
glycopeptides  
IN Bayer, Robert J., San Diego, CA, UNITED STATES  
PA Neose Technologies, Inc., Horsham, PA (U.S. corporation)  
PI US 2003180835 A1 20030925  
AI US 2003-391035 A1 20030317 (10)  
RLI Continuation of Ser. No. US 2001-855320, filed on 14 May 2001, PENDING  
PRAI US 2000-203851P 20000512 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 2077  
INCL INCLM: 435/068.100  
INCLS: 530/395.000; 435/193.000  
NCL NCLM: 435/068.100  
NCLS: 530/395.000; 435/193.000  
IC [7]  
ICM: C12P021-06  
ICS: C12N009-10; C07K014-00  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 29 OF 201 USPATFULL on STN  
AN 2003:250484 USPATFULL  
TI Humanized antibodies to human gp39, compositions containing and  
therapeutic use thereof  
IN Black, Amelia, Cardiff, CA, UNITED STATES  
Hanna, Nabil, Olivenhian, CA, UNITED STATES  
Padlan, Eduardo A., Kensington, MD, UNITED STATES  
Newman, Roland L., San Diego, CA, UNITED STATES  
PA IDEC PHARMACEUTICALS CORPORATION (U.S. corporation)  
PI US 2003175269 A1 20030918  
AI US 2002-171680 A1 20020617 (10)  
RLI Continuation of Ser. No. US 1999-332595, filed on 14 Jun 1999, GRANTED,  
Pat. No. US 6506383  
DT Utility  
FS APPLICATION  
LN.CNT 2229  
INCL INCLM: 424/141.100  
INCLS: 530/388.150; 435/007.210  
NCL NCLM: 424/141.100  
NCLS: 530/388.150; 435/007.210  
IC [7]  
ICM: A61K039-395  
ICS: C07K016-44; G01N033-567  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 30 OF 201 USPATFULL on STN  
AN 2003:245990 USPATFULL  
TI Method of producing single chain protein in plant cells  
IN Hein, Mich B., Fallbrook, CA, UNITED STATES  
Hiatt, Andrew, San Diego, CA, UNITED STATES  
PA The Scripps Research Institute (U.S. corporation)  
PI US 2003172407 A1 20030911  
AI US 2003-374603 A1 20030227 (10)

RLI Continuation of Ser. No. US 1998-200657, filed on 25 Nov 1998, PENDING  
Continuation of Ser. No. US 1996-642406, filed on 3 May 1996, GRANTED,  
Pat. No. US 5959177 Continuation-in-part of Ser. No. US 1992-971951,  
filed on 5 Nov 1992, GRANTED, Pat. No. US 5639947 Continuation of Ser.  
No. US 1990-591823, filed on 2 Oct 1990, GRANTED, Pat. No. US 5202422  
Continuation-in-part of Ser. No. US 1989-427765, filed on 27 Oct 1989,  
ABANDONED  
DT Utility  
FS APPLICATION  
LN.CNT 4699  
INCL INCLM: 800/288.000  
INCLS: 530/387.100  
NCL NCLM: 800/288.000  
NCLS: 530/387.100  
IC [7]  
ICM: A01H001-00  
ICS: C12N015-82; C07K016-00  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 31 OF 201 USPATFULL on STN  
AN 2003:244866 USPATFULL  
TI Compositions and methods for modulation of immune responses  
IN Soderstrom, Karl Petter, San Francisco, CA, UNITED STATES  
PI US 2003171280 A1 20030911  
AI US 2002-210148 A1 20020731 (10)  
PRAI US 2001-308598P 20010731 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 4601  
INCL INCLM: 514/012.000  
INCLS: 530/327.000  
NCL NCLM: 514/012.000  
NCLS: 530/327.000  
IC [7]  
ICM: A61K038-17  
ICS: C07K007-06  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 32 OF 201 USPATFULL on STN  
AN 2003:244864 USPATFULL  
TI Compounds that bind HER2  
IN Dennis, Mark S., San Carlos, CA, UNITED STATES  
PA GENENTECH, INC. (U.S. corporation)  
PI US 2003171278 A1 20030911  
AI US 2002-196394 A1 20020715 (10)  
RLI Continuation of Ser. No. US 2000-609721, filed on 30 Jun 2000, ABANDONED  
PRAI US 1999-142232P 19990702 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 3598  
INCL INCLM: 514/012.000  
INCLS: 514/013.000; 514/014.000; 514/015.000; 530/324.000; 530/325.000;  
530/326.000; 530/327.000; 530/328.000  
NCL NCLM: 514/012.000  
NCLS: 514/013.000; 514/014.000; 514/015.000; 530/324.000; 530/325.000;  
530/326.000; 530/327.000; 530/328.000  
IC [7]  
ICM: A61K038-10  
ICS: A61K038-08; C07K007-08; C07K007-06  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 33 OF 201 USPATFULL on STN  
AN 2003:243824 USPATFULL  
TI Treating Autoimmune Diseases with Humanized Anti-CD40L Antibody  
IN Black, Amelia, Los Getos, CA, UNITED STATES  
Hanna, Nabil, Rancho Santa Fee, CA, UNITED STATES  
Padlan, Eduardo A., Kensington, MD, UNITED STATES  
Newman, Roland A., San Diego, CA, UNITED STATES  
PA IDEC PHARMACEUTICALS CORPORATION (U.S. corporation)  
PI US 2003170233 A1 20030911  
AI US 2002-171681 A1 20020617 (10)  
RLI Continuation of Ser. No. US 1999-332595, filed on 14 Jun 1999, GRANTED,  
Pat. No. US 6506383 Division of Ser. No. US 1995-554840, filed on 7 Nov  
1995, GRANTED, Pat. No. US 6001358  
DT Utility  
FS APPLICATION

LN.CNT 2281  
INCL INCLM: 424/141.100  
INCLS: 530/388.150  
NCL NCLM: 424/141.100  
NCLS: 530/388.150  
IC [7]  
ICM: A61K039-395  
ICS: C07K016-42

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 34 OF 201 USPATFULL on STN  
AN 2003:239374 USPATFULL  
TI Method of producing heteromultimeric mammalian proteins in plants  
IN Hein, Mich B., Fallbrook, CA, UNITED STATES  
Hiatt, Andrew, San Diego, CA, UNITED STATES  
PA The Scripps Research Institute (U.S. corporation)  
PI US 2003167534 A1 20030904  
AI US 2003-372614 A1 20030225 (10)  
RLI Continuation of Ser. No. US 1998-200657, filed on 25 Nov 1998, PENDING  
Continuation of Ser. No. US 1996-642406, filed on 3 May 1996, GRANTED,  
Pat. No. US 5959177 Continuation-in-part of Ser. No. US 1992-971951,  
filed on 5 Nov 1992, GRANTED, Pat. No. US 5639947 Continuation of Ser.  
No. US 1990-591823, filed on 2 Oct 1990, GRANTED, Pat. No. US 5202422  
Continuation-in-part of Ser. No. US 1989-427765, filed on 27 Oct 1989,  
ABANDONED  
DT Utility  
FS APPLICATION  
LN.CNT 4695  
INCL INCLM: 800/288.000  
NCL NCLM: 800/288.000  
IC [7]  
ICM: A01H001-00  
ICS: C12N015-82

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 35 OF 201 USPATFULL on STN  
AN 2003:201379 USPATFULL  
TI Expression and export of angiogenesis inhibitors as immunofusins  
IN Lo, Kin-Ming, Lexington, MA, UNITED STATES  
Li, Yue, Bedford, MA, UNITED STATES  
Gillies, Stephen D., Carlisle, MA, UNITED STATES  
PI US 2003139365 A1 20030724  
AI US 2002-292418 A1 20021112 (10)  
RLI Continuation of Ser. No. US 1999-383315, filed on 25 Aug 1999, ABANDONED  
PRAI US 1998-97883P 19980825 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 2327  
INCL INCLM: 514/044.000  
INCLS: 514/012.000; 435/069.700; 435/320.100; 435/325.000; 530/350.000;  
536/023.200  
NCL NCLM: 514/044.000  
NCLS: 514/012.000; 435/069.700; 435/320.100; 435/325.000; 530/350.000;  
536/023.200  
IC [7]  
ICM: A61K048-00  
ICS: C07K014-47; C12P021-02; C12N005-06; A61K038-17

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 36 OF 201 USPATFULL on STN  
AN 2003:194129 USPATFULL  
TI Binding domain-immunoglobulin fusion proteins  
IN Ledbetter, Jeffrey A., Shoreline, WA, UNITED STATES  
Hayden-Ledbetter, Martha S., Shoreline, WA, UNITED STATES  
PA Genecraft, Inc., Shoreline, WA, UNITED STATES, 98177 (U.S. corporation)  
PI US 2003133939 A1 20030717  
AI US 2002-53530 A1 20020117 (10)  
DT Utility  
FS APPLICATION  
LN.CNT 4040  
INCL INCLM: 424/178.100  
INCLS: 435/069.100; 435/320.100; 530/391.100; 435/344.000; 536/023.530  
NCL NCLM: 424/178.100  
NCLS: 435/069.100; 435/320.100; 530/391.100; 435/344.000; 536/023.530  
IC [7]  
ICM: A61K039-395

ICS: C07H021-04; C07K016-46; C12N005-06  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 37 OF 201 USPATFULL on STN  
AN 2003:172748 USPATFULL  
TI Binding domain-immunoglobulin fusion proteins  
IN Ledbetter, Jeffrey A., Shoreline, WA, UNITED STATES  
Hayden-Ledbetter, Martha S., Shoreline, WA, UNITED STATES  
Thompson, Peter A., Danville, CA, UNITED STATES  
PA Genecraft, Inc., Shoreline, WA (U.S. corporation)  
PI US 2003118592 A1 20030626  
AI US 2002-207655 A1 20020725 (10)  
RLI Continuation-in-part of Ser. No. US 2002-53530, filed on 17 Jan 2002,  
PENDING  
PRAI US 2001-367358P 20010117 (60)  
US 2002-385691P 20020603 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 7939  
INCL INCLM: 424/178.100  
INCLS: 530/391.100  
NCL NCLM: 424/178.100  
NCLS: 530/391.100  
IC [7]  
ICM: A61K039-395  
ICS: C07K016-46

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 38 OF 201 USPATFULL on STN  
AN 2003:165447 USPATFULL  
TI Muscle cells and their use in cardiac repair  
IN Edge, Albert, Cambridge, MA, UNITED STATES  
Dinsmore, Jonathan, Brookline, MA, UNITED STATES  
PI US 2003113301 A1 20030619  
AI US 2002-105035 A1 20020321 (10)  
RLI Continuation-in-part of Ser. No. US 2000-624885, filed on 24 Jul 2000,  
PENDING  
PRAI US 1999-145849P 19990723 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 3064  
INCL INCLM: 424/093.210  
INCLS: 424/093.700  
NCL NCLM: 424/093.210  
NCLS: 424/093.700  
IC [7]  
ICM: A61K048-00

L4 ANSWER 39 OF 201 USPATFULL on STN  
AN 2003:145864 USPATFULL  
TI Human cytokine receptor  
IN Presnell, Scott R., Tacoma, WA, UNITED STATES  
Xu, Wenfeng, Mukilteo, WA, UNITED STATES  
Kindsvogel, Wayne, Seattle, WA, UNITED STATES  
Chen, Zhi, Bellevue, WA, UNITED STATES  
Hughes, Steven D., Seattle, WA, UNITED STATES  
PI US 2003099608 A1 20030529  
AI US 2002-104919 A1 20020322 (10)  
PRAI US 2001-279222P 20010327 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 9645  
INCL INCLM: 424/085.100  
INCLS: 435/069.500; 435/320.100; 435/325.000; 530/351.000; 536/023.500  
NCL NCLM: 424/085.100  
NCLS: 435/069.500; 435/320.100; 435/325.000; 530/351.000; 536/023.500  
IC [7]  
ICM: A61K038-19  
ICS: C07K014-52; C07H021-04; C12P021-02; C12N005-06  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 40 OF 201 USPATFULL on STN  
AN 2003:135731 USPATFULL  
TI Transgenic animals for producing specific isotypes of human antibodies  
via non-cognate switch regions  
IN Green, Larry L., San Francisco, CA, UNITED STATES

Ivanov, Vladimir E., Fremont, CA, UNITED STATES  
Davis, C. Geoffrey, Burlingame, CA, UNITED STATES  
PI US 2003093820 A1 20030515  
AI US 2001-999321 A1 20011130 (9)  
PRAI WO 2000-US15782 20000608  
DT Utility  
FS APPLICATION  
LN.CNT 3765  
INCL INCLM: 800/008.000  
INCLS: 435/069.100; 435/326.000; 435/320.100; 536/023.530  
NCL NCLM: 800/008.000  
NCLS: 435/069.100; 435/326.000; 435/320.100; 536/023.530  
IC [7]  
ICM: A01K067-00  
ICS: C07H021-04; C12N005-06  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 41 OF 201 USPATFULL on STN  
AN 2003:119705 USPATFULL  
TI Fusion molecules and treatment of IgE-mediated allergic diseases  
IN Saxon, Andrew, Santa Monica, CA, UNITED STATES  
Zhang, Ke, Los Angeles, CA, UNITED STATES  
Zhu, Daocheng, Los Angeles, CA, UNITED STATES  
PI US 2003082190 A1 20030501  
AI US 2001-847208 A1 20010501 (9)  
DT Utility  
FS APPLICATION  
LN.CNT 7500  
INCL INCLM: 424/178.100  
INCLS: 530/391.100; 435/069.700; 435/320.100; 435/334.000; 536/023.530  
NCL NCLM: 424/178.100  
NCLS: 530/391.100; 435/069.700; 435/320.100; 435/334.000; 536/023.530  
IC [7]  
ICM: A61K039-395  
ICS: C07H021-04; C12P021-02; C12N005-06; C07K016-28  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 42 OF 201 USPATFULL on STN  
AN 2003:112973 USPATFULL  
TI Mouse cytokine receptor  
IN Presnell, Scott R., Tacoma, WA, UNITED STATES  
Xu, Wenfeng, Mukilteo, WA, UNITED STATES  
Kindsvogel, Wayne, Seattle, WA, UNITED STATES  
Chen, Zhi, Bellevue, WA, UNITED STATES  
PI US 2003077706 A1 20030424  
AI US 2002-90365 A1 20020304 (10)  
PRAI US 2001-273035P 20010302 (60)  
US 2001-279232P 20010327 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 7834  
INCL INCLM: 435/069.100  
INCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500; 435/006.000  
NCL NCLM: 435/069.100  
NCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500; 435/006.000  
IC [7]  
ICM: A61K038-17  
ICS: C07K014-715; C12Q001-68; C07H021-04; C12P021-02; C12N005-06  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 43 OF 201 USPATFULL on STN  
AN 2003:112545 USPATFULL  
TI Recombinant anti-CD4 antibodies for human therapy  
IN Hanna, Nabil, Olivenhain, CA, UNITED STATES  
Newman, Roland Anthony, San Diego, CA, UNITED STATES  
Reff, Mitchell Elliot, San Diego, CA, UNITED STATES  
PA IDEC Pharmaceuticals Corporation (U.S. corporation)  
PI US 2003077275 A1 20030424  
AI US 2002-211357 A1 20020805 (10)  
RLI Division of Ser. No. US 2000-612914, filed on 10 Jul 2000, PENDING  
Continuation of Ser. No. US 1995-523894, filed on 6 Sep 1995, GRANTED,  
Pat. No. US 6136310 Continuation of Ser. No. US 1995-476237, filed on 7  
Jun 1995, GRANTED, Pat. No. US 5756096 Continuation-in-part of Ser. No.  
US 1995-379072, filed on 25 Jan 1995, GRANTED, Pat. No. US 5658570  
Continuation of Ser. No. US 1992-912292, filed on 10 Jul 1992, ABANDONED  
Continuation-in-part of Ser. No. US 1992-856281, filed on 23 Mar 1992,



ABANDONED

DT Utility  
FS APPLICATION  
LN.CNT 3560  
INCL INCLM: 424/133.100  
INCLS: 530/387.300; 536/023.530; 435/327.000; 435/363.000; 435/320.100;  
435/069.100  
NCL NCLM: 424/133.100  
NCLS: 530/387.300; 536/023.530; 435/327.000; 435/363.000; 435/320.100;  
435/069.100

IC [7]  
ICM: A61K039-395  
ICS: C07H021-04; C12P021-02; C12N005-06  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 44 OF 201 USPATFULL on STN  
AN 2003:92706 USPATFULL  
TI Fusion molecules and methods for treatment of immune diseases  
IN Saxon, Andrew, Santa Monica, CA, UNITED STATES  
PI US 2003064063 A1 20030403  
AI US 2001-439 A1 20011024 (10)  
RLI continuation-in-part of Ser. No. US 2001-847208, filed on 1 May 2001,  
PENDING

DT Utility  
FS APPLICATION  
LN.CNT 4242  
INCL INCLM: 424/131.100  
INCLS: 530/387.200; 435/069.700; 435/327.000; 435/320.100; 536/023.530  
NCL NCLM: 424/131.100  
NCLS: 530/387.200; 435/069.700; 435/327.000; 435/320.100; 536/023.530  
IC [7]  
ICM: A61K039-395  
ICS: C07H021-04; C12P021-02; C12N005-06; C07K016-42  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 45 OF 201 USPATFULL on STN  
AN 2003:86229 USPATFULL  
TI Methods to generate and identify monoclonal antibodies to a large number  
of human antigens  
IN Chang, Nancy T., Houston, TX, UNITED STATES  
PI US 2003059834 A1 20030327  
AI US 2002-61910 A1 20020201 (10)  
PRAI US 2001-265701P 20010201 (60)

DT Utility  
FS APPLICATION  
LN.CNT 502  
INCL INCLM: 435/007.100  
INCLS: 435/069.100; 435/070.210; 435/320.100; 530/388.100  
NCL NCLM: 435/007.100  
NCLS: 435/069.100; 435/070.210; 435/320.100; 530/388.100  
IC [7]  
ICM: G01N033-53  
ICS: C12P021-04; C07K016-00  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 46 OF 201 USPATFULL on STN  
AN 2003:70942 USPATFULL  
TI Enhancement of antibody-cytokine fusion protein mediated immune  
responses by combined treatment with immunocytokine uptake enhancing  
agents  
IN Gillies, Stephen D., Carlisle, MA, UNITED STATES  
Lan, Yan, Belmont, MA, UNITED STATES  
Holden, Sylvia, Woburn, MA, UNITED STATES  
PI US 2003049227 A1 20030313  
AI US 2001-896909 A1 20010629 (9)  
PRAI US 2000-215038P 20000629 (60)

DT Utility  
FS APPLICATION  
LN.CNT 1559  
INCL INCLM: 424/085.100  
INCLS: 424/178.100; 530/351.000  
NCL NCLM: 424/085.100  
NCLS: 424/178.100; 530/351.000  
IC [7]  
ICM: A61K039-395

ICS: A61K038-19; C07K016-46  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 47 OF 201 USPATFULL on STN  
AN 2003:57473 USPATFULL  
TI In vitro modification of glycosylation patterns of recombinant  
glycopeptides  
IN Bayer, Robert J., San Diego, CA, UNITED STATES  
PA Neose Technologies, Inc., Horsham, PA, UNITED STATES (U.S. corporation)  
PI US 2003040037 A1 20030227  
AI US 2002-219197 A1 20020813 (10)  
RLI Continuation of Ser. No. US 2001-855320, filed on 14 May 2001, PENDING  
PRAI WO 2001-US15693 20010514  
US 2000-203851P 20000512 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 2071  
INCL INCLM: 435/068.100  
INCLS: 435/069.100; 435/193.000; 435/252.300  
NCL NCLM: 435/068.100  
NCLS: 435/069.100; 435/193.000; 435/252.300  
IC [7]  
ICM: C12P021-06  
ICS: C12N009-10; C12N001-21  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 48 OF 201 USPATFULL on STN  
AN 2003:52386 USPATFULL  
TI Expression of xenogenous (human) immunoglobulins in cloned, transgenic  
ungulates  
IN Robl, James M., Belchertown, MA, UNITED STATES  
Goldsby, Richard A., Leverett, MA, UNITED STATES  
Ferguson, Stacy E., Worcester, MA, UNITED STATES  
Kuroiwa, Yoshimi, Takasaki, JAPAN  
Tomizuka, Kazuma, Takasaki, JAPAN  
Ishida, Isao, Isehara, JAPAN  
PI US 2003037347 A1 20030220  
AI US 2001-988115 A1 20011116 (9)  
RLI Continuation-in-part of Ser. No. US 2000-714185, filed on 17 Nov 2000,  
PENDING  
PRAI US 2001-311625P 20010809 (60)  
US 2000-256458P 20001220 (60)  
US 1999-166410P 19991119 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 3863  
INCL INCLM: 800/006.000  
INCLS: 800/015.000; 800/014.000; 800/016.000; 800/017.000; 435/326.000  
NCL NCLM: 800/006.000  
NCLS: 800/015.000; 800/014.000; 800/016.000; 800/017.000; 435/326.000  
IC [7]  
ICM: A01K067-027  
ICS: C12N005-06  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 49 OF 201 USPATFULL on STN  
AN 2003:39264 USPATFULL  
TI METHOD OF USE OF TRANSGENIC PLANT EXPRESSED ANTIBODIES  
IN Hein, Mich B., Fallbrook, CA, UNITED STATES  
Hiatt, Andrew, San Diego, CA, UNITED STATES  
Ma, Julian K-C, London, UNITED KINGDOM  
PI US 2003028913 A1 20030206  
AI US 2000-491322 A1 20000125 (9)  
RLI Division of Ser. No. US 1998-200657, filed on 25 Nov 1998, PENDING  
Continuation of Ser. No. US 1996-642406, filed on 3 May 1996, GRANTED,  
Pat. No. US 5959177 Continuation of Ser. No. US 1992-971951, filed on 5  
Nov 1992, GRANTED, Pat. No. US 5639947 Continuation of Ser. No. US  
1990-591823, filed on 2 Oct 1990, GRANTED, Pat. No. US 5202422  
Continuation-in-part of Ser. No. US 1989-427765, filed on 27 Oct 1989,  
ABANDONED  
DT Utility  
FS APPLICATION  
LN.CNT 4767  
INCL INCLM: 800/278.000  
NCL NCLM: 800/278.000  
IC [7]

ICM: C12N015-87

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 50 OF 201 USPATFULL on STN  
AN 2003:37608 USPATFULL  
TI Cytokine receptor zcytor19  
IN Presnell, Scott R., Tacoma, WA, UNITED STATES  
Xu, Wenfeng, Mukilteo, WA, UNITED STATES  
Novak, Julia E., Bainbridge Island, WA, UNITED STATES  
Whitmore, Theodore E., Redmond, WA, UNITED STATES  
Grant, Francis J., Seattle, WA, UNITED STATES  
PI US 2003027253 A1 20030206  
AI US 2001-995898 A1 20011128 (9)  
PRAI US 2000-253561P 20001128 (60)  
US 2001-267211P 20010207 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 7156  
INCL INCLM: 435/069.100  
INCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500; 435/006.000  
NCL NCLM: 435/069.100  
NCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500; 435/006.000  
IC [7]  
ICM: C12Q001-68  
ICS: C07H021-04; C07K014-715; C12P021-02; C12N005-06  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 51 OF 201 USPATFULL on STN  
AN 2003:17032 USPATFULL  
TI Non-agonistic antibodies to human gp39, compositions containing, and  
therapeutic use thereof  
IN Darrell, Anderson, Escondido, CA, UNITED STATES  
Pan, Li-Zhen, San Diego, CA, UNITED STATES  
Hanna, Nabil, Rancho Santa Fe, CA, UNITED STATES  
Rastetter, William H., Rancho Santa Fe, CA, UNITED STATES  
Kloetzer, William S., Carlsbad, CA, UNITED STATES  
PI US 2003012781 A1 20030116  
AI US 2001-874141 A1 20010606 (9)  
PRAI US 2000-209584P 20000606 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 2456  
INCL INCLM: 424/131.100  
INCLS: 424/093.210  
NCL NCLM: 424/131.100  
NCLS: 424/093.210  
IC [7]  
ICM: A61K048-00  
ICS: A61K039-395  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 52 OF 201 USPATFULL on STN  
AN 2003:3494 USPATFULL  
TI Vitro modification of glycosylation patterns of recombinant  
glycopeptides  
IN Bayer, Robert J., San Diego, CA, UNITED STATES  
PA Neose Technologies, Inc., Horsham, PA, UNITED STATES (U.S. corporation)  
PI US 2003003529 A1 20030102  
AI US 2002-198806 A1 20020719 (10)  
RLI Division of Ser. No. US 2001-855320, filed on 14 May 2001, PENDING  
PRAI WO 2001-US15693 20010514  
US 2000-203851P 20000512 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 2076  
INCL INCLM: 435/068.100  
INCLS: 435/069.100; 435/193.000; 530/322.000  
NCL NCLM: 435/068.100  
NCLS: 435/069.100; 435/193.000; 530/322.000  
IC [7]  
ICM: C12P021-06  
ICS: C12N009-10; C07K009-00  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 53 OF 201 USPATFULL on STN  
AN 2003:240319 USPATFULL

TI Multiple cytokine protein complexes  
 IN Gillies, Stephen D., Carlisle, MA, United States  
 Lo, Kin-Ming, Lexington, MA, United States  
 PA EMD Lexigen Research Center Corp., Billerica, MA, United States (U.S. corporation)  
 PI US 6617135 B1 20030909  
 AI US 2000-634368 20000809 (9)  
 PRAI US 1999-147924P 19990809 (60)  
 DT Utility  
 FS GRANTED  
 LN.CNT 3036  
 INCL INCLM: 435/069.700  
 INCLS: 435/252.300; 435/254.110; 435/320.100; 435/325.000; 435/069.520; 530/350.000; 530/387.300; 530/402.000  
 NCL NCLM: 435/069.700  
 NCLS: 435/069.520; 435/252.300; 435/254.110; 435/320.100; 435/325.000; 530/350.000; 530/387.300; 530/402.000  
 IC [7]  
 ICM: C12N015-62  
 ICS: C12N015-63; C07K014-54  
 EXF 424/134.1; 424/185.1; 424/192.1; 435/69.7; 435/69.1; 435/252.3; 435/254.11; 435/320.1; 435/325; 435/69.52; 530/387.3; 530/350; 530/387.1; 530/402; 536/23.4  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 54 OF 201 USPATFULL on STN  
 AN 2003:13072 USPATFULL  
 TI Methods of suppressing immune responses to transplanted tissues and organs with gp39-specific antibodies  
 IN Black, Amelia, Cardiff, CA, United States  
 Hanna, Nabil, Olivenhian, CA, United States  
 Padlan, Eduardo A., Kensington, MD, United States  
 Newman, Roland A., San Diego, CA, United States  
 PA IDEC Pharmaceuticals Corporation, San Diego, CA, United States (U.S. corporation)  
 PI US 6506383 B1 20030114  
 AI US 1999-332595 19990614 (9)  
 RLI Division of Ser. No. US 1995-554840, filed on 7 Nov 1995, now patented, Pat. No. US 6001358  
 DT Utility  
 FS GRANTED  
 LN.CNT 2606  
 INCL INCLM: 424/154.100  
 INCLS: 424/130.100; 424/133.100; 424/141.100; 424/143.100; 424/144.100; 424/153.100; 424/173.100; 530/387.100; 530/387.300; 530/388.100; 530/388.200; 530/388.220; 530/388.700; 530/388.730; 530/388.750  
 NCL NCLM: 424/154.100  
 NCLS: 424/130.100; 424/133.100; 424/141.100; 424/143.100; 424/144.100; 424/153.100; 424/173.100; 530/387.100; 530/387.300; 530/388.100; 530/388.200; 530/388.220; 530/388.700; 530/388.730; 530/388.750  
 IC [7]  
 ICM: A61K039-395  
 ICS: C07K016-28  
 EXF 424/130.1; 424/133.1; 424/144.1; 424/173.1; 530/387.1; 530/388.2; 530/388.73  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 55 OF 201 BIOTECHDS COPYRIGHT 2004 THE THOMSON CORP. on STN  
 DUPLICATE 3  
 AN 2003-02087 BIOTECHDS  
 TI Novel therapeutic agent useful for treating an amyloidogenic disorder, e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
 \*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked to a peptide capable of binding amyloidogenic protein;  
 vector-mediated gene transfer, expression in host cell for recombinant protein production and disease therapy  
 AU GEFTER M L; ISRAEL D I; JOYAL J L; GOSSELIN M  
 PA PRAECIS PHARM INC  
 PI WO 2002042462 30 May 2002  
 AI WO 2001-US44581 27 Nov 2001  
 PRAI US 2000-257186 20 Dec 2000; US 2000-253302 27 Nov 2000  
 DT Patent  
 LA English  
 OS WPI: 2002-636427 [68]

L4 ANSWER 56 OF 201 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 4

AN 10189297 IFIPAT;IFIUDB;IFICDB  
 TI THERAPEUTIC AGENTS AND METHODS OF USE THEREOF FOR TREATING AN  
 AMYLOIDOGENIC DISEASE; COMPOUND FOR USE IN THE TREATMENT OF ALZHEIMER'S  
 AND CREUZFELDT-JACOB DISEASES  
 IN Gefter Malcolm L; Gosselin Michael; Israel David I; Joyal John L  
 PA Praecis Pharmaceuticals Inc (46269)  
 PI US 2002133001 A1 20020919  
 AI US 2001-996357 20011127  
 PRAI US 2000-250198P 20001129 (Provisional)  
 US 2000-253302P 20001127 (Provisional)  
 US 2000-257186P 20001220 (Provisional)  
 FI US 2002133001 20020919  
 DT Utility; Patent Application - First Publication  
 FS CHEMICAL  
 APPLICATION  
 CLMN 78  
 GI 13 Figure(s).  
 FIG. 1 depicts a Western blot analysis of COS cell lysates and medium  
 harvested from COS cells expressing the Fc region of mouse IgG1 fused to  
 amino acid residues 1-40, 1-42, 10-25, 1630, 17-21, or 17-21 (A21L) of  
 P-amyloid with or without an Nterminal triple glycine cap.  
 FIG. 2 depicts an immunohistochemistry analysis of coronal brain sections  
 from 20-22 week mice transgenic for both the Swedish mutation of amyloid  
 precursor protein and presenilin of mouse IgG1 fused to various segments  
 of P-amyloid, medium from nontransfected COS cells, or anti-beta-amyloid  
 polyclonal antibody.  
 FIG. 3 depicts the synthetic oligonucleotides that were used to assemble  
 the synthetic APP/IgG gene. These oligonucleotides contain unique  
 restriction endonuclease sites needed for the assembly.  
 FIG. 4 is a schematic representation of the pTig expression vector.  
 FIG. 5 is a schematic representation of the assembly of synthetic A beta  
 1-40 and A beta 1-42, with and without a triple Gly linker group between  
 the tPA propeptide and the beta -amyloid peptide.  
 FIG. 6 depicts the DNA sequence, amino acid composition, and restriction  
 endonuclease recognition sites of the synthetic beta-amyloid gene.  
 FIG. 7A depicts the sequence of the oligonucleotides used to assemble  
 subfragments of the synthetic beta-amyloid gene and a compilation of the  
 chimeric beta-amyloid/IgG1 constructs that were made.  
 FIG. 7B depicts the sequence of the oligonucleotides used to assemble  
 subfragments of the synthetic beta-amyloid gene and a compilation of the  
 chimeric beta-amyloid/IgG1 constructs that were made.  
 FIG. 8 is a graph demonstrating that \*\*\*Fc\*\*\* \*\*\*receptor\*\*\*  
 -mediated fibril uptake by cells occurs in the presence of either the A  
 beta (1630)-Fc fusion protein or the alpha-beta-amyloid antibody.  
 FIG. 9 is a graph demonstrating that the A beta (16-30)-Fc fusion protein  
 interferes with the binding of soluble betaamyloid peptide to amyloid  
 fibrils.  
 FIG. 10 is brain section stained with Thioflavin S, demonstrating that  
 treatment of an Alzheimer's disease model transgenic mouse with the A  
 beta (16-30)-Fc fusion protein results in a decrease in plaque at the  
 site of administration.  
 FIG. 11 depicts the coding region of the tPA Delta pro/16-30/Fc cDNA  
 synthetic gene synthetic gene (SEQ ID NO:11).  
 FIG. 12 depicts the amino acid sequence of the tPA Delta pro/1630/Fc  
 fusion protein (SEQ ID NO:12). Annotated functional elements are also  
 shown. The A beta (16-30)-Fc protein is set forth herein as SEQ ID NO: 13

L4 ANSWER 57 OF 201 USPATFULL on STN DUPLICATE 5  
 AN 2002:251724 USPATFULL  
 TI Soluble zalpha11 cytokine receptors  
 IN Sprecher, Cindy A., Seattle, WA, UNITED STATES  
 Novak, Julia E., Bainbridge Island, WA, UNITED STATES  
 West, James W., Seattle, WA, UNITED STATES  
 Presnell, Scott R., Tacoma, WA, UNITED STATES  
 Holly, Richard D., Seattle, WA, UNITED STATES  
 Nelson, Andrew J., Shoreline, WA, UNITED STATES  
 PI US 2002137677 A1 20020926  
 US 6777539 B2 20040817  
 AI US 2001-825561 A1 20010403 (9)  
 PRAI US 2000-194731P 20000405 (60)  
 US 2000-222121P 20000728 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 8392  
 INCL INCLM: 514/012.000  
 INCLS: 530/350.000; 536/023.500; 435/069.100; 435/325.000; 435/320.100

NCL NCLM: 530/350.000  
NCLS: 530/351.000  
IC [7]  
ICM: A61K038-17  
ICS: C07H021-04; C07K014-705; C12P021-02; C12N005-06  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 58 OF 201 USPATFULL on STN DUPLICATE 6  
AN 2002:236242 USPATFULL  
TI Novel cytokine zalphall Ligand  
IN Novak, Julia E., Bainbridge Island, WA, UNITED STATES  
Presnell, Scott R., Tacoma, WA, UNITED STATES  
Sprecher, Cindy A., Seattle, WA, UNITED STATES  
Foster, Donald C., Lake Forest Park, WA, UNITED STATES  
Holly, Richard D., Seattle, WA, UNITED STATES  
Gross, Jane A., Seattle, WA, UNITED STATES  
Johnston, Janet V., Seattle, WA, UNITED STATES  
Nelson, Andrew J., Shoreline, WA, UNITED STATES  
Dillon, Stacey R., Seattle, WA, UNITED STATES  
Hammond, Angela K., Maple Valley, WA, UNITED STATES  
PI US 2002128446 A1 20020912  
US 6605272 B2 20030812  
AI US 2001-923246 A1 20010803 (9)  
RLI Division of Ser. No. US 2000-522217, filed on 9 Mar 2000, PATENTED  
PRAI US 1999-123547P 19990309 (60)  
US 1999-123904P 19990311 (60)  
US 1999-142013P 19990701 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 8753  
INCL INCLM: 530/351.000  
INCLS: 435/069.500; 536/023.500; 435/320.100; 435/325.000  
NCL NCLM: 424/085.200  
NCLS: 424/085.100; 424/169.100; 424/173.100; 424/174.100; 514/002.000;  
514/012.000  
IC [7]  
ICM: C07K014-52  
ICS: C07H021-04; C12P021-02; C12N005-06  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 59 OF 201 USPATFULL on STN  
AN 2002:272465 USPATFULL  
TI Recombinant antibodies for human therapy  
IN Newman, Roland A., San Diego, CA, UNITED STATES  
Hanna, Nabil, Olivenhain, CA, UNITED STATES  
Raab, Ronald W., San Diego, CA, UNITED STATES  
PA IDEC Pharmaceuticals Corporation, San Diego, CA (U.S. corporation)  
PI US 2002150580 A1 20021017  
AI US 2001-850165 A1 20010508 (9)  
RLI Continuation of Ser. No. US 1998-82472, filed on 21 May 1998, ABANDONED  
Continuation of Ser. No. US 1995-476237, filed on 7 Jun 1995, GRANTED,  
Pat. No. US 5756096 Continuation-in-part of Ser. No. US 1995-397072,  
filed on 17 Apr 1995, ABANDONED Continuation of Ser. No. US 1992-912292,  
filed on 10 Jul 1992, ABANDONED Continuation-in-part of Ser. No. US  
1992-856281, filed on 23 Mar 1992, ABANDONED Continuation-in-part of  
Ser. No. US 1991-735064, filed on 25 Jul 1991, ABANDONED  
DT Utility  
FS APPLICATION  
LN.CNT 3119  
INCL INCLM: 424/154.100  
INCLS: 530/388.800; 435/069.100; 435/326.000; 435/320.100; 536/023.530  
NCL NCLM: 424/154.100  
NCLS: 530/388.800; 435/069.100; 435/326.000; 435/320.100; 536/023.530  
IC [7]  
ICM: A61K039-395  
ICS: C07H021-04; C12P021-02; C12N005-06; C07K016-30  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 60 OF 201 USPATFULL on STN  
AN 2002:266431 USPATFULL  
TI MUCOSAL VASCULAR ADDRESSINS AND USES THEREOF  
IN BRISKIN, MICHAEL J., LEXINGTON, MA, UNITED STATES  
RINGLER, DOUGLAS J., REVERE, MA, UNITED STATES  
PICARELLA, DOMINIC, SUDBURY, MA, UNITED STATES  
NEWMAN, WALTER, BOSTON, MA, UNITED STATES  
PI US 2002147314 A1 20021010

AI US 1997-875849 A1 19970908 (8)  
WO 1996-US2153 19960212  
DT Utility  
FS APPLICATION  
LN.CNT 3801  
INCL INCLM: 530/391.100  
INCLS: 530/391.700; 530/395.000; 530/402.000; 530/866.000  
NCL NCLM: 530/391.100  
NCLS: 530/391.700; 530/395.000; 530/402.000; 530/866.000  
IC [7]  
ICM: A61K039-395  
ICS: C07K017-14; C12P021-08; C07K016-00; C07K001-00; C08H001-00  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 61 OF 201 USPATFULL on STN  
AN 2002:266429 USPATFULL  
TI Hybrid antibodies and uses thereof  
IN O'Keefe, Theresa, Waltham, MA, UNITED STATES  
Rao, Patricia, Acton, MA, UNITED STATES  
PI US 2002147312 A1 20021010  
AI US 2002-60714 A1 20020130 (10)  
PRAI US 2001-265914P 20010202 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 2979  
INCL INCLM: 530/387.300  
INCLS: 530/388.150  
NCL NCLM: 530/387.300  
NCLS: 530/388.150  
IC [7]  
ICM: C07K016-28  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 62 OF 201 USPATFULL on STN  
AN 2002:258804 USPATFULL  
TI GENERATION OF MODIFIED MOLECULES WITH INCREASED SERUM HALF-LIVES  
IN GALLO, MICHAEL, SAN JOSE, CA, UNITED STATES  
JUNGHANS, RICHARD, BOSTON, MA, UNITED STATES  
FOORD, ORIT, FOSTER CITY, CA, UNITED STATES  
PI US 2002142374 A1 20021003  
AI US 1999-375924 A1 19990817 (9)  
PRAI US 1998-96868P 19980817 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 2060  
INCL INCLM: 435/069.100  
INCLS: 435/069.600; 530/387.300; 530/388.100; 530/388.230  
NCL NCLM: 435/069.100  
NCLS: 435/069.600; 530/387.300; 530/388.100; 530/388.230  
IC [7]  
ICM: C12P021-06  
ICS: C12P021-04; C12P021-08; C07K016-00  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 63 OF 201 USPATFULL on STN  
AN 2002:227904 USPATFULL  
TI In vitro methods of producing and identifying immunoglobulin molecules  
in eukaryotic cells  
IN Zauderer, Maurice, Pittsford, NY, UNITED STATES  
Smith, Ernest S., Ontario, NY, UNITED STATES  
PA University of Rochester, Rochester, NY, 14642 (U.S. corporation)  
PI US 2002123057 A1 20020905  
AI US 2001-987456 A1 20011114 (9)  
PRAI US 2000-249268P 20001117 (60)  
US 2001-262067P 20010118 (60)  
US 2001-271424P 20010227 (60)  
US 2001-298087P 20010615 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 7215  
INCL INCLM: 435/006.000  
INCLS: 435/007.100; 435/069.100; 435/326.000; 435/320.100; 536/023.530  
NCL NCLM: 435/006.000  
NCLS: 435/007.100; 435/069.100; 435/326.000; 435/320.100; 536/023.530  
IC [7]  
ICM: C12Q001-68

ICS: G01N033-53; C07H021-04; C12P021-02; C12N005-06  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 64 OF 201 USPATFULL on STN  
AN 2002:221013 USPATFULL  
TI ErbB4 antagonists  
IN Gerritsen, Mary E., San Mateo, CA, UNITED STATES  
Sliwowski, Mark X., San Carlos, CA, UNITED STATES  
PI US 2002119148 A1 20020829  
AI US 2001-940101 A1 20010827 (9)  
PRAI US 2000-229679P 20000901 (60)  
US 2001-265516P 20010131 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 3728  
INCL INCLM: 424/143.100  
NCL NCLM: 424/143.100  
IC [7]  
ICM: A61K039-395

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 65 OF 201 USPATFULL on STN  
AN 2002:157065 USPATFULL  
TI Expression and export of interferon-alpha proteins as Fc fusion proteins  
IN Lo, Kin-Ming, Lexington, MA, UNITED STATES  
Sun, Yaping, Arlington, MA, UNITED STATES  
Gillies, Stephen D., Carlisle, MA, UNITED STATES  
PI US 2002081664 A1 20020627  
AI US 2001-977034 A1 20011011 (9)  
RLI Division of Ser. No. US 2000-575503, filed on 19 May 2000, ABANDONED  
PRAI US 1999-134895P 19990519 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 1923  
INCL INCLM: 435/069.500  
INCLS: 435/325.000; 435/320.100; 536/023.530; 530/351.000; 530/391.100  
NCL NCLM: 435/069.500  
NCLS: 435/325.000; 435/320.100; 536/023.530; 530/351.000; 530/391.100  
IC [7]  
ICM: C12P021-02  
ICS: C07H021-04; C12N005-06; C07K016-46

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 66 OF 201 USPATFULL on STN  
AN 2002:148269 USPATFULL  
TI Multivalent target binding protein  
IN Leung, Shui-on, Shatin, HONG KONG  
PI US 2002076406 A1 20020620  
AI US 2001-911610 A1 20010725 (9)  
PRAI US 2000-220782P 20000725 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 1776  
INCL INCLM: 424/135.100  
NCL NCLM: 424/135.100  
IC [7]  
ICM: A61K039-395

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 67 OF 201 USPATFULL on STN  
AN 2002:98889 USPATFULL  
TI Methods for modulating T cell unresponsiveness  
IN Boussiotis, Vassiliki A., Brookline, MA, UNITED STATES  
Freeman, Gordon J., Brookline, MA, UNITED STATES  
Nadler, Lee M., Newton, MA, UNITED STATES  
PA Dana Farber Cancer institute (U.S. corporation)  
PI US 2002051784 A1 20020502  
AI US 2001-995519 A1 20011128 (9)  
RLI Continuation of Ser. No. US 1995-457483, filed on 1 Jun 1995, PENDING  
Continuation-in-part of Ser. No. US 1994-207932, filed on 8 Mar 1994,  
PENDING Continuation-in-part of Ser. No. WO 1995-US2916, filed on 8 Mar  
1995, UNKNOWN  
DT Utility  
FS APPLICATION  
LN.CNT 1803  
INCL INCLM: 424/144.100



INCLS: 424/146.100  
NCL NCLM: 424/144.100  
NCLS: 424/146.100  
IC [7]  
ICM: A61K039-395  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 68 OF 201 USPATFULL on STN  
AN 2002:48297 USPATFULL  
TI Transgenic avian species for making human and chimeric antibodies  
IN Singh, Sujay, San Diego, CA, UNITED STATES  
Dias, Peter, Carlsbad, CA, UNITED STATES  
PI US 2002028488 A1 20020307  
AI US 2001-884579 A1 20010618 (9)  
PRAI US 2000-212456P 20000619 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 2642  
INCL INCLM: 435/070.210  
INCLS: 800/019.000; 530/388.100  
NCL NCLM: 435/070.210  
NCLS: 800/019.000; 530/388.100  
IC [7]  
ICM: A01K067-027  
ICS: C12P021-04; C07K016-00  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 69 OF 201 USPATFULL on STN  
AN 2002:32520 USPATFULL  
TI In vitro modification of glycosylation patterns of recombinant  
glycopeptides  
IN Bayer, Robert, San Diego, CA, UNITED STATES  
PI US 2002019342 A1 20020214  
AI US 2001-855320 A1 20010514 (9)  
PRAI US 2000-203851P 20000512 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 2069  
INCL INCLM: 514/008.000  
INCLS: 435/014.000  
NCL NCLM: 514/008.000  
NCLS: 435/014.000  
IC [7]  
ICM: A61K038-16  
ICS: C12Q001-54  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 70 OF 201 USPATFULL on STN  
AN 2002:21834 USPATFULL  
TI Human cytokine receptor  
IN Presnell, Scott R, Tacoma, WA, UNITED STATES  
Xu, Wenfeng, Mukilteo, WA, UNITED STATES  
Kindsvogel, Wayne, Seattle, WA, UNITED STATES  
Chen, Zhi, Seattle, WA, UNITED STATES  
PI US 2002012669 A1 20020131  
AI US 2000-728911 A1 20001201 (9)  
PRAI US 1999-169049P 19991203 (60)  
US 2000-232219P 20000913 (60)  
US 2000-244610P 20001031 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 7478  
INCL INCLM: 424/192.100  
INCLS: 530/350.000; 536/023.500; 435/348.000; 435/326.000; 435/410.000;  
435/252.100; 435/254.100; 435/255.100; 435/317.100; 435/069.100;  
530/387.200; 530/388.100; 530/387.300; 530/389.100; 530/391.100;  
514/012.000; 435/007.100; 435/006.000  
NCL NCLM: 424/192.100  
NCLS: 530/350.000; 536/023.500; 435/348.000; 435/326.000; 435/410.000;  
435/252.100; 435/254.100; 435/255.100; 435/317.100; 435/069.100;  
530/387.200; 530/388.100; 530/387.300; 530/389.100; 530/391.100;  
514/012.000; 435/007.100; 435/006.000  
IC [7]  
ICM: A61K038-00  
ICS: C12Q001-68; C07H021-04; A61K039-00; C12N001-20; C12N001-16;  
C12N001-14; C12N001-12; C12P021-06; G01N033-53

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 71 OF 201 USPATFULL on STN  
AN 2002:326103 USPATFULL  
TI Multimeric immunotoxins  
IN Vallera, Daniel A., St. Louis Park, MN, United States  
Blazar, Bruce R., Golden Valley, MN, United States  
PA Regents of the University of Minnesota, Minneapolis, MN, United States  
(U.S. corporation)  
PI US 6492498 B1 20021210  
AI US 1999-440344 19991115 (9)  
DT Utility  
FS GRANTED  
LN.CNT 1661  
INCL INCLM: 530/391.700  
INCLS: 530/300.000; 530/350.000; 530/387.100; 424/183.100  
NCL NCLM: 530/391.700  
NCLS: 424/183.100; 530/300.000; 530/350.000; 530/387.100  
IC [7]  
ICM: C07K016-00  
EXF 530/387.1; 530/387.3; 530/388.75; 530/388.8; 530/388.85; 530/300;  
530/350; 424/130.1; 424/134.1; 424/181.1; 424/183.1; 512/2  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 72 OF 201 USPATFULL on STN  
AN 2002:238640 USPATFULL  
TI Methods for stimulating T cell responses to tumor cells expressing LFA-3  
and a CD28 or CTLA4 ligand  
IN Boussiotis, Vassiliki A., Brookline, MA, United States  
Freeman, Gordon J., Brookline, MA, United States  
Nadler, Lee M., Newton, MA, United States  
PA Dana-Farber Cancer Institute, UNITED STATES (non-U.S. corporation)  
PI US 6451305 B1 20020917  
AI US 1995-457483 19950601 (8)  
RLI Continuation-in-part of Ser. No. US 1994-207932, filed on 8 Mar 1994  
Continuation-in-part of Ser. No. WO 1995-US2916, filed on 8 Mar 1995  
DT Utility  
FS GRANTED  
LN.CNT 1671  
INCL INCLM: 424/093.210  
INCLS: 424/093.200; 424/093.700; 435/325.000; 435/365.100; 435/440.000;  
435/455.000  
NCL NCLM: 424/093.210  
NCLS: 424/093.200; 424/093.700; 435/325.000; 435/365.100; 435/440.000;  
435/455.000  
IC [7]  
ICM: A61K048-00  
ICS: C12N005-10  
EXF 424/93.2; 424/93.21; 435/325; 435/365.1; 435/440  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 73 OF 201 USPATFULL on STN  
AN 2002:216830 USPATFULL  
TI Methods of treating autoimmune diseases with gp39-specific antibodies  
IN Black, Amelia, Cardiff, CA, United States  
Hanna, Nabil, Olivenhian, CA, United States  
Padlan, Eduardo A., Kensington, MD, United States  
Newman, Roland A., San Diego, CA, United States  
PA IDEC Pharmaceuticals Corporation, San Diego, CA, United States (U.S.  
corporation)  
PI US 6440418 B1 20020827  
AI US 1997-925339 19970908 (8)  
RLI Continuation-in-part of Ser. No. US 1995-554840, filed on 7 Nov 1995,  
now patented, Pat. No. US 6001358  
DT Utility  
FS GRANTED  
LN.CNT 2625  
INCL INCLM: 424/154.100  
INCLS: 424/130.100; 424/133.100; 424/141.100; 424/143.100; 424/144.100;  
424/153.100; 424/173.100; 530/387.100; 530/387.300; 530/388.100;  
530/388.200; 530/388.220; 530/388.700; 530/388.730; 530/388.750  
NCL NCLM: 424/154.100  
NCLS: 424/130.100; 424/133.100; 424/141.100; 424/143.100; 424/144.100;  
424/153.100; 424/173.100; 530/387.100; 530/387.300; 530/388.100;  
530/388.200; 530/388.220; 530/388.700; 530/388.730; 530/388.750  
IC [7]

ICM: A61K039-395  
ICS: C07K016-28  
EXF 424/130.1; 424/133.1; 424/141.1; 424/153.1; 424/173.1; 530/387.1;  
530/388.2; 530/388.73  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 74 OF 201 USPATFULL on STN  
AN 2002:168417 USPATFULL  
TI Transgenic plants expressing assembled secretory antibodies  
IN Hein, Mich B., Fallbrook, CA, United States  
Hiatt, Andrew, San Diego, CA, United States  
PA The Scripps Research Institute, La Jolla, CA, United States (U.S.  
corporation)  
PI US 6417429 B1 20020709  
AI US 1998-199534 19981125 (9)  
RLI Continuation of Ser. No. US 1996-642406, filed on 3 May 1996, now  
patented, Pat. No. US 5959177, issued on 28 Sep 1999  
Continuation-in-part of Ser. No. US 1992-971951, filed on 5 Nov 1992,  
now patented, Pat. No. US 5639947, issued on 17 Jun 1997 Continuation of  
Ser. No. US 1990-591823, filed on 2 Oct 1990, now patented, Pat. No. US  
5202422, issued on 13 Apr 1993 Continuation-in-part of Ser. No. US  
1989-427765, filed on 27 Oct 1989, now abandoned  
DT Utility  
FS GRANTED  
LN.CNT 4784  
INCL INCLM: 800/288.000  
INCLS: 800/295.000; 800/298.000; 800/278.000; 536/023.600; 536/023.700;  
536/024.100; 536/023.530; 435/419.000; 435/468.000  
NCL NCLM: 800/288.000  
NCLS: 435/419.000; 435/468.000; 536/023.530; 536/023.600; 536/023.700;  
536/024.100; 800/278.000; 800/295.000; 800/298.000  
IC [7]  
ICM: C12N016-00  
ICS: A01H003-00; A01H005-00  
EXF 800/295; 800/298; 800/278; 800/288; 536/23.6; 536/23.7; 536/24.1;  
536/23.53; 435/419; 435/468; 530/388.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 75 OF 201 USPATFULL on STN  
AN 2002:143943 USPATFULL  
TI Hybrid immunoglobulins  
IN Capon, Daniel J., San Mateo, CA, United States  
Lasky, Laurence A., Sausalito, CA, United States  
PA Genentech, Inc., South San Francisco, CA, United States (U.S.  
corporation)  
PI US 6406697 B1 20020618  
AI US 1997-906549 19970805 (8)  
RLI Continuation of Ser. No. US 1995-451848, filed on 26 May 1995, now  
patented, Pat. No. US 5714147 Continuation of Ser. No. US 1994-185670,  
filed on 21 Jan 1994, now patented, Pat. No. US 5514582 Continuation of  
Ser. No. US 1992-986931, filed on 8 Dec 1992, now patented, Pat. No. US  
5428130 Continuation of Ser. No. US 1991-808122, filed on 16 Dec 1991,  
now patented, Pat. No. US 5225538 Division of Ser. No. US 1989-440625,  
filed on 22 Nov 1989, now patented, Pat. No. US 5116964  
Continuation-in-part of Ser. No. US 1989-315015, filed on 23 Feb 1989,  
now patented, Pat. No. US 5089833  
DT Utility  
FS GRANTED  
LN.CNT 2685  
INCL INCLM: 424/178.100  
INCLS: 435/069.700; 514/002.000; 530/350.000; 536/023.400  
NCL NCLM: 424/178.100  
NCLS: 435/069.700; 514/002.000; 530/350.000; 536/023.400  
IC [7]  
ICM: C07K016-46  
ICS: C12N015-62  
EXF 435/69.7; 530/350; 424/178.1; 536/23.4; 514/2  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 76 OF 201 USPATFULL on STN  
AN 2002:122462 USPATFULL  
TI Directed switch-mediated DNA recombination  
IN Jakobovits, Aya, Menlo Park, CA, United States  
Gallo, Michael Lajos, San Jose, CA, United States  
Yang, Xiao-Ping, Foster City, CA, United States  
PA Abgenix, Inc., Fremont, CA, United States (U.S. corporation)

Japan Tobacco, Inc., Tokyo, JAPAN (non-U.S. corporation)  
 PI US 6395515 B1 20020528  
 AI US 1999-369635 19990806 (9)  
 RLI Continuation of Ser. No. US 1997-878166, filed on 17 Jun 1997, now  
 patented, Pat. No. US 5985615 Continuation of ser. No. US 1996-619109,  
 filed on 20 Mar 1996, now patented, Pat. No. US 5714352  
 DT Utility  
 FS GRANTED  
 LN.CNT 1361  
 INCL INCLM: 435/069.600  
 INCLS: 435/320.100; 435/325.000; 435/455.000; 536/023.100; 800/004.000;  
 800/014.000; 800/025.000  
 NCL NCLM: 435/069.600  
 NCLS: 435/320.100; 435/325.000; 435/455.000; 536/023.100; 800/004.000;  
 800/014.000; 800/025.000  
 IC [7]  
 ICM: C12P021-04  
 ICS: C12N015-00; C12N015-09; C12N015-63; C12N015-70  
 EXF 800/4; 800/14; 800/25; 435/69.6; 435/325; 435/320.1; 435/455; 536/23.1  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 77 OF 201 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN  
 DUPLICATE  
 AN 2002:34568735 BIOTECHNO  
 TI \*\*\*Immunoglobulin\*\*\* \*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\*  
 \*\*\*regions\*\*\* regulate immunity and tolerance to idiotypes of antibody  
 variable regions  
 AU Reitan S.K.; Hannestad K.  
 CS K. Hannestad, Department of Immunology, School of Medicine, University of  
 Tromso, N-9037 Tromso, Norway.  
 E-mail: kristian.hannestad@fagmed.uit.no  
 SO Proceedings of the National Academy of Sciences of the United States of  
 America, (28 MAY 2002), 99/11 (7588-7593), 49 reference(s)  
 CODEN: PNASA6 ISSN: 0027-8424  
 DT Journal; Article  
 CY United States  
 LA English  
 SL English

L4 ANSWER 78 OF 201 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 2001:78268 CAPLUS  
 DN 134:146376  
 TI Fc fusion proteins for enhancing the immunogenicity of protein and peptide  
 antigens  
 IN Gillies, Stephen D.; Lo, Kin Ming; Wesolowski, John S., Jr.  
 PA Lexigen Pharmaceuticals Corp., USA  
 SO PCT Int. Appl., 78 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001007081	A1	20010201	WO 2000-US19816	20000721
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2378866	AA	20010201	CA 2000-2378866	20000721
EP 1198250	A1	20020424	EP 2000-950483	20000721
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
BR 2000012569	A	20020528	BR 2000-12569	20000721
JP 2003505431	T2	20030212	JP 2001-511964	20000721
NO 2002000255	A	20020315	NO 2002-255	20020117
ZA 2002000501	A	20030121	ZA 2002-501	20020121
PRAI US 1999-144965P	P	19990721		
WO 2000-US19816	W	20000721		

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 79 OF 201 USPATFULL on STN  
 AN 2001:176635 USPATFULL  
 TI Icam-related protein  
 IN Gallatin, W. Michael, Mercer Island, WA, United States  
 Vazeux, Rosemay, Seattle, WA, United States  
 PA ICOS Corporation (U.S. corporation)  
 PI US 2001029293 A1 20011011  
 AI US 2001-753436 A1 20010103 (9)  
 RLI Continuation of Ser. No. US 1999-382289, filed on 24 Aug 1999, ABANDONED  
 Continuation-in-part of Ser. No. US 1995-487113, filed on 7 Jun 1995,  
 GRANTED, Pat. No. US 5837822 Continuation-in-part of Ser. No. US  
 1993-102852, filed on 5 Aug 1993, ABANDONED Continuation-in-part of Ser.  
 No. US 1993-9266, filed on 22 Jan 1993, ABANDONED Continuation-in-part  
 of Ser. No. WO 1993-US787, filed on 26 Jan 1993, UNKNOWN  
 Continuation-in-part of Ser. No. US 1992-894061, filed on 5 Jun 1992,  
 ABANDONED Continuation-in-part of Ser. No. US 1992-889724, filed on 26  
 May 1992, ABANDONED Continuation-in-part of Ser. No. US 1992-827689,  
 filed on 27 Jan 1992, ABANDONED  
 DT Utility  
 FS APPLICATION  
 LN.CNT 7122  
 INCL INCLM: 530/387.300  
 INCLS: 435/007.920  
 NCL NCLM: 530/387.300  
 NCLS: 435/007.920  
 IC [7]  
 ICM: G01N033-537  
 ICS: G01N033-543

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 80 OF 201 USPATFULL on STN  
 AN 2001:185455 USPATFULL  
 TI Cytokine zalphall Ligand  
 IN Novak, Julia E., Bainbridge Island, WA, United States  
 Presnell, Scott R., Tacoma, WA, United States  
 Sprecher, Cindy A., Seattle, WA, United States  
 Foster, Donald C., Lake Forest Park, WA, United States  
 Holly, Richard D., Seattle, WA, United States  
 Gross, Jane A., Seattle, WA, United States  
 Johnston, Janet V., Seattle, WA, United States  
 Nelson, Andrew J., Shoreline, WA, United States  
 Dillon, Stacey R., Seattle, WA, United States  
 Hammond, Angela K., Maple Valley, WA, United States  
 PA ZymoGenetics, Inc., Seattle, WA, United States (U.S. corporation)  
 PI US 6307024 B1 20011023  
 AI US 2000-522217 20000309 (9)  
 PRAI US 1999-123547P 19990309 (60)  
 US 1999-123904P 19990311 (60)  
 US 1999-142013P 19990701 (60)  
 DT Utility  
 FS GRANTED  
 LN.CNT 7160  
 INCL INCLM: 530/351.000  
 INCLS: 530/350.000; 435/069.100; 435/069.700; 424/143.100; 424/145.100  
 NCL NCLM: 530/351.000  
 NCLS: 424/143.100; 424/145.100; 435/069.100; 435/069.700; 530/350.000  
 IC [7]  
 ICM: C07K014-00  
 ICS: C12P021-06; C12P021-04; A61K039-395  
 EXF 530/380; 530/351; 435/69.1; 435/69.7; 424/143.1; 424/145.1  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 81 OF 201 USPATFULL on STN  
 AN 2001:131067 USPATFULL  
 TI Methods for the preparation of positively charged proteins  
 IN Grinna, Lynn, Middleburg, CA, United States  
 PA XOMA Corporation, Berkeley, CA, United States (U.S. corporation)  
 PI US 6274348 B1 20010814  
 AI US 1997-885366 19970630 (8)  
 RLI Continuation of Ser. No. US 1993-64693, filed on 19 May 1993, now  
 patented, Pat. No. US 5643570 Continuation-in-part of Ser. No. US  
 1992-885911, filed on 19 May 1992, now abandoned  
 DT Utility  
 FS GRANTED  
 LN.CNT 1361  
 INCL INCLM: 435/071.100

NCL INCLS: 435/383.000; 435/395.000; 435/404.000; 530/350.000  
NCLM: 435/071.100  
IC NCLS: 435/383.000; 435/395.000; 435/404.000; 530/350.000  
[7]  
ICM: C12P021-00  
ICS: C12N005-02; C12N005-00; C07K001-02  
EXF 435/71; 435/71.1; 435/383; 435/395; 435/404; 530/350; 530/402; 530/403  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 82 OF 201 WPIDS COPYRIGHT 2004 THE THOMSON CORP on STN  
AN 2001-316421 [33] WPIDS  
DNN N2001-227440 DNC C2001-097519  
TI Modifying antibody useful in therapeutics, involves recombining first  
polynucleotide or character string encoding antibody with second  
polynucleotide or character string to produce library of modified  
antibodies.  
DC B04 D16 T01  
IN BASS, S H; KARRER, E; PATTEN, P A; WHALEN, R  
PA (MAXY-N) MAXYGEN INC  
CYC 95  
PI WO 2001032712 A2 20010510 (200133)\* EN 109 C07K016-00  
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ  
NL OA PT SD SE SL SZ TR TZ UG ZW  
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM  
DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC  
LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE  
SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW  
AU 2001014561 A 20010514 (200149) C07K016-00  
EP 1230269 A2 20020814 (200261) EN C07K016-00  
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT  
RO SE SI TR  
ADT WO 2001032712 A2 WO 2000-US30247 20001101; AU 2001014561 A AU 2001-14561  
20001101; EP 1230269 A2 EP 2000-976844 20001101, WO 2000-US30247 20001101  
FDT AU 2001014561 A Based on WO 2001032712; EP 1230269 A2 Based on WO  
2001032712  
PRAI US 2000-176002P 20000112; US 1999-163370P 19991103  
IC ICM C07K016-00  
ICS A61K039-21; A61K039-42; C07K014-16; C07K016-10; C07K016-12;  
C07K016-46; C12N001-21; C12N015-13; C12N015-49; C12N015-62;  
G06F017-30

L4 ANSWER 83 OF 201 WPIDS COPYRIGHT 2004 THE THOMSON CORP on STN  
AN 2001-191523 [19] WPIDS  
DNC C2001-057409  
TI Novel multifunctional fusion protein or protein complexes useful for  
treating cancer and viral infections, comprise two different cytokine  
molecules and a targeting group.  
DC B04 D16  
IN GILLIES, S D; LO, K M; LO, K  
PA (LEXI-N) LEXIGEN PHARM CORP; (GILL-I) GILLIES S D; (LOKK-I) LO K; (EMDL-N)  
EMD LEXIGEN RES CENT CORP  
CYC 95  
PI WO 2001010912 A1 20010215 (200119)\* EN 59 C07K019-00  
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ  
NL OA PT SD SE SL SZ TZ UG ZW  
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM  
DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC  
LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE  
SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW  
AU 2000066268 A 20010305 (200130) C07K019-00  
EP 1200479 A1 20020502 (200236) EN C07K019-00  
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT  
RO SE SI  
NO 2002000641 A 20020408 (200236) C07K000-00  
BR 2000013231 A 20020723 (200257) C07K019-00  
KR 2002026368 A 20020409 (200267) C07K019-00  
CZ 2002000389 A3 20021211 (200309) C07K019-00  
HU 2002002442 A2 20021128 (200309) C07K019-00  
JP 2003507012 W 20030225 (200317) 111 C12N015-09  
CN 1382158 A 20021127 (200322) C07K019-00  
ZA 2002000789 A 20030326 (200327) 106 C07K000-00  
US 6617135 B1 20030909 (200361) C12N015-62  
SK 2002000184 A3 20030911 (200363) C07K019-00  
MX 2002001417 A1 20020801 (200367) A61K038-20  
US 2004072299 A1 20040415 (200426) C07K016-46  
ADT WO 2001010912 A1 WO 2000-US21715 20000809; AU 2000066268 A AU 2000-66268

20000809; EP 1200479 A1 EP 2000-953896 20000809, WO 2000-US21715 20000809;  
 NO 2002000641 A WO 2000-US21715 20000809, NO 2002-641 20020208; BR  
 2000013231 A BR 2000-13231 20000809, WO 2000-US21715 20000809; KR  
 2002026368 A KR 2002-701705 20020207; CZ 2002000389 A3 WO 2000-US21715  
 20000809, CZ 2002-389 20000809; HU 2002002442 A2 WO 2000-US21715 20000809,  
 HU 2002-2442 20000809; JP 2003507012 W WO 2000-US21715 20000809, JP  
 2001-515719 20000809; CN 1382158 A CN 2000-813726 20000809; ZA 2002000789  
 A ZA 2002-789 20020129; US 6617135 B1 Provisional US 1999-147924P  
 19990809, US 2000-634368 20000809; SK 2002000184 A3 WO 2000-US21715  
 20000809, SK 2002-184 20000809; MX 2002001417 A1 WO 2000-US21715 20000809,  
 MX 2002-1417 20020208; US 2004072299 A1 Provisional US 1999-147924P  
 19990809, Cont of US 2000-634368 20000809, US 2003-603064 20030624  
 FDT AU 2000066268 A Based on WO 2001010912; EP 1200479 A1 Based on WO  
 2001010912; BR 2000013231 A Based on WO 2001010912; CZ 2002000389 A3 Based  
 on WO 2001010912; HU 2002002442 A2 Based on WO 2001010912; JP 2003507012 W  
 Based on WO 2001010912; SK 2002000184 A3 Based on WO 2001010912; MX  
 2002001417 A1 Based on WO 2001010912; US 2004072299 A1 Cont of US 6617135  
 PRAI US 1999-147924P 19990809; US 2000-634368 20000809;  
 US 2003-603064 20030624  
 IC ICM A61K038-20; C07K000-00; C07K016-46; C07K019-00; C12N015-09;  
 C12N015-62  
 ICS A61K031-7088; A61K035-12; A61K038-00; A61K039-395; A61K048-00;  
 A61P031-12; A61P035-00; A61P037-04; C07K014-53; C07K016-08;  
 C07K016-32; C12N001-15; C12N001-19; C12N001-21; C12N005-10;  
 C12N015-63; C12P021-02  
 ICA C07K014-52; C07K014-535; C07K014-54; C07K014-55; C07K016-30  
 ICI C07K014:52, C07K014:535, C07K014:54, C07K014:55, C07K016-30  
 L4 ANSWER 84 OF 201 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation.  
 on STN  
 AN 2001:813180 SCISEARCH  
 GA The Genuine Article (R) Number: 480WE  
 TI In situ class switching and differentiation to IgA-producing cells in the  
 gut lamina propria  
 AU Fagarasan S; Kinoshita K; Muramatsu M; Ikuta K; Honjo T (Reprint)  
 CS Kyoto Univ, Grad Sch Med, Dept Med Chem, Sakyo Ku, Yoshida Konoe Cho,  
 Kyoto 6068501, Japan (Reprint); Kyoto Univ, Grad Sch Med, Dept Med Chem,  
 Sakyo Ku, Kyoto 6068501, Japan  
 CYA Japan  
 SO NATURE, (11 OCT 2001) Vol. 413, No. 6856, pp. 639-643.  
 Publisher: MACMILLAN PUBLISHERS LTD, PORTERS SOUTH, 4 CRINAN ST, LONDON N1  
 9XW, ENGLAND.  
 ISSN: 0028-0836.  
 DT Article; Journal  
 LA English  
 REC Reference Count: 31  
 \*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*  
 L4 ANSWER 85 OF 201 USPATFULL on STN  
 AN 2000:141878 USPATFULL  
 TI Recombinant anti-CD4 antibodies for human therapy  
 IN Hanna, Nabil, Olivenhain, CA, United States  
 Newman, Roland Anthony, San Diego, CA, United States  
 Reff, Mitchell Elliot, San Diego, CA, United States  
 PA IDEC Pharmaceuticals Corporation, San Diego, CA, United States (U.S.  
 corporation)  
 PI US 6136310 20001024  
 AI US 1995-523894 19950906 (8)  
 RLI Continuation-in-part of Ser. No. US 1995-476237, filed on 7 Jun 1995,  
 now patented, Pat. No. US 5756096 which is a continuation-in-part of  
 Ser. No. US 1995-379072, filed on 25 Jan 1995, now patented, Pat. No. US  
 5658570 which is a continuation of Ser. No. US 1992-912292, filed on 10  
 Jul 1992, now abandoned which is a continuation-in-part of Ser. No. US  
 1992-856281, filed on 23 Mar 1992, now abandoned which is a  
 continuation-in-part of Ser. No. US 1991-735064, filed on 25 Jul 1991,  
 now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 3398  
 INCL INCLM: 424/154.100  
 INCLS: 530/387.300; 424/133.100; 424/141.100  
 NCL NCLM: 424/154.100  
 NCLS: 424/133.100; 424/141.100; 530/387.300  
 IC [7]  
 ICM: A61K039-395  
 ICS: C12P021-08

EXF 530/387.3; 424/133.1; 424/141.1; 424/154.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 86 OF 201 USPATFULL on STN  
AN 2000:102415 USPATFULL  
TI Fusion proteins comprising ICAM-R polypeptides and immunoglobulin constant regions  
IN Gallatin, W. Michael, Seattle, WA, United States  
Vazeux, Rosemay, Seattle, WA, United States  
PA ICOS Corporation, Bothell, WA, United States (U.S. corporation)  
PI US 6100383 20000808  
AI US 1995-475680 19950607 (8)  
RLI Division of Ser. No. US 1994-286754, filed on 5 Aug 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-102852, filed on 5 Aug 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-9266, filed on 22 Jan 1993, now abandoned And a continuation-in-part of Ser. No. WO 1993-US787, filed on 26 Jan 1993 which is a continuation-in-part of Ser. No. US 1992-894061, filed on 5 Jun 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-889724, filed on 26 May 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-827689, filed on 27 Jan 1992, now abandoned  
DT Utility  
FS Granted  
LN.CNT 6203  
INCL INCLM: 530/387.300  
INCLS: 530/300.000; 530/350.000; 435/069.700  
NCL NCLM: 530/387.300  
NCLS: 435/069.700; 530/300.000; 530/350.000  
IC [7]  
ICM: C12P021-08  
EXF 530/387.3; 530/388.2; 530/300; 530/350; 424/134.1; 424/133.1; 435/69.7  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 87 OF 201 USPATFULL on STN  
AN 2000:98222 USPATFULL  
TI Cells with multiple altered epitopes on a surface antigen for use in transplantation  
IN Chappel, Scott C., Milton, MA, United States  
PA Diacrin, Inc., Charlestown, MA, United States (U.S. corporation)  
PI US 6096537 20000801  
AI US 1997-946637 19971007 (8)  
RLI Continuation of Ser. No. US 1994-240150, filed on 10 May 1994, now patented, Pat. No. US 5679340 which is a continuation-in-part of Ser. No. US 1994-220741, filed on 31 Mar 1994, now abandoned  
DT Utility  
FS Granted  
LN.CNT 940  
INCL INCLM: 435/325.000  
INCLS: 424/422.000; 424/133.100; 424/143.100; 424/093.700; 435/007.100; 435/007.200; 435/007.210; 530/388.220  
NCL NCLM: 435/325.000  
NCLS: 424/093.700; 424/133.100; 424/143.100; 424/422.000; 435/007.100; 435/007.200; 435/007.210; 530/388.220  
IC [7]  
ICM: C12N005-00  
ICS: A61F013-00; G01N033-53; C07K016-00  
EXF 424/93.7; 424/422; 424/133.1; 424/143.1; 435/325; 435/7.1; 435/7.2; 435/7.21; 530/388.22  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 88 OF 201 USPATFULL on STN  
AN 2000:84089 USPATFULL  
TI Antibodies which specifically bind to a novel .kappa./.mu.-like protein tyrosineospatase, PTP.lambda., and hybridoma cell lines producing the same  
IN Cheng, Jill, Burlingame, CA, United States  
Lasky, Laurence A., Sausalito, CA, United States  
PA Genentech, Inc., S. San Francisco, CA, United States (U.S. corporation)  
PI US 6083748 20000704  
AI US 1997-991953 19971216 (8)  
RLI Division of Ser. No. US 1996-652971, filed on 24 May 1996, now patented, Pat. No. US 5814507, issued on 29 Sep 1998  
DT Utility  
FS Granted  
LN.CNT 3514



INCL INCLM: 435/338.000  
INCLS: 435/331.000; 435/334.000; 530/388.100; 530/388.220; 530/388.260  
NCL NCLM: 435/338.000  
NCLS: 435/331.000; 435/334.000; 530/388.100; 530/388.220; 530/388.260  
IC [7]  
ICM: C07K016-00  
ICS: C12N005-12  
EXF 530/387.1; 530/387.3; 530/387.9; 530/388.26; 530/388.1; 530/389.1;  
530/391.1; 530/388.22; 435/331; 435/334; 435/338  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 89 OF 201 USPATFULL on STN  
AN 2000:34422 USPATFULL  
TI Antibodies to ICAM-related protein  
IN Gallatin, W. Michael, Seattle, WA, United States  
Vazeux, Rosemay, Seattle, WA, United States  
PA ICOS Corporation, Bothell, WA, United States (U.S. corporation)  
PI US 6040176 20000321  
AI US 1996-714017 19960912 (8)  
RLI Continuation of Ser. No. US 1994-286754, filed on 5 Aug 1994, now  
abandoned which is a continuation-in-part of Ser. No. US 1993-102852,  
filed on 5 Aug 1993, now abandoned which is a continuation-in-part of  
Ser. No. US 1993-9266, filed on 22 Jan 1993, now abandoned which is a  
continuation-in-part of Ser. No. WO 1993-US787, filed on 26 Jan 1993  
which is a continuation-in-part of Ser. No. US 1992-894061, filed on 5  
Jun 1992, now abandoned which is a continuation-in-part of Ser. No. US  
1992-889724, filed on 26 May 1992, now abandoned which is a  
continuation-in-part of Ser. No. US 1992-827689, filed on 27 Jan 1992,  
now abandoned  
DT Utility  
FS Granted  
LN.CNT 6171  
INCL INCLM: 435/326.000  
INCLS: 530/388.100  
NCL NCLM: 435/326.000  
NCLS: 530/388.100  
IC [7]  
ICM: C12N005-00  
ICS: C07K016-00; C12P021-08  
EXF 530/388.1; 530/388.22; 435/326  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 90 OF 201 USPATFULL on STN  
AN 1999:163215 USPATFULL  
TI Humanized antibodies to human gp39, compositions containing thereof  
IN Black, Amelia, Cardiff, CA, United States  
Hanna, Nabil, Olivenhian, CA, United States  
Padlan, Eduardo A., Kensington, MD, United States  
Newman, Roland A., San Diego, CA, United States  
PA Idec Pharmaceuticals Corporation, San Diego, CA, United States (U.S.  
corporation)  
PI US 6001358 19991214  
AI US 1995-554840 19951107 (8)  
DT Utility  
FS Granted  
LN.CNT 2693  
INCL INCLM: 424/154.100  
INCLS: 424/130.100; 424/133.100; 424/144.100; 424/143.100; 424/153.100;  
424/154.100; 424/173.100; 424/141.100; 530/387.100; 530/387.300;  
530/388.100; 530/388.200; 530/388.220; 530/388.700; 530/388.730;  
530/388.750; 536/023.530  
NCL NCLM: 424/154.100  
NCLS: 424/130.100; 424/133.100; 424/141.100; 424/143.100; 424/144.100;  
424/153.100; 424/173.100; 530/387.100; 530/387.300; 530/388.100;  
530/388.200; 530/388.220; 530/388.700; 530/388.730; 530/388.750;  
536/023.530  
IC [6]  
ICM: A61K039-395  
ICS: C07K016-28  
EXF 424/130.1; 424/133.1; 424/141.1; 424/143.1; 424/144.1; 424/154.1;  
424/173.1; 424/153.1; 435/69.6; 435/70.21; 435/320.1; 435/172.2;  
435/172.3; 530/387.3; 530/388.22; 530/388.75; 530/388.2; 530/388.7;  
530/388.73; 530/388.1; 530/387.1; 536/23.53  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 91 OF 201 USPATFULL on STN

AN 1999:150946 USPATFULL  
TI Methods for identifying modulators of protein kinase C phosphorylation  
of ICAM-related protein  
IN Gallatin, W. Michael, Mercer Island, WA, United States  
Vazeux, Rosemay, Seattle, WA, United States  
PA ICOS Corporation, Bothwell, WA, United States (U.S. corporation)  
PI US 5989843 19991123  
AI US 1996-720420 19960927 (8)  
RLI Continuation-in-part of Ser. No. US 1995-487113, filed on 7 Jun 1995,  
now patented, Pat. No. US 5837822 which is a continuation-in-part of  
Ser. No. US 1993-102852, filed on 5 Aug 1993, now abandoned which is a  
continuation-in-part of Ser. No. US 1993-9266, filed on 22 Jan 1993, now  
abandoned And Ser. No. WO 1993-US787, filed on 26 Jan 1993 which is a  
continuation-in-part of Ser. No. US 1992-894061, filed on 5 Jun 1992,  
now abandoned which is a continuation-in-part of Ser. No. US  
1992-889724, filed on 26 May 1992 which is a continuation-in-part of  
Ser. No. US 1992-827689, filed on 27 Jan 1992  
DT Utility  
FS Granted  
LN.CNT 7311  
INCL INCLM: 435/015.000  
INCLS: 435/004.000  
NCL NCLM: 435/015.000  
NCLS: 435/004.000  
IC [6]  
ICM: C12Q001-48  
EXF 435/4; 435/7.1; 435/7.2; 435/15; 436/518; 450/300; 450/324; 450/344;  
450/345; 450/350  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 92 OF 201 USPATFULL on STN  
AN 1999:146315 USPATFULL  
TI Directed switch-mediated DNA recombination  
IN Jakobovits, Aya, Menlo Park, CA, United States  
Gallo, Michael Lajos, San Jose, CA, United States  
Yang, Xiao-Ping, Foster City, CA, United States  
PA Abgenix, Inc., Fremont, CA, United States (U.S. corporation)  
Japan Tobacco Inc., Tokyo, Japan (non-U.S. corporation)  
PI US 5985615 19991116  
AI US 1997-878166 19970617 (8)  
RLI Continuation of Ser. No. US 1996-619109, filed on 20 Mar 1996, now  
patented, Pat. No. US 5714352  
DT Utility  
FS Granted  
LN.CNT 1492  
INCL INCLM: 435/069.600  
INCLS: 435/252.300; 435/325.000; 435/328.000; 435/355.000; 435/372.200;  
435/463.000  
NCL NCLM: 435/069.600  
NCLS: 435/252.300; 435/325.000; 435/328.000; 435/355.000; 435/372.200;  
435/463.000  
IC [6]  
ICM: C12N001-21  
ICS: C12N005-10; C12N005-20; C12N015-00  
EXF 536/23.1; 536/23.53; 435/69.1; 435/70.21; 435/172.3; 435/320.1; 435/325;  
435/326; 435/328; 435/372.3; 435/252.3; 435/69.6; 435/463; 435/372.2;  
435/355  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 93 OF 201 USPATFULL on STN  
AN 1999:137001 USPATFULL  
TI K.kappa./mu.-like protein tyrosine phosphatase, PTP .lambda.  
IN Cheng, Jill, Burlingame, CA, United States  
Lasky, Laurence A., Saulito, CA, United States  
PA Genentech, Inc., So. San Francisco, CA, United States (U.S. corporation)  
PI US 5976852 19991102  
AI US 1996-769399 19961219 (8)  
RLI Division of Ser. No. US 1996-652971, filed on 24 May 1996, now patented,  
Pat. No. US 5814507  
DT Utility  
FS Granted  
LN.CNT 3522  
INCL INCLM: 435/196.000  
INCLS: 435/252.300; 435/320.100; 435/325.000; 536/023.200; 935/022.000  
NCL NCLM: 435/196.000  
NCLS: 435/252.300; 435/320.100; 435/325.000; 536/023.200

IC [6]  
ICM: C12N009-16  
ICS: C12N001-20; C12N005-00; C07H021-04  
EXF 435/240.2; 435/252.3; 435/320.1; 435/196; 435/325; 536/23.2; 935/22  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 94 OF 201 USPATFULL on STN  
AN 1999:117748 USPATFULL  
TI Transgenic plants expressing assembled secretory antibodies  
IN Hein, Mich B., Fallbrook, CA, United States  
Hiatt, Andrew, San Diego, CA, United States  
Ma, Julian K-C, London, United Kingdom  
PA The Scripps Research Institute, La Jolla, CA, United States (U.S. corporation)  
PI US 5959177 19990928  
AI US 1996-642406 19960503 (8)  
RLI Continuation-in-part of Ser. No. US 1992-971951, filed on 5 Nov 1992, now patented, Pat. No. US 5639947 which is a continuation of Ser. No. US 1990-591823, filed on 2 Oct 1990, now patented, Pat. No. US 5202422 which is a continuation-in-part of Ser. No. US 1989-427765, filed on 27 Oct 1989, now abandoned  
DT Utility  
FS Granted  
LN.CNT 4721  
INCL INCLM: 800/288.000  
INCLS: 800/295.000; 435/419.000; 435/069.100; 435/320.100; 536/023.500; 536/023.530; 536/024.100  
NCL NCLM: 800/288.000  
NCLS: 435/069.100; 435/320.100; 435/419.000; 536/023.500; 536/023.530; 536/024.100; 800/295.000

IC [6]  
ICM: C12N015-00  
ICS: C12N015-29; C12N015-82; A01H005-00  
EXF 800/209; 435/172.3; 435/320.1; 435/419; 435/69.1; 536/23.5; 536/25.53; 536/24.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 95 OF 201 USPATFULL on STN  
AN 1999:85238 USPATFULL  
TI .kappa./mu.-Like protein tyrosine phosphatase, PTP .lambda.  
IN Cheng, Jill, Burlingame, CA, United States  
Lasky, Laurence A., Saulito, CA, United States  
PA Genentech, Inc., S. San Francisco, CA, United States (U.S. corporation)  
PI US 5928887 19990727  
AI US 1997-991258 19971216 (8)  
RLI Division of Ser. No. US 1996-652971, filed on 24 May 1996, now patented, Pat. No. US 5814507  
DT Utility  
FS Granted  
LN.CNT 3235  
INCL INCLM: 435/021.000  
INCLS: 435/196.000; 536/023.200  
NCL NCLM: 435/021.000  
NCLS: 435/196.000; 536/023.200  
IC [6]  
ICM: C12Q001-42  
ICS: C12N009-16; C07H021-04  
EXF 435/21; 435/196; 536/23.2  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 96 OF 201 USPATFULL on STN  
AN 1999:30947 USPATFULL  
TI Modulators of the interaction between ICAM-R and .alpha..sub.d /CD18  
IN Gallatin, W. Michael, Seattle, WA, United States  
Vazeux, Rosemay, Seattle, WA, United States  
PA ICOS Corporation, Bothell, WA, United States (U.S. corporation)  
PI US 5880268 19990309  
AI US 1995-483932 19950607 (8)  
RLI Division of Ser. No. US 1994-286754, filed on 5 Aug 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-102852, filed on 5 Aug 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-9266, filed on 22 Jan 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-894061, filed on 5 Jun 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-889724, filed on 26 May 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-827689, filed on 27 Jan 1992,

now abandoned  
DT Utility  
FS Granted  
LN.CNT 5823  
INCL INCLM: 530/387.300  
INCLS: 530/387.900; 530/388.100; 530/388.220  
NCL NCLM: 530/387.300  
NCLS: 530/387.900; 530/388.100; 530/388.220  
IC [6]  
ICM: C12P021-08  
ICS: C07K016-00  
EXF 530/300; 530/350; 530/387.1; 530/387.9; 530/388.1; 530/388.22;  
530/388.25; 530/388.7; 530/388.73; 530/388.75; 530/389.1; 530/389.6;  
530/387.3

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 97 OF 201 USPATFULL on STN  
AN 1999:18933 USPATFULL  
TI Method for monitoring an inflammatory disease state by detecting  
circulating ICAM-R  
IN Gallatin, W. Michael, Seattle, WA, United States  
Vazeux, Rosemay, Seattle, WA, United States  
PA ICOS Corporation, Bothell, WA, United States (U.S. corporation)  
PI US 5869262 19990209  
AI US 1995-473503 19950607 (8)  
RLI Division of Ser. No. US 1994-286754, filed on 5 Aug 1994, now abandoned  
which is a continuation-in-part of Ser. No. US 1993-102852, filed on 5  
Aug 1993, now abandoned which is a continuation-in-part of Ser. No. US  
1993-9266, filed on 22 Jan 1993, now abandoned which is a  
continuation-in-part of Ser. No. US 1992-894061, filed on 5 Jun 1992,  
now abandoned which is a continuation-in-part of Ser. No. US  
1992-889724, filed on 26 May 1992, now abandoned which is a  
continuation-in-part of Ser. No. US 1992-827689, filed on 27 Jan 1992,  
now abandoned

DT Utility  
FS Granted  
LN.CNT 5859  
INCL INCLM: 435/007.100  
INCLS: 435/007.920; 435/007.940; 435/007.950; 436/811.000  
NCL NCLM: 435/007.100  
NCLS: 435/007.920; 435/007.940; 435/007.950; 436/811.000  
IC [6]  
ICM: G01N033-53  
EXF 424/131.1; 424/9; 424/142.1; 424/144.1; 436/86; 436/811; 435/7.1;  
435/7.92; 435/7.94; 435/7.95; 530/388.2; 530/388.22

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 98 OF 201 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 1999:799445 CAPLUS  
DN 132:92211  
TI High pathogenic potential of low-affinity autoantibodies in experimental  
autoimmune hemolytic anemia  
AU Fossati-Jimack, Liliane; Reiningier, Luc; Chicheportiche, Yves; Clynes,  
Raphael; Ravetch, Jeffrey V.; Honjo, Tasuku; Izui, Shozo  
CS Department of Pathology, University of Geneva, Geneva, 1211/4, Switz.  
SO Journal of Experimental Medicine (1999), 190(11), 1689-1696  
CODEN: JEMEAV; ISSN: 0022-1007  
PB Rockefeller University Press  
DT Journal  
LA English

RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 99 OF 201 USPATFULL on STN  
AN 1998:144218 USPATFULL  
TI Humanized antibodies specific for ICAM related protein  
IN Gallatin, W. Michael, Seattle, WA, United States  
Vazeux, Rosemay, Seattle, WA, United States  
PA ICOS Corporation, Bothell, WA, United States (U.S. corporation)  
PI US 5837822 19981117  
AI US 1995-487113 19950607 (8)  
RLI Continuation-in-part of Ser. No. US 1993-102852, filed on 5 Aug 1993,  
now abandoned which is a continuation-in-part of Ser. No. US 1993-9266,  
filed on 22 Jan 1993, now abandoned which is a continuation-in-part of  
Ser. No. US 1992-894061, filed on 5 Jun 1992, now abandoned which is a  
continuation-in-part of Ser. No. US 1992-889724, filed on 26 May 1992,

now abandoned which is a continuation-in-part of Ser. No. US  
1992-827689, filed on 27 Jan 1992, now abandoned

DT Utility  
FS Granted  
LN.CNT 6796  
INCL INCLM: 530/387.300  
INCLS: 530/388.100; 530/388.220  
NCL NCLM: 530/387.300  
NCLS: 530/388.100; 530/388.220  
IC [6]  
ICM: C12P021-08  
EXF 530/387.1; 530/387.3; 530/388.1; 530/388.22; 530/867  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 100 OF 201 USPATFULL on STN  
AN 1998:119029 USPATFULL  
TI .kappa./mu.-like protein tyrosine phosphatase, PTP .lambda.  
IN Cheng, Jill, Burlingame, CA, United States  
Lasky, Laurence A., Saulito, CA, United States  
PA Genentech, Inc., South San Francisco, CA, United States (U.S.  
corporation)  
PI US 5814507 19980929  
AI US 1996-652971 19960524 (8)  
DT Utility  
FS Granted  
LN.CNT 2996  
INCL INCLM: 435/196.000  
INCLS: 530/387.300  
NCL NCLM: 435/196.000  
NCLS: 530/387.300  
IC [6]  
ICM: C12N009-16  
ICS: C12P021-08  
EXF 435/196; 530/387.3  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 101 OF 201 USPATFULL on STN  
AN 1998:115830 USPATFULL  
TI ICAM-related protein variants  
IN Gallatin, W. Michael, Seattle, WA, United States  
Vazeux, Rosemay, Seattle, WA, United States  
PA ICOS Corporation, Bothell, WA, United States (U.S. corporation)  
PI US 5811517 19980922  
AI US 1995-483389 19950607 (8)  
RLI Division of Ser. No. US 1994-286754, filed on 5 Aug 1994, now abandoned  
which is a continuation-in-part of Ser. No. US 1993-102852, filed on 5  
Aug 1993, now abandoned which is a continuation-in-part of Ser. No. US  
1993-9266, filed on 2 Dec 1993, now abandoned which is a  
continuation-in-part of Ser. No. US 1992-894061, filed on 5 Jun 1992,  
now abandoned which is a continuation-in-part of Ser. No. US  
1992-889724, filed on 26 May 1992, now abandoned which is a  
continuation-in-part of Ser. No. US 1992-827689, filed on 27 Jan 1992,  
now abandoned  
DT Utility  
FS Granted  
LN.CNT 5991  
INCL INCLM: 530/350.000  
INCLS: 536/023.400; 536/023.100; 435/069.100; 435/069.700; 435/320.100;  
435/325.000; 435/252.300  
NCL NCLM: 530/350.000  
NCLS: 435/069.100; 435/069.700; 435/252.300; 435/320.100; 435/325.000;  
536/023.100; 536/023.400  
IC [6]  
ICM: C07K019-00  
ICS: C12N015-62  
EXF 536/23.5; 536/23.1; 530/350; 530/395; 435/69.1; 435/69.7; 435/252.3;  
435/320.1; 435/325  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 102 OF 201 USPATFULL on STN  
AN 1998:75369 USPATFULL  
TI Method to identify compounds which modulate ICAM-related protein  
interactions  
IN Gallatin, W. Michael, Seattle, WA, United States  
Vazeux, Rosemay, Seattle, WA, United States  
PA ICOS Corporation, Bothell, WA, United States (U.S. corporation)

PI US 5773218 19980630  
AI US 1995-482882 19950607 (8)  
RLI Division of Ser. No. US 1994-286754, filed on 5 Aug 1994 which is a continuation-in-part of Ser. No. US 1993-102852, filed on 5 Aug 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-9266, filed on 22 Jan 1993, now abandoned And Ser. No. US 1992-894061, filed on 5 Jun 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-889724, filed on 26 May 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-827689, filed on 27 Jan 1992, now abandoned  
DT Utility  
FS Granted  
LN.CNT 5498  
INCL INCLM: 435/006.000  
NCL NCLM: 435/006.000  
IC [6]  
ICM: C12Q001-68  
EXF 435/6; 435/7.2; 435/69.1; 536/23.5  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 103 OF 201 USPATFULL on STN  
AN 1998:57523 USPATFULL  
TI Recombinant antibodies for human therapy  
IN Newman, Roland A., San Diego, CA, United States  
Hanna, Nabil, Olivenhain, CA, United States  
Raab, Ronald W., San Diego, CA, United States  
PA IDEC Pharmaceuticals Corporation, San Diego, CA, United States (U.S. corporation)  
PI US 5756096 19980526  
AI US 1995-476237 19950607 (8)  
RLI Continuation-in-part of Ser. No. US 1995-379072, filed on 25 Jan 1995, now patented, Pat. No. US 5658570 which is a continuation of Ser. No. US 1992-912292, filed on 10 Jul 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-856281, filed on 23 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-735064, filed on 25 Jul 1991, now abandoned  
DT Utility  
FS Granted  
LN.CNT 1919  
INCL INCLM: 424/154.100  
INCLS: 424/133.100; 424/141.100; 530/387.100  
NCL NCLM: 424/154.100  
NCLS: 424/133.100; 424/141.100; 530/387.100  
IC [6]  
ICM: A61K039-395  
EXF 424/133.1; 424/141.1; 424/154.1; 530/387.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 104 OF 201 USPATFULL on STN  
AN 1998:51191 USPATFULL  
TI Recombinant antibodies for human therapy  
IN Newman, Roland A., San Diego, CA, United States  
Hanna, Nabil, Olivenhain, CA, United States  
Raab, Ronald W., San Diego, CA, United States  
PA IDEC Pharmaceuticals Corporation, San Diego, CA, United States (U.S. corporation)  
PI US 5750105 19980512  
AI US 1995-476349 19950607 (8)  
RLI Division of Ser. No. US 1995-379072, filed on 5 Dec 1995 which is a continuation of Ser. No. US 1992-912292, filed on 10 Jul 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-856281, filed on 23 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-735064, filed on 25 Jul 1991, now abandoned  
DT Utility  
FS Granted  
LN.CNT 2110  
INCL INCLM: 424/133.100  
INCLS: 424/177.100; 424/137.100; 424/138.100; 530/387.300  
NCL NCLM: 424/133.100  
NCLS: 424/137.100; 424/138.100; 424/177.100; 530/387.300  
IC [6]  
ICM: A61K039-395  
ICS: A61K039-40; A61K039-42; C12P021-08  
EXF 424/130.1; 424/133.1; 424/177.1; 424/137.1; 424/138.1; 530/387.3  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 105 OF 201 USPATFULL on STN  
AN 1998:25104 USPATFULL  
TI Expression and export technology of proteins as immunofusins  
IN Lo, Kin-Ming, Wellesley, MA, United States  
Sudo, Yukio, Lexington, MA, United States  
Gillies, Stephen D., Carlisle, MA, United States  
PA Fuji ImmunoPharmaceuticals Corp., Lexington, MA, United States (U.S. corporation)  
PI US 5726044 19980310  
AI US 1995-528122 19950914 (8)  
RLI Continuation-in-part of Ser. No. US 1994-305700, filed on 14 Sep 1994, now patented, Pat. No. US 5541087  
DT Utility  
FS Granted  
LN.CNT 1312  
INCL INCLM: 435/069.700  
INCLS: 435/069.800; 435/070.100; 435/320.100; 435/328.000; 536/023.530  
NCL NCLM: 435/069.700  
NCLS: 435/069.800; 435/070.100; 435/320.100; 435/328.000; 536/023.530  
IC [6]  
ICM: C07K016-46  
ICS: C12N015-13; C12N015-11  
EXF 536/23.5; 536/23.53; 435/320.1; 435/328; 435/69.7; 435/69.8; 435/70.1; 435/69.3

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 106 OF 201 USPATFULL on STN  
AN 1998:11898 USPATFULL  
TI Directed switch-mediated DNA recombination  
IN Jakobovits, Aya, Menlo Park, CA, United States  
PA Xenotech Incorporated, Foster City, CA, United States (U.S. corporation)  
PI US 5714352 19980203  
AI US 1996-619109 19960320 (8)  
DT Utility  
FS Granted  
LN.CNT 1450  
INCL INCLM: 435/172.300  
INCLS: 435/320.100; 435/328.000; 435/372.300  
NCL NCLM: 435/462.000  
NCLS: 435/320.100; 435/328.000; 435/372.300  
IC [6]  
ICM: C12N015-63  
ICS: C12N015-79; C12N005-08; C12N005-24  
EXF 435/69.1; 435/70.21; 435/172.3; 435/320.1; 435/325; 435/326; 435/328; 435/372.3; 536/23.1; 536/23.53

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 107 OF 201 USPATFULL on STN  
AN 97:112606 USPATFULL  
TI Recombinant antibodies for human therapy  
IN Newman, Roland A., San Diego, CA, United States  
Hanna, Nabil, Olivenhain, CA, United States  
Raab, Ronald W., San Diego, CA, United States  
PA Idec Pharmaceuticals Corporation, San Diego, CA, United States (U.S. corporation)  
PI US 5693780 19971202  
AI US 1995-481869 19950607 (8)  
RLI Division of Ser. No. US 1995-379072, filed on 25 Jan 1995 which is a continuation of Ser. No. US 1992-912292, filed on 10 Jul 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-856281, filed on 23 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-735064, filed on 25 Jul 1991, now abandoned  
DT Utility  
FS Granted  
LN.CNT 1755  
INCL INCLM: 536/023.530  
INCLS: 435/252.300; 435/320.100  
NCL NCLM: 536/023.530  
NCLS: 435/252.300; 435/320.100  
IC [6]  
ICM: C07H021-04  
ICS: C12N001-20; C12N015-00  
EXF 536/23.53; 435/320.1; 435/252.3

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 108 OF 201 USPATFULL on STN

AN 97:99175 USPATFULL  
TI Recombinant antibodies for human therapy  
IN Newman, Roland A., San Diego, CA, United States  
Hanna, Nabil, Olivenhain, CA, United States  
Raab, Ronald W., San Diego, CA, United States  
PA IDEC Pharmaceuticals Corporation, San Diego, CA, United States (U.S. corporation)  
PI US 5681722 19971028  
AI US 1995-478039 19950607 (8)  
RLI Division of Ser. No. US 1995-379072, filed on 25 Jan 1995 which is a continuation of Ser. No. US 1992-912292, filed on 10 Jul 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-856281, filed on 23 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-735064, filed on 25 Jul 1991, now abandoned  
DT Utility  
FS Granted  
LN.CNT 2117  
INCL INCLM: 435/069.700  
INCLS: 536/023.530; 536/024.320; 435/069.700; 435/091.200; 435/006.000; 530/387.300  
NCL NCLM: 435/069.700  
NCLS: 435/006.000; 435/091.200; 530/387.300; 536/023.530; 536/024.330  
IC [6]  
ICM: C12P021-08  
ICS: C12P021-04; C12P019-34; C07H021-04  
EXF 536/23.53; 536/24.33; 435/6; 530/387.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 109 OF 201 USPATFULL on STN  
AN 97:96549 USPATFULL  
TI Cells with multiple altered epitopes on a surface antigen for use in transplantation  
IN Chappel, Scott C., Milton, MA, United States  
PA Diacrin, Inc., Charlestown, MA, United States (U.S. corporation)  
PI US 5679340 19971021  
AI US 1994-240150 19940510 (8)  
RLI Continuation-in-part of Ser. No. US 1994-220741, filed on 31 Mar 1994, now abandoned  
DT Utility  
FS Granted  
LN.CNT 994  
INCL INCLM: 424/093.100  
INCLS: 435/240.200  
NCL NCLM: 424/093.100  
NCLS: 435/325.000; 435/366.000; 435/368.000; 435/370.000; 435/371.000; 435/372.000  
IC [6]  
ICM: C12N005-00  
ICS: A01N063-00  
EXF 424/93.1; 435/240.2  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 110 OF 201 USPATFULL on STN  
AN 97:73287 USPATFULL  
TI Recombinant antibodies for human therapy  
IN Newman, Roland A., San Diego, CA, United States  
Hanna, Nabil, Olivenhain, CA, United States  
Raab, Ronald W., San Diego, CA, United States  
PA Idec Pharmaceuticals Corporation, San Diego, CA, United States (U.S. corporation)  
PI US 5658570 19970819  
AI US 1995-379072 19950125 (8)  
RLI Continuation of Ser. No. US 1992-912292, filed on 10 Jul 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-856281, filed on 23 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-735064, filed on 25 Jul 1991, now abandoned  
DT Utility  
FS Granted  
LN.CNT 1829  
INCL INCLM: 424/184.100  
INCLS: 530/388.220; 435/070.210; 435/172.200; 435/172.300; 435/069.600; 935/096.000  
NCL NCLM: 424/184.100  
NCLS: 435/069.600; 435/070.210; 530/388.220  
IC [6]  
ICM: C07K016-28



ICS: A61K039-38; C12P021-04  
EXF 424/184.1; 530/388.22; 435/69.6; 435/70.21; 435/172.2; 435/172.3; 935/96  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 111 OF 201 USPATFULL on STN  
AN 97:56338 USPATFULL  
TI BPI-immunoglobulin fusion proteins  
IN Theofan, Georgia, Torrance, CA, United States  
Grinna, Lynn S., Middleburg, VA, United States  
Horwitz, Arnold, Los Angeles, CA, United States  
PA XOMA Corporation, Berkeley, CA, United States (U.S. corporation)  
PI US 5643570 19970701  
AI US 1993-64693 19930519 (8)  
RLI Continuation-in-part of Ser. No. US 1992-885911, filed on 19 May 1992,  
now abandoned  
DT Utility  
FS Granted  
LN.CNT 1593  
INCL INCLM: 424/134.100  
INCLS: 435/252.300; 435/172.300; 435/320.100; 435/069.100; 530/387.300;  
536/023.400  
NCL NCLM: 424/134.100  
NCLS: 435/069.100; 435/252.300; 435/320.100; 530/387.300; 536/023.400  
IC [6]  
ICM: C12N015-12  
ICS: C12N015-00; A61K039-395; C07K019-00  
EXF 530/387.3; 435/240.2; 435/252.3; 435/69.1; 435/172.3; 435/320.1;  
424/85.8; 424/134.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 112 OF 201 USPATFULL on STN  
AN 96:103888 USPATFULL  
TI CD27 ligand  
IN Beckmann, M. Patricia, Poulsbo, WA, United States  
Goodwin, Raymond G., Seattle, WA, United States  
Giri, Judith G., Seattle, WA, United States  
Armitage, Richard J., Bainbridge Island, WA, United States  
PA Immunex Corporation, Seattle, WA, United States (U.S. corporation)  
PI US 5573924 19961112  
AI US 1993-106507 19930813 (8)  
RLI Continuation-in-part of Ser. No. US 1992-941648, filed on 8 Sep 1992,  
now abandoned  
DT Utility  
FS Granted  
LN.CNT 1789  
INCL INCLM: 435/069.500  
INCLS: 435/240.200; 435/252.000; 435/003.000; 435/320.100; 530/351.000;  
536/023.500; 930/140.000  
NCL NCLM: 435/069.500  
NCLS: 435/252.300; 435/320.100; 435/365.100; 530/351.000; 536/023.500;  
930/140.000  
IC [6]  
ICM: C12N015-19  
ICS: C07K014-52  
EXF 530/350; 530/351; 530/403; 530/399; 536/23.5; 435/69.3; 435/69.5X;  
435/240.1; 435/240.2; 435/252.3; 435/320.1; 930/140  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 113 OF 201 USPATFULL on STN  
AN 96:67909 USPATFULL  
TI Expression and export technology of proteins as immunofusins  
IN Lo, Kin-Ming, Wellesley, MA, United States  
Sudo, Yukio, Lexington, MA, United States  
Gillies, Stephen D., Hingham, MA, United States  
PA Fuji ImmunoPharmaceuticals Corporation, Lexington, MA, United States  
(U.S. corporation)  
PI US 5541087 19960730  
AI US 1994-305700 19940914 (8)  
DT Utility  
FS Granted  
LN.CNT 1142  
INCL INCLM: 435/697.000  
INCLS: 435/069.800; 435/070.100; 435/240.100; 435/252.300; 435/320.100;  
530/387.300; 530/391.100; 530/391.700; 530/402.000; 530/344.000;  
530/345.000; 536/023.100; 536/023.400; 536/023.530  
NCL NCLM: 435/069.700

NCLS: 435/069.800; 435/070.100; 435/252.300; 435/320.100; 435/355.000;  
435/369.000; 530/344.000; 530/345.000; 530/387.300; 530/391.100;  
530/391.700; 530/402.000; 536/023.100; 536/023.400; 536/023.530

IC [6]

ICM: C07K016-46

ICS: C12N015-13; C12N015-11

EXF 435/69.7; 435/69.8; 435/70.1; 435/240.1; 435/252.3; 435/320.1;  
530/387.3; 530/387.1; 530/391.1; 530/866; 530/867; 530/402; 530/344;  
530/345; 530/391.7; 530/23.53; 530/23.1; 530/23.4

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 114 OF 201 USPATFULL on STN

AN 96:38806 USPATFULL

TI Recombinant DNA encoding hybrid immunoglobulins

IN Capon, Daniel J., San Mateo, CA, United States

Lasky, Laurence A., Sausalito, CA, United States

PA Genentech, Inc., San Francisco, CA, United States (U.S. corporation)

PI US 5514582 19960507

AI US 1994-185670 19940121 (8)

RLI Continuation of Ser. No. US 1992-986931, filed on 8 Dec 1992, now  
patented, Pat. No. US 5428130 which is a continuation of Ser. No. US  
1991-808122, filed on 16 Dec 1991, now patented, Pat. No. US 5225538  
which is a division of Ser. No. US 1989-440625, filed on 22 Nov 1989,  
now patented, Pat. No. US 5116964 which is a continuation-in-part of  
Ser. No. US 1989-315015, filed on 23 Feb 1989, now patented, Pat. No. US  
5098833

DT Utility

FS Granted

LN.CNT 2644

INCL INCLM: 435/252.300

INCLS: 435/069.700; 435/320.100; 536/023.500; 536/023.520; 536/023.530

NCL NCLM: 435/252.300

NCLS: 435/069.700; 435/320.100; 536/023.500; 536/023.520; 536/023.530

IC [6]

ICM: C12N015-62

EXF 435/69.7; 435/252.3; 435/320.1; 536/23.4

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 115 OF 201 USPATFULL on STN

AN 95:58232 USPATFULL

TI Hybrid immunoglobulins

IN Capon, Daniel J., San Mateo, CA, United States

Lasky, Laurence A., Sausalito, CA, United States

PA Genentech, Inc., San Francisco, CA, United States (U.S. corporation)

PI US 5428130 19950627

AI US 1992-986931 19921208 (7)

RLI Continuation of Ser. No. US 1991-808122, filed on 16 Dec 1991, now  
patented, Pat. No. US 5225538 which is a continuation of Ser. No. US  
1989-440625, filed on 22 Nov 1989, now patented, Pat. No. US 5116964  
which is a continuation-in-part of Ser. No. US 1989-315015, filed on 23  
Feb 1989, now patented, Pat. No. US 5098833

DT Utility

FS Granted

LN.CNT 2630

INCL INCLM: 530/350.000

INCLS: 530/387.100; 536/023.400; 435/064.700

NCL NCLM: 530/350.000

NCLS: 435/069.700; 530/387.100; 536/023.400

IC [6]

ICM: C07K013-00

EXF 435/69.7; 435/252.3; 435/320.1; 530/350; 530/387.1; 536/23.4

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 116 OF 201 USPATFULL on STN

AN 92:42890 USPATFULL

TI Hybrid immunoglobulins

IN Capon, Daniel J., San Mateo, CA, United States

Lasky, Laurence A., Sausalito, CA, United States

PA Genentech, Inc., South San Francisco, CA, United States (U.S.  
corporation)

PI US 5116964 19920526

AI US 1989-440625 19891122 (7)

RLI Continuation-in-part of Ser. No. US 1989-315015, filed on 23 Feb 1989

DT Utility

FS Granted

LN.CNT 2533

INCL INCLM: 536/027.000  
INCLS: 435/069.700; 435/252.300; 435/320.110; 530/350.000  
NCL NCLM: 536/023.500  
NCLS: 424/134.100; 435/069.700; 435/252.300; 435/320.100; 530/350.000;  
530/387.300; 536/023.510; 536/023.530  
IC [5]  
ICM: C07H021-04  
ICS: C12N015-62; C12P021-02  
EXF 435/69.7; 435/172.3; 435/252.3; 435/320; 436/512; 530/350; 530/387;  
536/27

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 117 OF 201 BIOTECHDS COPYRIGHT 2004 THE THOMSON CORP. on STN  
AN 1991-01425 BIOTECHDS  
TI Cloned DNA comprising two parts coding for domains of CD4;  
for producing a peptide for use in therapy of AIDS; chimeric antibody  
construction; antibody engineering; potential application in HIV virus  
inhibition

PA Roche  
PI EP 394827 31 Oct 1990  
AI EP 1990-107393 19 Apr 1990  
PRAI EP 1989-117606 23 Sep 1989; EP 1989-107572 26 Apr 1989  
DT Patent  
LA English  
OS WPI: 1990-328885 [44]

L4 ANSWER 118 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAE26332 peptide DGENE  
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
to a peptide capable of binding amyloidogenic protein -  
Geftter M L; Israel D I; Joyal J L; Gosselin M  
(PRAE-N) PRAECIS PHARM INC.  
PI WO 2002042462 A2 20020530 79p  
AI WO 2001-US44581 20011127  
PRAI US 2000-253302P 20001127  
US 2000-250198P 20001129  
US 2000-257186P 20001220  
DT Patent  
LA English  
OS 2002-636427 [68]  
DESC Human beta-amyloid peptide mutant (Abeta residues 1-40).

L4 ANSWER 119 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAE26331 peptide DGENE  
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
to a peptide capable of binding amyloidogenic protein -  
Geftter M L; Israel D I; Joyal J L; Gosselin M  
(PRAE-N) PRAECIS PHARM INC.  
PI WO 2002042462 A2 20020530 79p  
AI WO 2001-US44581 20011127  
PRAI US 2000-253302P 20001127  
US 2000-250198P 20001129  
US 2000-257186P 20001220  
DT Patent  
LA English  
OS 2002-636427 [68]  
DESC Human beta-amyloid peptide mutant (Abeta residues 1-29).

L4 ANSWER 120 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAE26330 peptide DGENE  
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
to a peptide capable of binding amyloidogenic protein -  
Geftter M L; Israel D I; Joyal J L; Gosselin M  
(PRAE-N) PRAECIS PHARM INC.  
PI WO 2002042462 A2 20020530 79p  
AI WO 2001-US44581 20011127  
PRAI US 2000-253302P 20001127  
US 2000-250198P 20001129  
US 2000-257186P 20001220  
DT Patent

LA English  
OS 2002-636427 [68]  
DESC Human beta-amyloid peptide mutant (Abeta residues 10-25).

L4 ANSWER 121 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAE26302 peptide DGENE  
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
to a peptide capable of binding amyloidogenic protein -  
IN Gefter M L; Israel D I; Joyal J L; Gosselin M  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 2002042462 A2 20020530 79p  
AI WO 2001-US44581 20011127  
PRAI US 2000-253302P 20001127  
US 2000-250198P 20001129  
US 2000-257186P 20001220

DT Patent  
LA English  
OS 2002-636427 [68]  
DESC Human beta-amyloid peptide (beta-AP) with glycine linker #2.

L4 ANSWER 122 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAE26301 peptide DGENE  
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
to a peptide capable of binding amyloidogenic protein -  
IN Gefter M L; Israel D I; Joyal J L; Gosselin M  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 2002042462 A2 20020530 79p  
AI WO 2001-US44581 20011127  
PRAI US 2000-253302P 20001127  
US 2000-250198P 20001129  
US 2000-257186P 20001220

DT Patent  
LA English  
OS 2002-636427 [68]  
DESC Human beta-amyloid peptide (beta-AP) with glycine linker #1.

L4 ANSWER 123 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAE26300 peptide DGENE  
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
to a peptide capable of binding amyloidogenic protein -  
IN Gefter M L; Israel D I; Joyal J L; Gosselin M  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 2002042462 A2 20020530 79p  
AI WO 2001-US44581 20011127  
PRAI US 2000-253302P 20001127  
US 2000-250198P 20001129  
US 2000-257186P 20001220

DT Patent  
LA English  
OS 2002-636427 [68]  
CR N-PSDB: AAD43954  
DESC Human beta-amyloid peptide (beta-AP) #5.

L4 ANSWER 124 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAE26299 peptide DGENE  
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
to a peptide capable of binding amyloidogenic protein -  
IN Gefter M L; Israel D I; Joyal J L; Gosselin M  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 2002042462 A2 20020530 79p  
AI WO 2001-US44581 20011127  
PRAI US 2000-253302P 20001127  
US 2000-250198P 20001129  
US 2000-257186P 20001220

DT Patent  
LA English  
OS 2002-636427 [68]  
DESC Human tPA secretory leader peptide.

L4 ANSWER 125 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAE26298 peptide DGENE  
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
to a peptide capable of binding amyloidogenic protein -  
IN Gefter M L; Israel D I; Joyal J L; Gosselin M  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 2002042462 A2 20020530 79p  
AI WO 2001-US44581 20011127  
PRAI US 2000-253302P 20001127  
US 2000-250198P 20001129  
US 2000-257186P 20001220  
DT Patent  
LA English  
OS 2002-636427 [68]  
DESC Peptide #20 capable of binding an amyloidogenic protein.

L4 ANSWER 126 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAE26297 peptide DGENE  
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
to a peptide capable of binding amyloidogenic protein -  
IN Gefter M L; Israel D I; Joyal J L; Gosselin M  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 2002042462 A2 20020530 79p  
AI WO 2001-US44581 20011127  
PRAI US 2000-253302P 20001127  
US 2000-250198P 20001129  
US 2000-257186P 20001220  
DT Patent  
LA English  
OS 2002-636427 [68]  
DESC Peptide #19 capable of binding an amyloidogenic protein.

L4 ANSWER 127 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAE26296 peptide DGENE  
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
to a peptide capable of binding amyloidogenic protein -  
IN Gefter M L; Israel D I; Joyal J L; Gosselin M  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 2002042462 A2 20020530 79p  
AI WO 2001-US44581 20011127  
PRAI US 2000-253302P 20001127  
US 2000-250198P 20001129  
US 2000-257186P 20001220  
DT Patent  
LA English  
OS 2002-636427 [68]  
DESC Peptide #18 capable of binding an amyloidogenic protein.

L4 ANSWER 128 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAE26295 peptide DGENE  
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
to a peptide capable of binding amyloidogenic protein -  
IN Gefter M L; Israel D I; Joyal J L; Gosselin M  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 2002042462 A2 20020530 79p  
AI WO 2001-US44581 20011127  
PRAI US 2000-253302P 20001127  
US 2000-250198P 20001129  
US 2000-257186P 20001220  
DT Patent  
LA English  
OS 2002-636427 [68]  
DESC Peptide #17 capable of binding an amyloidogenic protein.

L4 ANSWER 129 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAE26294 peptide DGENE  
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,

e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
to a peptide capable of binding amyloidogenic protein -  
IN Gefter M L; Israel D I; Joyal J L; Gosselin M  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 2002042462 A2 20020530 79p  
AI WO 2001-US44581 20011127  
PRAI US 2000-253302P 20001127  
US 2000-250198P 20001129  
US 2000-257186P 20001220  
DT Patent  
LA English  
OS 2002-636427 [68]  
DESC Peptide #16 capable of binding an amyloidogenic protein.

L4 ANSWER 130 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAE26293 peptide DGENE  
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
to a peptide capable of binding amyloidogenic protein -  
IN Gefter M L; Israel D I; Joyal J L; Gosselin M  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 2002042462 A2 20020530 79p  
AI WO 2001-US44581 20011127  
PRAI US 2000-253302P 20001127  
US 2000-250198P 20001129  
US 2000-257186P 20001220  
DT Patent  
LA English  
OS 2002-636427 [68]  
DESC Peptide #15 capable of binding an amyloidogenic protein.

L4 ANSWER 131 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAE26292 peptide DGENE  
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
to a peptide capable of binding amyloidogenic protein -  
IN Gefter M L; Israel D I; Joyal J L; Gosselin M  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 2002042462 A2 20020530 79p  
AI WO 2001-US44581 20011127  
PRAI US 2000-253302P 20001127  
US 2000-250198P 20001129  
US 2000-257186P 20001220  
DT Patent  
LA English  
OS 2002-636427 [68]  
DESC Peptide #14 capable of binding an amyloidogenic protein.

L4 ANSWER 132 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAE26291 peptide DGENE  
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
to a peptide capable of binding amyloidogenic protein -  
IN Gefter M L; Israel D I; Joyal J L; Gosselin M  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 2002042462 A2 20020530 79p  
AI WO 2001-US44581 20011127  
PRAI US 2000-253302P 20001127  
US 2000-250198P 20001129  
US 2000-257186P 20001220  
DT Patent  
LA English  
OS 2002-636427 [68]  
DESC Peptide #13 capable of binding an amyloidogenic protein.

L4 ANSWER 133 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAE26290 peptide DGENE  
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
to a peptide capable of binding amyloidogenic protein -  
IN Gefter M L; Israel D I; Joyal J L; Gosselin M

PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 2002042462 A2 20020530 79p  
AI WO 2001-US44581 20011127  
PRAI US 2000-253302P 20001127  
US 2000-250198P 20001129  
US 2000-257186P 20001220  
DT Patent  
LA English  
OS 2002-636427 [68]  
DESC Peptide #12 capable of binding an amyloidogenic protein.

L4 ANSWER 134 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAE26289 peptide DGENE  
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
to a peptide capable of binding amyloidogenic protein -  
Gefter M L; Israel D I; Joyal J L; Gosselin M  
(PRAE-N) PRAECIS PHARM INC.  
PI WO 2002042462 A2 20020530 79p  
AI WO 2001-US44581 20011127  
PRAI US 2000-253302P 20001127  
US 2000-250198P 20001129  
US 2000-257186P 20001220  
DT Patent  
LA English  
OS 2002-636427 [68]  
DESC Peptide #11 capable of binding an amyloidogenic protein.

L4 ANSWER 135 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAE26288 peptide DGENE  
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
to a peptide capable of binding amyloidogenic protein -  
Gefter M L; Israel D I; Joyal J L; Gosselin M  
(PRAE-N) PRAECIS PHARM INC.  
PI WO 2002042462 A2 20020530 79p  
AI WO 2001-US44581 20011127  
PRAI US 2000-253302P 20001127  
US 2000-250198P 20001129  
US 2000-257186P 20001220  
DT Patent  
LA English  
OS 2002-636427 [68]  
DESC Peptide #10 capable of binding an amyloidogenic protein.

L4 ANSWER 136 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAE26286 peptide DGENE  
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
to a peptide capable of binding amyloidogenic protein -  
Gefter M L; Israel D I; Joyal J L; Gosselin M  
(PRAE-N) PRAECIS PHARM INC.  
PI WO 2002042462 A2 20020530 79p  
AI WO 2001-US44581 20011127  
PRAI US 2000-253302P 20001127  
US 2000-250198P 20001129  
US 2000-257186P 20001220  
DT Patent  
LA English  
OS 2002-636427 [68]  
DESC Peptide #9 capable of binding an amyloidogenic protein.

L4 ANSWER 137 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAE26284 peptide DGENE  
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
to a peptide capable of binding amyloidogenic protein -  
Gefter M L; Israel D I; Joyal J L; Gosselin M  
(PRAE-N) PRAECIS PHARM INC.  
PI WO 2002042462 A2 20020530 79p  
AI WO 2001-US44581 20011127  
PRAI US 2000-253302P 20001127

US 2000-250198P 20001129  
US 2000-257186P 20001220  
DT Patent  
LA English  
OS 2002-636427 [68]  
DESC Peptide #8 capable of binding an amyloidogenic protein.

L4 ANSWER 138 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAE26283 peptide DGENE  
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
to a peptide capable of binding amyloidogenic protein -  
IN Gefter M L; Israel D I; Joyal J L; Gosselin M  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 2002042462 A2 20020530 79p  
AI WO 2001-US44581 20011127  
PRAI US 2000-253302P 20001127  
US 2000-250198P 20001129  
US 2000-257186P 20001220  
DT Patent  
LA English  
OS 2002-636427 [68]  
DESC Peptide #7 capable of binding an amyloidogenic protein.

L4 ANSWER 139 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAE26282 peptide DGENE  
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
to a peptide capable of binding amyloidogenic protein -  
IN Gefter M L; Israel D I; Joyal J L; Gosselin M  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 2002042462 A2 20020530 79p  
AI WO 2001-US44581 20011127  
PRAI US 2000-253302P 20001127  
US 2000-250198P 20001129  
US 2000-257186P 20001220  
DT Patent  
LA English  
OS 2002-636427 [68]  
DESC Peptide #6 capable of binding an amyloidogenic protein.

L4 ANSWER 140 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAE26281 peptide DGENE  
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
to a peptide capable of binding amyloidogenic protein -  
IN Gefter M L; Israel D I; Joyal J L; Gosselin M  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 2002042462 A2 20020530 79p  
AI WO 2001-US44581 20011127  
PRAI US 2000-253302P 20001127  
US 2000-250198P 20001129  
US 2000-257186P 20001220  
DT Patent  
LA English  
OS 2002-636427 [68]  
DESC Peptide #5 capable of binding an amyloidogenic protein.

L4 ANSWER 141 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAE26279 peptide DGENE  
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
to a peptide capable of binding amyloidogenic protein -  
IN Gefter M L; Israel D I; Joyal J L; Gosselin M  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 2002042462 A2 20020530 79p  
AI WO 2001-US44581 20011127  
PRAI US 2000-253302P 20001127  
US 2000-250198P 20001129  
US 2000-257186P 20001220  
DT Patent  
LA English



OS 2002-636427 [68]  
DESC Peptide #4 capable of binding an amyloidogenic protein.

L4 ANSWER 142 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAE26277 peptide DGENE  
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
to a peptide capable of binding amyloidogenic protein -  
IN Gefter M L; Israel D I; Joyal J L; Gosselin M  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 2002042462 A2 20020530 79p  
AI WO 2001-US44581 20011127  
PRAI US 2000-253302P 20001127  
US 2000-250198P 20001129  
US 2000-257186P 20001220

DT Patent  
LA English

OS 2002-636427 [68]  
DESC Peptide #3 capable of binding an amyloidogenic protein.

L4 ANSWER 143 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAE26276 peptide DGENE  
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
to a peptide capable of binding amyloidogenic protein -  
IN Gefter M L; Israel D I; Joyal J L; Gosselin M  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 2002042462 A2 20020530 79p  
AI WO 2001-US44581 20011127  
PRAI US 2000-253302P 20001127  
US 2000-250198P 20001129  
US 2000-257186P 20001220

DT Patent  
LA English

OS 2002-636427 [68]  
DESC Peptide #2 capable of binding an amyloidogenic protein.

L4 ANSWER 144 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAE26275 peptide DGENE  
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
to a peptide capable of binding amyloidogenic protein -  
IN Gefter M L; Israel D I; Joyal J L; Gosselin M  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 2002042462 A2 20020530 79p  
AI WO 2001-US44581 20011127  
PRAI US 2000-253302P 20001127  
US 2000-250198P 20001129  
US 2000-257186P 20001220

DT Patent  
LA English

OS 2002-636427 [68]  
DESC Peptide #1 capable of binding an amyloidogenic protein.

L4 ANSWER 145 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAE26274 Protein DGENE  
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
to a peptide capable of binding amyloidogenic protein -  
IN Gefter M L; Israel D I; Joyal J L; Gosselin M  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 2002042462 A2 20020530 79p  
AI WO 2001-US44581 20011127  
PRAI US 2000-253302P 20001127  
US 2000-250198P 20001129  
US 2000-257186P 20001220

DT Patent  
LA English

OS 2002-636427 [68]  
DESC Human beta amyloid-IgG1 Fc fusion protein.

L4 ANSWER 146 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN

AN AAE26273 Protein DGENE  
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
to a peptide capable of binding amyloidogenic protein -  
IN Gefter M L; Israel D I; Joyal J L; Gosselin M  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 2002042462 A2 20020530 79p  
AI WO 2001-US44581 20011127  
PRAI US 2000-253302P 20001127  
US 2000-250198P 20001129  
US 2000-257186P 20001220  
DT Patent  
LA English  
OS 2002-636427 [68]  
CR N-PSDB: AAD43943  
DESC Human tPA delta pro/16-30/Fc fusion protein.

L4 ANSWER 147 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAE26272 Protein DGENE  
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
to a peptide capable of binding amyloidogenic protein -  
IN Gefter M L; Israel D I; Joyal J L; Gosselin M  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 2002042462 A2 20020530 79p  
AI WO 2001-US44581 20011127  
PRAI US 2000-253302P 20001127  
US 2000-250198P 20001129  
US 2000-257186P 20001220  
DT Patent  
LA English  
OS 2002-636427 [68]  
DESC Human IgG1 heavy chain.

L4 ANSWER 148 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAE26271 peptide DGENE  
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
to a peptide capable of binding amyloidogenic protein -  
IN Gefter M L; Israel D I; Joyal J L; Gosselin M  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 2002042462 A2 20020530 79p  
AI WO 2001-US44581 20011127  
PRAI US 2000-253302P 20001127  
US 2000-250198P 20001129  
US 2000-257186P 20001220  
DT Patent  
LA English  
OS 2002-636427 [68]  
DESC Human beta-amyloid peptide (beta-AP) #4.

L4 ANSWER 149 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAE26270 peptide DGENE  
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
to a peptide capable of binding amyloidogenic protein -  
IN Gefter M L; Israel D I; Joyal J L; Gosselin M  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 2002042462 A2 20020530 79p  
AI WO 2001-US44581 20011127  
PRAI US 2000-253302P 20001127  
US 2000-250198P 20001129  
US 2000-257186P 20001220  
DT Patent  
LA English  
OS 2002-636427 [68]  
DESC Human tissue plasminogen activator (tPA) signal peptide.

L4 ANSWER 150 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAE26269 peptide DGENE  
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*

\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
 to a peptide capable of binding amyloidogenic protein -  
 IN Gefter M L; Israel D I; Joyal J L; Gosselin M  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI WO 2002042462 A2 20020530 79p  
 AI WO 2001-US44581 20011127  
 PRAI US 2000-253302P 20001127  
 US 2000-250198P 20001129  
 US 2000-257186P 20001220  
 DT Patent  
 LA English  
 OS 2002-636427 [68]  
 DESC Human islet amyloid polypeptide (IAPP) peptide.

L4 ANSWER 151 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
 AN AAE26268 peptide DGENE  
 TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
 e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
 \*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
 to a peptide capable of binding amyloidogenic protein -  
 IN Gefter M L; Israel D I; Joyal J L; Gosselin M  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI WO 2002042462 A2 20020530 79p  
 AI WO 2001-US44581 20011127  
 PRAI US 2000-253302P 20001127  
 US 2000-250198P 20001129  
 US 2000-257186P 20001220  
 DT Patent  
 LA English  
 OS 2002-636427 [68]  
 DESC Human amyloidogenic peptide.

L4 ANSWER 152 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
 AN AAE26267 peptide DGENE  
 TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
 e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
 \*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
 to a peptide capable of binding amyloidogenic protein -  
 IN Gefter M L; Israel D I; Joyal J L; Gosselin M  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI WO 2002042462 A2 20020530 79p  
 AI WO 2001-US44581 20011127  
 PRAI US 2000-253302P 20001127  
 US 2000-250198P 20001129  
 US 2000-257186P 20001220  
 DT Patent  
 LA English  
 OS 2002-636427 [68]  
 DESC Human beta-amyloid peptide (beta-AP) #3.

L4 ANSWER 153 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
 AN AAE26266 peptide DGENE  
 TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
 e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
 \*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
 to a peptide capable of binding amyloidogenic protein -  
 IN Gefter M L; Israel D I; Joyal J L; Gosselin M  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI WO 2002042462 A2 20020530 79p  
 AI WO 2001-US44581 20011127  
 PRAI US 2000-253302P 20001127  
 US 2000-250198P 20001129  
 US 2000-257186P 20001220  
 DT Patent  
 LA English  
 OS 2002-636427 [68]  
 DESC Human beta-amyloid peptide (beta-AP) #2.

L4 ANSWER 154 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
 AN AAE26265 peptide DGENE  
 TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
 e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
 \*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
 to a peptide capable of binding amyloidogenic protein -  
 IN Gefter M L; Israel D I; Joyal J L; Gosselin M  
 PA (PRAE-N) PRAECIS PHARM INC.

PI WO 2002042462 A2 20020530 79p  
 AI WO 2001-US44581 20011127  
 PRAI US 2000-253302P 20001127  
 US 2000-250198P 20001129  
 US 2000-257186P 20001220  
 DT Patent  
 LA English  
 OS 2002-636427 [68]  
 DESC Human beta-amyloid peptide (beta-AP) #1.

L4 ANSWER 155 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
 AN AAR44420 Protein DGENE  
 TI New fusion proteins for treating bacterial infections - comprising a bactericidal-permeability-increasing protein and a immunoglobulin heavy chain constant domain  
 IN Grinna L S; Horwitz A; Theofan G  
 PA (XOMA) XOMA CORP.  
 PI WO 9323434 A2 19931125 75p  
 AI WO 1993-US4754 19930519  
 PRAI US 1992-885911 19920519  
 DT Patent  
 LA English  
 OS 1993-386485 [48]  
 CR N-PSDB: AAQ52488  
 DESC pING4512 encoded fusion protein.

L4 ANSWER 156 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
 AN AAR44419 Peptide DGENE  
 TI New fusion proteins for treating bacterial infections - comprising a bactericidal-permeability-increasing protein and a immunoglobulin heavy chain constant domain  
 IN Grinna L S; Horwitz A; Theofan G  
 PA (XOMA) XOMA CORP.  
 PI WO 9323434 A2 19931125 75p  
 AI WO 1993-US4754 19930519  
 PRAI US 1992-885911 19920519  
 DT Patent  
 LA English  
 OS 1993-386485 [48]  
 DESC rBPI-IgG fusion N-terminal sequence.

L4 ANSWER 157 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
 AN AAR44418 Peptide DGENE  
 TI New fusion proteins for treating bacterial infections - comprising a bactericidal-permeability-increasing protein and a immunoglobulin heavy chain constant domain  
 IN Grinna L S; Horwitz A; Theofan G  
 PA (XOMA) XOMA CORP.  
 PI WO 9323434 A2 19931125 75p  
 AI WO 1993-US4754 19930519  
 PRAI US 1992-885911 19920519  
 DT Patent  
 LA English  
 OS 1993-386485 [48]  
 DESC IgG hinge region upstream fragment.

L4 ANSWER 158 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
 AN AAR44417 Peptide DGENE  
 TI New fusion proteins for treating bacterial infections - comprising a bactericidal-permeability-increasing protein and a immunoglobulin heavy chain constant domain  
 IN Grinna L S; Horwitz A; Theofan G  
 PA (XOMA) XOMA CORP.  
 PI WO 9323434 A2 19931125 75p  
 AI WO 1993-US4754 19930519  
 PRAI US 1992-885911 19920519  
 DT Patent  
 LA English  
 OS 1993-386485 [48]  
 DESC IgG 5' fragment.

L4 ANSWER 159 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
 AN AAD43969 DNA DGENE  
 TI Novel therapeutic agent useful for treating an amyloidogenic disorder, e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
 \*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked

to a peptide capable of binding amyloidogenic protein -  
IN Gefter M L; Israel D I; Joyal J L; Gosselin M  
PA (PRAE-N) PRAECIS PHARM INC.

PI WO 2002042462 A2 20020530 79p

AI WO 2001-US44581 20011127

PRAI US 2000-253302P 20001127

US 2000-250198P 20001129

US 2000-257186P 20001220

DT Patent

LA English

OS 2002-636427 [68]

DESC Human beta-amyloid gene fragment, DI-235.

L4 ANSWER 160 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN

AN AAD43968 DNA DGENE

TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked

to a peptide capable of binding amyloidogenic protein -

IN Gefter M L; Israel D I; Joyal J L; Gosselin M

PA (PRAE-N) PRAECIS PHARM INC.

PI WO 2002042462 A2 20020530 79p

AI WO 2001-US44581 20011127

PRAI US 2000-253302P 20001127

US 2000-250198P 20001129

US 2000-257186P 20001220

DT Patent

LA English

OS 2002-636427 [68]

DESC Human beta-amyloid gene fragment, DI-234-3G.

L4 ANSWER 161 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN

AN AAD43967 DNA DGENE

TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked

to a peptide capable of binding amyloidogenic protein -

IN Gefter M L; Israel D I; Joyal J L; Gosselin M

PA (PRAE-N) PRAECIS PHARM INC.

PI WO 2002042462 A2 20020530 79p

AI WO 2001-US44581 20011127

PRAI US 2000-253302P 20001127

US 2000-250198P 20001129

US 2000-257186P 20001220

DT Patent

LA English

OS 2002-636427 [68]

DESC Human beta-amyloid gene fragment, DI-234.

L4 ANSWER 162 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN

AN AAD43966 DNA DGENE

TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked

to a peptide capable of binding amyloidogenic protein -

IN Gefter M L; Israel D I; Joyal J L; Gosselin M

PA (PRAE-N) PRAECIS PHARM INC.

PI WO 2002042462 A2 20020530 79p

AI WO 2001-US44581 20011127

PRAI US 2000-253302P 20001127

US 2000-250198P 20001129

US 2000-257186P 20001220

DT Patent

LA English

OS 2002-636427 [68]

DESC Human beta-amyloid gene fragment, DI-233.

L4 ANSWER 163 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN

AN AAD43965 DNA DGENE

TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked

to a peptide capable of binding amyloidogenic protein -

IN Gefter M L; Israel D I; Joyal J L; Gosselin M

PA (PRAE-N) PRAECIS PHARM INC.

PI WO 2002042462 A2 20020530 79p

AI WO 2001-US44581 20011127  
PRAI US 2000-253302P 20001127  
US 2000-250198P 20001129  
US 2000-257186P 20001220  
DT Patent  
LA English  
OS 2002-636427 [68]  
DESC Human beta-amyloid gene fragment, DI-232-3G.

L4 ANSWER 164 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAD43964 DNA DGENE  
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
to a peptide capable of binding amyloidogenic protein -  
IN Gefter M L; Israel D I; Joyal J L; Gosselin M  
PA (PRAE-N) PRAECIS PHARM INC.

PI WO 2002042462 A2 20020530 79p

AI WO 2001-US44581 20011127  
PRAI US 2000-253302P 20001127  
US 2000-250198P 20001129  
US 2000-257186P 20001220

DT Patent  
LA English

OS 2002-636427 [68]

DESC Human beta-amyloid gene fragment, DI-232.

L4 ANSWER 165 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAD43963 DNA DGENE

TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
to a peptide capable of binding amyloidogenic protein -  
IN Gefter M L; Israel D I; Joyal J L; Gosselin M  
PA (PRAE-N) PRAECIS PHARM INC.

PI WO 2002042462 A2 20020530 79p

AI WO 2001-US44581 20011127  
PRAI US 2000-253302P 20001127  
US 2000-250198P 20001129  
US 2000-257186P 20001220

DT Patent  
LA English

OS 2002-636427 [68]

DESC Human beta-amyloid gene fragment, DI-231.

L4 ANSWER 166 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAD43962 DNA DGENE

TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
to a peptide capable of binding amyloidogenic protein -

IN Gefter M L; Israel D I; Joyal J L; Gosselin M  
PA (PRAE-N) PRAECIS PHARM INC.

PI WO 2002042462 A2 20020530 79p

AI WO 2001-US44581 20011127  
PRAI US 2000-253302P 20001127  
US 2000-250198P 20001129  
US 2000-257186P 20001220

DT Patent  
LA English

OS 2002-636427 [68]

DESC DI230 oligo used to assemble beta-amyloid gene subfragment.

L4 ANSWER 167 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAD43961 DNA DGENE

TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
to a peptide capable of binding amyloidogenic protein -

IN Gefter M L; Israel D I; Joyal J L; Gosselin M  
PA (PRAE-N) PRAECIS PHARM INC.

PI WO 2002042462 A2 20020530 79p

AI WO 2001-US44581 20011127  
PRAI US 2000-253302P 20001127  
US 2000-250198P 20001129  
US 2000-257186P 20001220

DT Patent  
LA English  
OS 2002-636427 [68]  
DESC DI229 oligo used to assemble beta-amyloid gene subfragment.

L4 ANSWER 168 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAD43960 DNA DGENE  
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
to a peptide capable of binding amyloidogenic protein -  
Gefter M L; Israel D I; Joyal J L; Gosselin M  
(PRAE-N) PRAECIS PHARM INC.  
PI WO 2002042462 A2 20020530 79p  
AI WO 2001-US44581 20011127  
PRAI US 2000-253302P 20001127  
US 2000-250198P 20001129  
US 2000-257186P 20001220

DT Patent  
LA English  
OS 2002-636427 [68]  
DESC DI228 oligo used to assemble beta-amyloid gene subfragment.

L4 ANSWER 169 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAD43959 DNA DGENE  
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
to a peptide capable of binding amyloidogenic protein -  
Gefter M L; Israel D I; Joyal J L; Gosselin M  
(PRAE-N) PRAECIS PHARM INC.  
PI WO 2002042462 A2 20020530 79p  
AI WO 2001-US44581 20011127  
PRAI US 2000-253302P 20001127  
US 2000-250198P 20001129  
US 2000-257186P 20001220

DT Patent  
LA English  
OS 2002-636427 [68]  
DESC DI227 oligo used to assemble beta-amyloid gene subfragment.

L4 ANSWER 170 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAD43958 DNA DGENE  
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
to a peptide capable of binding amyloidogenic protein -  
Gefter M L; Israel D I; Joyal J L; Gosselin M  
(PRAE-N) PRAECIS PHARM INC.  
PI WO 2002042462 A2 20020530 79p  
AI WO 2001-US44581 20011127  
PRAI US 2000-253302P 20001127  
US 2000-250198P 20001129  
US 2000-257186P 20001220

DT Patent  
LA English  
OS 2002-636427 [68]  
DESC DI226 oligo used to assemble beta-amyloid gene subfragment.

L4 ANSWER 171 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAD43957 DNA DGENE  
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
to a peptide capable of binding amyloidogenic protein -  
Gefter M L; Israel D I; Joyal J L; Gosselin M  
(PRAE-N) PRAECIS PHARM INC.  
PI WO 2002042462 A2 20020530 79p  
AI WO 2001-US44581 20011127  
PRAI US 2000-253302P 20001127  
US 2000-250198P 20001129  
US 2000-257186P 20001220

DT Patent  
LA English  
OS 2002-636427 [68]  
DESC DI225 oligo used to assemble beta-amyloid gene subfragment.

L4 ANSWER 172 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAD43956 DNA DGENE  
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
to a peptide capable of binding amyloidogenic protein -  
IN Gefter M L; Israel D I; Joyal J L; Gosselin M  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 2002042462 A2 20020530 79p  
AI WO 2001-US44581 20011127  
PRAI US 2000-253302P 20001127  
US 2000-250198P 20001129  
US 2000-257186P 20001220  
DT Patent  
LA English  
OS 2002-636427 [68]  
DESC DI224 oligo used to assemble beta-amyloid gene subfragment.

L4 ANSWER 173 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAD43955 DNA DGENE  
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
to a peptide capable of binding amyloidogenic protein -  
IN Gefter M L; Israel D I; Joyal J L; Gosselin M  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 2002042462 A2 20020530 79p  
AI WO 2001-US44581 20011127  
PRAI US 2000-253302P 20001127  
US 2000-250198P 20001129  
US 2000-257186P 20001220  
DT Patent  
LA English  
OS 2002-636427 [68]  
DESC DI223 oligo used to assemble beta-amyloid gene subfragment.

L4 ANSWER 174 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAD43954 DNA DGENE  
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
to a peptide capable of binding amyloidogenic protein -  
IN Gefter M L; Israel D I; Joyal J L; Gosselin M  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 2002042462 A2 20020530 79p  
AI WO 2001-US44581 20011127  
PRAI US 2000-253302P 20001127  
US 2000-250198P 20001129  
US 2000-257186P 20001220  
DT Patent  
LA English  
OS 2002-636427 [68]  
CR P-PSDB: AAE26300  
DESC Human beta-amyloid gene.

L4 ANSWER 175 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAD43953 DNA DGENE  
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
to a peptide capable of binding amyloidogenic protein -  
IN Gefter M L; Israel D I; Joyal J L; Gosselin M  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 2002042462 A2 20020530 79p  
AI WO 2001-US44581 20011127  
PRAI US 2000-253302P 20001127  
US 2000-250198P 20001129  
US 2000-257186P 20001220  
DT Patent  
LA English  
OS 2002-636427 [68]  
DESC Human beta-amyloid DNA fragment, DI222-4.

L4 ANSWER 176 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAD43952 DNA DGENE



TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
to a peptide capable of binding amyloidogenic protein -  
Gefter M L; Israel D I; Joyal J L; Gosselin M  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 2002042462 A2 20020530 79p  
AI WO 2001-US44581 20011127  
PRAI US 2000-253302P 20001127  
US 2000-250198P 20001129  
US 2000-257186P 20001220  
DT Patent  
LA English  
OS 2002-636427 [68]  
DESC Human beta-amyloid DNA fragment, DI222-40.

L4 ANSWER 177 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAD43951 DNA DGENE  
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
to a peptide capable of binding amyloidogenic protein -  
Gefter M L; Israel D I; Joyal J L; Gosselin M  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 2002042462 A2 20020530 79p  
AI WO 2001-US44581 20011127  
PRAI US 2000-253302P 20001127  
US 2000-250198P 20001129  
US 2000-257186P 20001220  
DT Patent  
LA English  
OS 2002-636427 [68]  
DESC Human beta-amyloid DNA fragment, DI221.

L4 ANSWER 178 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAD43950 DNA DGENE  
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
to a peptide capable of binding amyloidogenic protein -  
Gefter M L; Israel D I; Joyal J L; Gosselin M  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 2002042462 A2 20020530 79p  
AI WO 2001-US44581 20011127  
PRAI US 2000-253302P 20001127  
US 2000-250198P 20001129  
US 2000-257186P 20001220  
DT Patent  
LA English  
OS 2002-636427 [68]  
DESC Human beta-amyloid DNA fragment, DI220.

L4 ANSWER 179 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAD43949 DNA DGENE  
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
to a peptide capable of binding amyloidogenic protein -  
Gefter M L; Israel D I; Joyal J L; Gosselin M  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 2002042462 A2 20020530 79p  
AI WO 2001-US44581 20011127  
PRAI US 2000-253302P 20001127  
US 2000-250198P 20001129  
US 2000-257186P 20001220  
DT Patent  
LA English  
OS 2002-636427 [68]  
DESC Human beta-amyloid DNA fragment, DI219.

L4 ANSWER 180 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAD43948 DNA DGENE  
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
to a peptide capable of binding amyloidogenic protein -

IN Gefter M L; Israel D I; Joyal J L; Gosselin M  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 2002042462 A2 20020530 79p  
AI WO 2001-US44581 20011127  
PRAI US 2000-253302P 20001127  
US 2000-250198P 20001129  
US 2000-257186P 20001220  
DT Patent  
LA English  
OS 2002-636427 [68]  
DESC Human beta-amyloid DNA fragment, DI218.

L4 ANSWER 181 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAD43947 DNA DGENE  
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
to a peptide capable of binding amyloidogenic protein -  
IN Gefter M L; Israel D I; Joyal J L; Gosselin M  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 2002042462 A2 20020530 79p  
AI WO 2001-US44581 20011127  
PRAI US 2000-253302P 20001127  
US 2000-250198P 20001129  
US 2000-257186P 20001220  
DT Patent  
LA English  
OS 2002-636427 [68]  
DESC Human beta-amyloid DNA fragment, DI217-3G.

L4 ANSWER 182 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAD43946 DNA DGENE  
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
to a peptide capable of binding amyloidogenic protein -  
IN Gefter M L; Israel D I; Joyal J L; Gosselin M  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 2002042462 A2 20020530 79p  
AI WO 2001-US44581 20011127  
PRAI US 2000-253302P 20001127  
US 2000-250198P 20001129  
US 2000-257186P 20001220  
DT Patent  
LA English  
OS 2002-636427 [68]  
DESC Human beta-amyloid DNA fragment, DI217.

L4 ANSWER 183 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAD43945 DNA DGENE  
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
to a peptide capable of binding amyloidogenic protein -  
IN Gefter M L; Israel D I; Joyal J L; Gosselin M  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 2002042462 A2 20020530 79p  
AI WO 2001-US44581 20011127  
PRAI US 2000-253302P 20001127  
US 2000-250198P 20001129  
US 2000-257186P 20001220  
DT Patent  
LA English  
OS 2002-636427 [68]  
DESC DI216 oligo used to assemble synthetic APP/IgG gene.

L4 ANSWER 184 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAD43944 DNA DGENE  
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
\*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
to a peptide capable of binding amyloidogenic protein -  
IN Gefter M L; Israel D I; Joyal J L; Gosselin M  
PA (PRAE-N) PRAECIS PHARM INC.  
PI WO 2002042462 A2 20020530 79p  
AI WO 2001-US44581 20011127

PRAI US 2000-253302P 20001127  
 US 2000-250198P 20001129  
 US 2000-257186P 20001220  
 DT Patent  
 LA English  
 OS 2002-636427 [68]  
 DESC DI215 oligo used to assemble synthetic APP/IgG gene.

L4 ANSWER 185 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
 AN AAD43943 DNA DGENE  
 TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
 e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
 \*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
 to a peptide capable of binding amyloidogenic protein -  
 IN Gefter M L; Israel D I; Joyal J L; Gosselin M  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI WO 2002042462 A2 20020530 79p  
 AI WO 2001-US44581 20011127  
 PRAI US 2000-253302P 20001127  
 US 2000-250198P 20001129  
 US 2000-257186P 20001220  
 DT Patent  
 LA English  
 OS 2002-636427 [68]  
 CR P-PSDB: AAE26273  
 DESC Human tPA $\Delta$ tapro/16-30/Fc fusion DNA.

L4 ANSWER 186 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
 AN AAD43942 DNA DGENE  
 TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
 e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
 \*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
 to a peptide capable of binding amyloidogenic protein -  
 IN Gefter M L; Israel D I; Joyal J L; Gosselin M  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI WO 2002042462 A2 20020530 79p  
 AI WO 2001-US44581 20011127  
 PRAI US 2000-253302P 20001127  
 US 2000-250198P 20001129  
 US 2000-257186P 20001220  
 DT Patent  
 LA English  
 OS 2002-636427 [68]  
 DESC Mouse IgG1 fragment amplifying 3' PCR primer.

L4 ANSWER 187 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
 AN AAD43941 DNA DGENE  
 TI Novel therapeutic agent useful for treating an amyloidogenic disorder,  
 e.g. Alzheimer's disease, comprises an \*\*\*immunoglobulin\*\*\*  
 \*\*\*heavy\*\*\* \*\*\*chain\*\*\* \*\*\*constant\*\*\* \*\*\*region\*\*\* linked  
 to a peptide capable of binding amyloidogenic protein -  
 IN Gefter M L; Israel D I; Joyal J L; Gosselin M  
 PA (PRAE-N) PRAECIS PHARM INC.  
 PI WO 2002042462 A2 20020530 79p  
 AI WO 2001-US44581 20011127  
 PRAI US 2000-253302P 20001127  
 US 2000-250198P 20001129  
 US 2000-257186P 20001220  
 DT Patent  
 LA English  
 OS 2002-636427 [68]  
 DESC Mouse IgG1 fragment amplifying 5' PCR primer.

L4 ANSWER 188 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
 AN AAT84744 DNA DGENE  
 TI Hybrid fusion protein for treating Gram-negative bacterial infections -  
 comprising bactericidal/permeability increasing protein and  
 immunoglobulin heavy chain constant domain  
 IN Grinna L S; Horwitz A; Theofan G  
 PA (XOMA) XOMA CORP.  
 PI US 5643570 A 19970701 31p  
 AI US 1993-64693 19930519  
 PRAI US 1993-64693 19930519  
 US 1992-885911 19920519  
 DT Patent  
 LA English

OS 1997-350186 [32]  
DESC Primer BPI-2 for bactericidal permeability increasing protein DNA.

L4 ANSWER 189 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAT84743 DNA DGENE  
TI Hybrid fusion protein for treating Gram-negative bacterial infections -  
comprising bactericidal/permeability increasing protein and  
immunoglobulin heavy chain constant domain  
IN Grinna L S; Horwitz A; Theofan G  
PA (XOMA) XOMA CORP.  
PI US 5643570 A 19970701 31p  
AI US 1993-64693 19930519  
PRAI US 1993-64693 19930519  
US 1992-885911 19920519  
DT Patent  
LA English  
OS 1997-350186 [32]  
DESC Primer BPI-23 for bactericidal permeability increasing protein DNA.

L4 ANSWER 190 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAT84742 DNA DGENE  
TI Hybrid fusion protein for treating Gram-negative bacterial infections -  
comprising bactericidal/permeability increasing protein and  
immunoglobulin heavy chain constant domain  
IN Grinna L S; Horwitz A; Theofan G  
PA (XOMA) XOMA CORP.  
PI US 5643570 A 19970701 31p  
AI US 1993-64693 19930519  
PRAI US 1993-64693 19930519  
US 1992-885911 19920519  
DT Patent  
LA English  
OS 1997-350186 [32]  
DESC Primer BPI-14 for bactericidal permeability increasing protein DNA.

L4 ANSWER 191 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAT84741 DNA DGENE  
TI Hybrid fusion protein for treating Gram-negative bacterial infections -  
comprising bactericidal/permeability increasing protein and  
immunoglobulin heavy chain constant domain  
IN Grinna L S; Horwitz A; Theofan G  
PA (XOMA) XOMA CORP.  
PI US 5643570 A 19970701 31p  
AI US 1993-64693 19930519  
PRAI US 1993-64693 19930519  
US 1992-885911 19920519  
DT Patent  
LA English  
OS 1997-350186 [32]  
DESC Primer BPI-6 for bactericidal permeability increasing protein DNA.

L4 ANSWER 192 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAT84740 DNA DGENE  
TI Hybrid fusion protein for treating Gram-negative bacterial infections -  
comprising bactericidal/permeability increasing protein and  
immunoglobulin heavy chain constant domain  
IN Grinna L S; Horwitz A; Theofan G  
PA (XOMA) XOMA CORP.  
PI US 5643570 A 19970701 31p  
AI US 1993-64693 19930519  
PRAI US 1993-64693 19930519  
US 1992-885911 19920519  
DT Patent  
LA English  
OS 1997-350186 [32]  
DESC Primer BPI-11 for bactericidal permeability increasing protein DNA.

L4 ANSWER 193 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAT84739 DNA DGENE  
TI Hybrid fusion protein for treating Gram-negative bacterial infections -  
comprising bactericidal/permeability increasing protein and  
immunoglobulin heavy chain constant domain  
IN Grinna L S; Horwitz A; Theofan G  
PA (XOMA) XOMA CORP.  
PI US 5643570 A 19970701 31p  
AI US 1993-64693 19930519

PRAI US 1993-64693 19930519  
US 1992-885911 19920519  
DT Patent  
LA English  
OS 1997-350186 [32]  
DESC Primer BPI-5 for bactericidal permeability increasing protein DNA.

L4 ANSWER 194 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAQ52488 DNA DGENE  
TI New fusion proteins for treating bacterial infections - comprising a  
bactericidal-permeability-increasing protein and a immunoglobulin heavy  
chain constant domain  
IN Grinna L S; Horwitz A; Theofan G  
PA (XOMA) XOMA CORP.  
PI WO 9323434 A2 19931125 75p  
AI WO 1993-US4754 19930519  
PRAI US 1992-885911 19920519  
DT Patent  
LA English  
OS 1993-386485 [48]  
CR P-PSDB: AAR44420  
DESC pING4512 coding region.

L4 ANSWER 195 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAQ52484 DNA DGENE  
TI New fusion proteins for treating bacterial infections - comprising a  
bactericidal-permeability-increasing protein and a immunoglobulin heavy  
chain constant domain  
IN Grinna L S; Horwitz A; Theofan G  
PA (XOMA) XOMA CORP.  
PI WO 9323434 A2 19931125 75p  
AI WO 1993-US4754 19930519  
PRAI US 1992-885911 19920519  
DT Patent  
LA English  
OS 1993-386485 [48]  
DESC Primer BPI-14.

L4 ANSWER 196 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAQ52483 DNA DGENE  
TI New fusion proteins for treating bacterial infections - comprising a  
bactericidal-permeability-increasing protein and a immunoglobulin heavy  
chain constant domain  
IN Grinna L S; Horwitz A; Theofan G  
PA (XOMA) XOMA CORP.  
PI WO 9323434 A2 19931125 75p  
AI WO 1993-US4754 19930519  
PRAI US 1992-885911 19920519  
DT Patent  
LA English  
OS 1993-386485 [48]  
DESC Primer BPI-6.

L4 ANSWER 197 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAQ52482 DNA DGENE  
TI New fusion proteins for treating bacterial infections - comprising a  
bactericidal-permeability-increasing protein and a immunoglobulin heavy  
chain constant domain  
IN Grinna L S; Horwitz A; Theofan G  
PA (XOMA) XOMA CORP.  
PI WO 9323434 A2 19931125 75p  
AI WO 1993-US4754 19930519  
PRAI US 1992-885911 19920519  
DT Patent  
LA English  
OS 1993-386485 [48]  
DESC Primer BPI-11.5.

L4 ANSWER 198 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAQ52481 DNA DGENE  
TI New fusion proteins for treating bacterial infections - comprising a  
bactericidal-permeability-increasing protein and a immunoglobulin heavy  
chain constant domain  
IN Grinna L S; Horwitz A; Theofan G  
PA (XOMA) XOMA CORP.  
PI WO 9323434 A2 19931125 75p

AI WO 1993-US4754 19930519  
PRAI US 1992-885911 19920519  
DT Patent  
LA English  
OS 1993-386485 [48]  
DESC Primer BPI-5.

L4 ANSWER 199 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAQ52480 DNA DGENE  
TI New fusion proteins for treating bacterial infections - comprising a  
bactericidal-permeability-increasing protein and a immunoglobulin heavy  
chain constant domain  
IN Grinna L S; Horwitz A; Theofan G  
PA (XOMA) XOMA CORP.  
PI WO 9323434 A2 19931125 75p  
AI WO 1993-US4754 19930519  
PRAI US 1992-885911 19920519  
DT Patent  
LA English  
OS 1993-386485 [48]  
DESC Primer CH2-2C-Dra.

L4 ANSWER 200 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAQ52479 DNA DGENE  
TI New fusion proteins for treating bacterial infections - comprising a  
bactericidal-permeability-increasing protein and a immunoglobulin heavy  
chain constant domain  
IN Grinna L S; Horwitz A; Theofan G  
PA (XOMA) XOMA CORP.  
PI WO 9323434 A2 19931125 75p  
AI WO 1993-US4754 19930519  
PRAI US 1992-885911 19920519  
DT Patent  
LA English  
OS 1993-386485 [48]  
DESC Primer KAO-gamma3.

L4 ANSWER 201 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAQ52478 DNA DGENE  
TI New fusion proteins for treating bacterial infections - comprising a  
bactericidal-permeability-increasing protein and a immunoglobulin heavy  
chain constant domain  
IN Grinna L S; Horwitz A; Theofan G  
PA (XOMA) XOMA CORP.  
PI WO 9323434 A2 19931125 75p  
AI WO 1993-US4754 19930519  
PRAI US 1992-885911 19920519  
DT Patent  
LA English  
OS 1993-386485 [48]  
DESC Primer CH2-Msc.

STN INTERNATIONAL LOGOFF AT 16:37:49 ON 18 NOV 2004